

NICOLAE TESTEMIȚANU STATE UNIVERSITY OF MEDICINE AND PHARMACY VASILE PROCOPISIN DEPARTMENT OF SOCIAL PHARMACY

MANAGEMENT AND PHARMACEUTICAL LEGISLATION

Ministry of Health of the Republic of Moldova

NICOLAE TESTEMIȚANU STATE UNIVERSITY OF MEDICINE AND PHARMACY FACULTY OF PHARMACY

VASILE PROCOPISIN DEPARTMENT OF SOCIAL PHARMACY

MANAGEMENT AND PHARMACEUTICAL LEGISLATION

practical work for the 4 th year students		
	(Name, First name of the student)	
	Group	
	a v. 20 – 20	

Learning guide and workbook for laboratory

ÎS FEP "Tipografia Centrală" Chisinau, 2023 Approved by the *Vasile Procopisin* Department of Social Pharmacy (Minutes No. 6 of 13 January 2023)

Approved by the Scientifici-methodical Commission of Pharmacy (Minutes No. 1 of 18 January 2023)

Approved by the Council of the Quality Management (Minutes No. 4 of 02 February 2023)

MANAGEMENT AND PHARMACEUTICAL LEGISLATION

Learning guide and workbook for laboratory practical work for the 4th year students, faculty of Pharmacy

Edition III, translated from Romanian

Coordinating author:

Stela ADAUJI, PhD, associate professor

Authors:

Mihail BRUMĂREL, PhD, associate professor Lucia SÎBII, university assistant Nicoleta CHEPTANARI-BÎRTA, university assistant Svetlana ŞCETININA, university assistant Tatiana ŞCHIOPU, university assistant

Reviewers:

Vladimir SAFTA, PhD, university professor **Mihail LUPU**, PhD, associate professor

DESCRIEREA CIP A CAMEREI NAȚIONALE A CĂRŢII DIN REPUBLICA MOLDOVA

Management and pharmaceutical legislation: Learning guide and workbook for laboratory practical work for the 4th year students / coordinating author: Stela Adauji; authors: Mihail Brumărel, Lucia Sîbii, Nicoleta Cheptanari-Bîrta [et al.]; Ministry of Health of the Republic of Moldova, *Nicolae Testemiţanu* State University of Medicine and Pharmacy, Faculty of Pharmacy, *Vasile Procopisin* Department of Social Pharmacy. – Ed. 3th, transl. from roum. – Chişinău: F.E.-P. "Tipografia Centrală", 2023. – 167 p.

Aut. indicaţi pe verso f. de tit. – Referinţe bibliogr.: p. 167 (8 tit.). – [100] ex. ISBN 978-5-88554-265-4.

615:349(076.5)

M 20

CONTENT

DISTRIBUTION OF TEACHING HOURS BY THEM	4
Theme 1. GENERAL FEATURES OF THE MANAGEMENT. MANAGEMENT SCHOOLS	. 5
Theme 2. FUNCTIONS OF MANAGEMENT. ELEMENTS OF MANAGEMENT IN	
PHARMACEUTICAL ACTIVITY.	8
Theme 3. MANAGEMENT OF LEADING PROCESS. DECISIONS IN THE LEADING	
PROCESS.	11
Theme 4. THE ORGANIZATION AS A SYSTEM AND OBJECT OF LEADERSHIP.	
ORGANIZATION MANAGEMENT. THE ERGONOMICS OF WORKPLACES	
IN THE ORGANIZATION	14
Theme 5. THE MANAGER OF PHARMACY. MANAGEMENT HUMAN RESOURCES.	
HUMAN RESOURCES OF THE PHARMACEUTICAL SYSTEM	20
TOTALIZATION no. 1 ON HOMEWORK 1 – 5	33
Theme 6. PHARMACEUTICAL SYSTEM. COORDINATION OF THE	
PHARMACEUTICAL SYSTEM	34
Theme 7. PHARMACEUTICAL ACTIVITY AND ITS AUTHORIZATION.	
ACCREDITATION OF PHARMACEUTICAL COMPANIES.	39
Theme 8. THE MEDICINES AND OTHER PHARMACEUTICAL PRODUCTS AS A	
STUDY OBJECT OF PHARMACEUTICAL ASSISTANCE. THE MARKETING	i
AUTHORIZATION OF MEDICINAL RODUCTS	45
Theme 9. QUALITY ASSURANCE OF MEDICINAL PRODUCTS. STATE CONTROL	
OF THE QUALITY OF DRUGS. PHARMACOVIGILANCE SYSTEM	51
Theme 10. INDUSTRIAL PRODUCTION OF MEDICINES. SUPPLY OF MEDICINES.	
THE PHARMACEUTICAL WAREHOUSE, ITS TASKS AND FUNCTIONS	58
TOTALIZATION no. 2 ON HOMEWORK 6 - 10	
Theme 11. THE OUTPATIENT PHARMACEUTICAL CARE SYSTEM.	
THE COMMUNITY PHARMACY, ITS TASK AND FUNCTIONS	66
Theme 12. THE LEGAL PRESCRIBING RULES FOR MEDICINES.	
Theme 13 RECEIVING, PRICING AND REGISTRATION OF PRESCRIPTION	
FUNCTIONS OF MANAGEMENT.	84
Theme 14. TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING IN PHARMACY	
AND QUALITY CONTROL OF EXTEMPORANEOUS PREPARATION. PACI	
LABELING AND DISPENSING MEDICINES FROM PHARMACY	
Thema 15. MANAGEMENT AND LEGISLATION OF PHARMACEUTICAL	
ASSISTANCE IN HOSPITAL	105
TOTALIZATION no. 3 ON HOMEWORK 11 - 15	
Theme 16.PHARMACEUTICAL RECORDS. THE PRICES FOR DRUGS AND OTHER	
PHARMACEUTICAL PRODUCTS	112
Theme 17. CIRCULATION RECORDS OF PHARMACEUTICAL PRODUCTS	117
Theme 18. EVIDENCE OF OTHER STOCK MOVEMENTS. CASH FLOW IN	
PHARMACEUTICAL COMPANIES.	127
Theme 19. LABOR AND WAGES RECORDS. CONSUMPTION, EXPENSES AND RESULT	'S
OF THE ECONOMIC ACTIVITY OF PHARMACEUTICAL ENTERPRISES	
Theme 20. MONITORING MANAGEMENT OF PHARMACEUTICAL ACTIVITY.	
INVENTORY OF MATERIAL ASSETS IN PHARMACEUTICAL COMPANIES	5 144
TOTALIZATION no. 4 ON HOMEWORK 16 - 20	152
THE CONTENT OF THE INDIVIDUAL WORK FOR STUDENTS DURING THE STUDY OF	
THE DISCIPLINE "MANAGEMENT AND LEGISLATION FARMACEUTICĂ"	
THE CONTENT OF THE INDIVIDUAL WORK FOR SEMESTER I	
THE CONTENT OF THE INDIVIDUAL WORKS FOR HE II SEMESTER	
BASIC LITERATURE	

DISTRIBUTION OF TEACHING HOURS BY THEM

mi en	hou	ırs
Theme	Course	Pr. work
1. General features of the management. Management schools.		4
2. Functions of management. Elements of management in pharmaceutical activity.	2	4
3. Management of leading process. Decisions in the leading process.		4
4. The organization as a system and object of leadership. Organization management. The ergonomics of workplaces in the organization.	2	4
5. The manager of the pharmaceutical company. Human resources management. Human resources of the pharmaceutical system.	2	8
Totalization no. 1 on homework 1-5.	-	4
6. Pharmaceutical system. Coordination of the pharmaceutical system.		4
7. Pharmaceutical activity and its authorization. Accreditation of pharmaceutical enterprises.	3	4
8. The medicines and other pharmaceutical products as a study object of pharmaceutical assistance. The marketing authorization of medicinal products.	2	4
9. Quality assurance of medicinal products. State control of the quality of drugs. Pharmacovigilence system.	2	8
10.Industrial production of medicines. Supply of medicines. The pharmaceutical warehouse, its tasks and functions. The pharmaceutical warehouse, its tasks and functions.	2	8
Totalization no. 2 on homework 6-10.	-	4
11. The outpatient pharmaceutical care system. The community pharmacy, its task and functions.	2	8
12.The legal prescribing rules for medicines.	2	4
13.Receiving, pricing and registration of prescription.		8
14. Technology of pharmaceutical compounding in pharmacy and quality control of extemporaneous preparation. Pack labeling and dispensing medicines from pharmacy.	2	4
15.Management and legislation of pharmaceutical assistance in hospital.	2	8
Totalization no. 3 on homework 11-15.	-	4
16.Pharmaceutical records. The prices for drugs and other pharmaceutical products.	2	4
17.Circulation records of pharmaceutical products.	_	4
18.Evidence of other stock movements. Cash flow in pharmaceutical companies.	2	4
19.Labor and wages records. Consumption and expenditure of pharmaceutical companies. The results of financial and economic activity in pharmaceutical company.	2	4
20.Monitoring management of pharmaceutical activity. Inventory of material assets in pharmaceutical companies.	1	4
Totalization no. 4 on homework 16-20.	-	4

Theme 1

GENERAL FEATURES OF THE MANAGE-MENT. MANAGEMENT SCHOOLS.

The purpose of the work. Obtaining knowledge by students in the field of evolution and theory of management and practical skills of planning, organization, coordination, motivation and control of various pharmaceutical activities. Get acquainted with contemporary approaches, doctrines and modern management schools.

Form of training: Seminar and laboratory practical work

Duration: 4 hours

Questions for self-learning:

- 1. Basic concepts of management.
- 2. The main elements of management. Stages of development of management.
- 3. Schools of management theory and their features:
 - a) classical school;
 - b) human behaviors school;
 - c) social school;
 - d) empirical school;
- 4. Situational management.
- 5. Comparative management.
- 6. Contemporary management.
- 7. The contribution of different schools to contemporary managerial theory and practice.


Exercises for self-solving

Exercise 1. Write in the table the type of schools of management theory and their approaches. Take into account the information about the scientifically directions and the main concepts of these schools and their contribution in the development of modern management.

Scientifically directions and main concepts	Basic concepts used in the modern management
1. Type of school	
Scientific principles of work organization. Rationalization of work operations. Division of work in the management. Approach of the management process.	
2. Type of school	
Interpersonal relationships - a factor for increasing the efficiency of work and the potential of each employee.	

Scientifically directions and main concepts	Basic concepts used in the modern management
3. Type of school	
Application of quantitative measurement methods. The development of theory of systems. Highlighting the "macro-" and "micro environmental" factors.	
4. Type of school	
It uses the science of leadership for efficient leaders, experience, the way to action.	

Exercise 2. Basing on the principles of human behaviors school and using the Maslow's pyramid make a ranking of the needs of pharmacists.



Exercise 3. Describe which of the managerial principles of savants Henri Fayol, Frederick Taylor, Douglas McGregor are currently being applied in the management of pharmaceutical companies. Argue the answer.

- a) Chain community pharmacy
- b) Individual community pharmacy
- c) Pharmaceutical warehouse
- d) Pharmacy with section of preparing medicines basing on prescriptions
- e) Pharmaceutical factory

Exercise 4. <u>Case study:</u> The management team of the enterprise "M-Inter-Pharma", a wholesale and retail trade company of pharmaceuticals, parapharmaceuticals and disinfectants, considers that all management decisions should be taken according to the same system, without analyzing the circumstances each time, because it is impossible to predict all possible situations and changes. For the adoption of decisions, specialists from various subdivisions are involved, but very rarely, since it is considered that it slows down the process of decision-making, and the effect of their application is minimal. As basic criteria for evaluating the managerial activity are considered the discipline of work and the authoritarian style of managerial management. Identify the actions of managers that are contrary to the fundamental principles of contemporary management. Determine how they influence the efficiency of the decision-making system in the enterprise.
Conclusions and suggestions of the student:
The teacher's signature

FUNCTIONS OF MANAGEMENT. ELEMENTS OF MANAGEMENT IN PHARMACEUTICAL ACTIVITY.

The purpose of the work. Get acquainted with the functions of modern management, their role and functions in the work of management and pharmaceutical management. To determine the specifics of pharmaceutical management: structure, goals and functions.

Form of training: Seminar and laboratory practical work

Duration: 4 hours

Questions for self-learning:

- 1. General features of management functions:
- 2. Planning function. The importance of planning. Types of planning in an organization.
- 3. Organizing function.
- 4. Coordinating function.
- 5. Motivating function. Financial and non-financial motivation of the staff.
- 6. Controlling function.

Exercises for self-solving

Exercise 1. Describe the strategic planning of the activities of a community pharmacy located:

 a) within the Family Physicians Center 	b) within a shopping center.
c) within an apartment building	d) nearby to another pharmacy

Exercise 2. Develop a motivation system for pharmaceutical staff in the following cases. Argue the answer. a) pharmacist, young graduate b) pharmacist with 10 years working experience pharmacist with 20 years working experience d) pharmacist, mother with minor children **Exercise 3.** Identify and list in the table below what are the strengths and weaknesses (in the internal environment) the development opportunities and risks (from the external environment) of a pharmaceutical company proposed by the professor. **S**- Strengths: **W**- Weaknesses: 1. 1. 2. 2. 3. 3. 4. 4. 5. 5. **O**- Opportunit **T**- Threats: 1. ies:

2.

3.

4.

5.

1.

2.

3.

4.

5.

tinuous training at the "V. Procopisin" depa in the pharmacy the quality management of the counter (OTC) and reimbursed medicine ling function in organization, propose an algo	a pharmacy after attending the courses of contribution of social pharmacy decided to improve medicines release: with prescription (Rx), over as. Using the knowledge of planning and controlorithm to implement this goal. Additional study: Deming-Shuhart (PDCA) Quality Improvement
Conclusions and suggestions of the stud	lent:
	The teacher's signature

Theme 3

MANAGEMENT OF LEADING PROCESS. DE-CISIONS IN THE LEADING PROCESS.

The purpose of the work. To get acquainted with general leading systems, methods and types. To acquire practical skills in selecting and applying the leadership methods in leading with the pharmaceutical system. To get acquainted with decision-making algorithms and some ways of using them in the practice of pharmaceutical management.

Form of training: Seminar and laboratory practical work


Duration: 4 hours

Questions for self-learning:


- 1. General features of leading process.
- 2. Classification of leadership methods.
- 3. Styles of leadership.
- 4. General notions about decisions and decisional process.
- 5. Classification of decisions.
- 6. Factors that influence the decisional process.
- 7. Stages of decisional process.
- 8. Methods and models of decision making.

Exercises for self-solving

Exercise 1. Write the meaning of the word <i>leadership</i> . Enumerate the styles of leader ship and their particularities.			



Exercise 3. In the figure below are presented the managerial styles of management through the prism of the relationship between the manager and the subordinate. Analyzing each of these 3 styles, describe the advantages and disadvantages of each indicated managerial leadership style.



Leadership style	Advantages	Disadvantages
	1.	1.
Authoritarian	2.	2.
	3.	3.
	1.	1.
Permissive	2.	2.
	3.	3.
	1.	1.
Democratic	2.	2.
	3.	3.

Exercise 4. The pharmacist manager of a pharmacy after attending the courses of continuous training found out that:

- 1. In the section of industrial medicines after the inventory arose a conflict because of a lack of material goods.
- 2. Head of department of industrial forms ordered nomenclature of drugs that are not required due to high prices, the staff of the department are not interested in the realization of these drugs.
- 3. Employees of the department of stocks receive instructions not only from the head of the department but also from the head of the production department. The head of the Stock Department is not responsible for the timely delivery of medicines with limited validity period.
- 4. Lately, the number of unjustified medicines refusals has increased, which has reduced the quality of pharmaceutical care.

Propose ideas for solving these situations using the concepts of decision-making process.

Questions:

- 1. Has the pharmacist reasonably used the management methodology in solving these situations?
- 2. Has the use of situational approach been argued in case no.1?
- 3. Which of the four styles approaches and leadership methods would have been rationally used in situations no. 2, 3, 4?

any used in situations no. 2, 3, 4?
Argue the answer.
Conclusions and suggestions of the student:

The teacher's signature _

Theme 4

THE ORGANIZATION AS A SYSTEM AND OBJECT OF LEADERSHIP. ORGANIZATION MANAGEMENT. THE ERGONOMICS OF WORKPLACES IN THE ORGANIZATION

The purpose of the work: To get acquainted with types of organizations, requirements for formal organization and its features. To acquire practical skills of endowment and ergonomic organization of jobs in the pharmaceutical companies. To learn the methods of studying the work and applying them to determine the effectiveness of pharmacists' work at different jobs in the pharmacy. To learn the content and basic elements of human resources management.

Form of training: Seminar.

Duration: 4 hours.

Question for self-learning:

- 1. The organization as a system and object of the leading process.
- 2. Formal and non-formal organization and their features.
- 3. The working environment of an organization.
- 4. Effective organizations.
- 5. The American, Japanese and European management system.
- 6. Ergonomics in the workplace. Work organization and ergonomics.
- 7. Time management. Methods to optimize time management.
- 8. Methods to study the work (time research, photographing the workday etc.).
- 9. Human resources management.
- 10. Functions of human resources management.
- 11. The manager and managerial hierarchy. Performances and skills needed by a leader.
- 12. Roles and managerial responsibilities.
- 13. Aspects of managerial ethics.

Exercises for self-solving:

Exercise 1. Describe the comparative features of the American and Japanese management models. There are 3 groups of students who prepare and present the directions of management in Japan, USA, Europe with ideas that could be used in the managerial activity of pharmaceutical companies from Republic of Moldova.

Nr. d/o	American management model	European management model	Japanese management model	
	1) DEISION FUNCTION			
1.				
2.				
3.				
4.				


Nr. d/o	American management model	European management model	Japanese management model				
	2) CONTROL FUNCTION						
1.							
2.							
3.							
4.							
	3	B) ORGANIZATION FUNCTION					
1.							
2.							
3.							
4.							
		4) STUFF FUNCTION					
1.							
2.							
3.							
4.							

Elements of comparative management that could be used in the managerial activity of pharmaceutical companies from Republic of Moldova

1	 	
2.		
3.		
ა	 	

Exercise 2. Draw the graphical model of the "Hierarchy of goals and objectives of the pharmaceutical organization," using the "Objectives Tree" and the organization goals classification scheme.

a) The organization goals classification scheme




- b) The rules of drawing the objective tree:
 - 1. The drawing of the tree starts with the top, forming the main common objective of zero level.
 - 2. Then, the main objective is divided in different levels sub-objectives (1, 2, 3 etc.).
 - 3. The basic principle of dividing: each sub-objective helps to fulfill the superior objective.
 - 4. Forming the objectives from zero to the other next levels, sub-objectives are detailed more concrete in: directions (1st level), ways (2nd level), problems and tasks (3rd, 4th, 5th level etc.).
 - 5. The dividing continues till the sub-objectives assure the realization of the main common objective.
 - 6. As a result of dividing is obtained the objectives tree that demonstrate all necessary steps to be taken to achieve the common object and the correlation between them.
 - 7. The level of achievement of each goal, solving a particular problem, can be measured based on the chosen criteria and indices.

The objective tree have to be branched, inverted crown down.

The problem-solving algorithm:

- 1. Study the rules of elaborating the objective tree;
- 2. Draw the graphical model of the objective tree of a pharmaceutical organization, assigning objectives by importance and duration.
- 3. Make 3 concrete objectives for each level.



Exercise 3. Choose from literature and fulfill the objective and the tasks of ergonomics: ERGONOMICS – content:
ERGONOMICS - Content:
Objective:
Tasks in order to achieve the objective:
Tasks for ergonomically work organization:

Ex	ercise 4. Write the methods to study the work:
	esearch:
Photos	graphing the workday:
11000	5- wpg v v, -
Г.	
	ercise 5. Make an analysis of time management of a pharmacist from a community
pharma	cy to determine:
pharma a) V	cy to determine: Vhich are the "thieves" of time?
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time?
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.
pharma a) V b) V	cy to determine: Vhich are the "thieves" of time? Vhat are the de facto activities of the pharmacist? Use the Eisenhower matrix.

Conclusions and suggestions of the stu	ıdent:
Conclusions and suggestions of the stu	ıdent:
Conclusions and suggestions of the stu	ıdent:
Conclusions and suggestions of the stu	ıdent:
Conclusions and suggestions of the stu	ıdent:
Conclusions and suggestions of the stu	ıdent:
Conclusions and suggestions of the stu	ıdent:
Conclusions and suggestions of the stu	ıdent:
Conclusions and suggestions of the stu	ident:
Conclusions and suggestions of the stu	ident:
Conclusions and suggestions of the stu	ident:
Conclusions and suggestions of the stu	ident:
Conclusions and suggestions of the stu	ident:
Conclusions and suggestions of the stu	ident:
Conclusions and suggestions of the stu	ident:
Conclusions and suggestions of the stu	ident:
Conclusions and suggestions of the stu	ident:
Conclusions and suggestions of the stu	
Conclusions and suggestions of the stu	
Conclusions and suggestions of the stu	The teacher's signature
Conclusions and suggestions of the stu	
Conclusions and suggestions of the stu	
Conclusions and suggestions of the stu	
Conclusions and suggestions of the stu	
Conclusions and suggestions of the stu	
Conclusions and suggestions of the stu	
Conclusions and suggestions of the stu	
Conclusions and suggestions of the stu	

Theme 5

THE MANAGER OF PHARMACY. MANAGE-MENT HUMAN RESOURCES. HUMAN RESO-URCES OF THE PHARMACEUTICAL SYSTEM.

The purpose of the work. To learn the characteristics of the manager and the specificity of the functional obligations of the management staff of the pharmaceutical companies. To acquire practical skills of endowing the work place of the leading staff and of communication manager-subordinate, manager-patient.

Form of training: Seminar and laboratory practical work

Duration: 8 hours

Questions for self-learning:

- 1. Pharmacy staff, nomenclature of specialties and pharmaceutical workplaces. Leading jobs in pharmaceutical companies.
- 2. Main aspects of leading in pharmaceutical companies. Requirements to the pharmacy manager personality.
- 3. Managerial roles and responsibilities.
- 4. Manager and management hierarchy. Performances and abilities needed by a pharmacy manager.
- 5. Organizing the pharmacist manager work. Relationship pharmacist manager subordinate.
- 6. Aspects of managerial ethics. Pharmaceutical ethics and deontology.
- 7. Human resources management in pharmaceutical enterprises.
- 8. Functions of human resources management.
- 9. Obligations and rights of pharmacists, the documents they are conducting, the order of filling workplaces.
- 10. Contract of employment. Content and order of completion.
- 11. Material responsibility in the pharmacy and its legalization.
- 12. General aspects of the certification of pharmacists.

Exercises for self-solving.

Exercise 1. Propose 5 mandatory characteristics (requirements) to the leader personality and 5 characteristics that are not admitted to the leader. Argue the answer.

Mandatory characteristics (requirements) to the leader personality	Characteristics that are not admitted to the leader

	elect and suggest son er. Argue the answer.	ne possibilitie	s to increase the	e effectiveness of
Exercise 3. A	s a pharmacy manag	er of a comm	unity pharmacy	set priorities for

1. medical assistance; 2. working with the staff of the pharmacy; 3. working with doctors, etc.

Note all tasks in the following table.

Activity	Duration	Content and deadline

Activity	Duration	Content and deadline
Exercise 4	Indicate the con	ntent and principles of human resources management:
Exercise 5	. Indicate the fun	ctions of human resources management and how to apply
them:		

Exercise 6. If the company has a vacancy, it can take various actions to hire a specialist in this position. Here, (in no order), are the main actions to be taken.

- Reception of applications
- Convening of selected candidates for interviews and tests
- Employment decision
- Sending the employment letter
- Sending the rejection letter
- Job description
- The first selection of candidates declared admitted based on the prepared file
- Defining the candidate's psychological and professional profile
- Conducting tests and employment interview
- Publishing an ad
- Employee integration

Develop the algorithm of the stages of hiring a person at work.

Exercise 7. When hiring a specialist, certain actions that require specific means must be carried out.

Determine the correlation between the elements in the two colums of the following table:

Operations and means necessary for the employment of staff

Nr.	Operations to be performed	Nr.	Means to carry them out
1.	Proposing a job	a.	A discussion with the candidate
2.	Employment decision	b.	Requesting references
3.	Knowing the candidate	c.	Publishing an ad
4.	Assessment of the candidate's profes-	d.	Requesting a curriculum vitae
	sional competences		
5.	Knowledge of the candidate's profile	e.	Sending a letter of employment
6.	Knowledge of the candidate's past per-	f.	Subjecting the candidate to a test
	formance		

Answers: (for each digit, indicate the corresponding letter)

- 1. -____
- 2. -____
- 3 -
- 4 –
- 5. -____
- 6. -

Exercise 8. Complete the proposed algorithm of the pharmacist manager actions and of the pharmacist who wishes to engage in the section of industrial medicines, who has a 6-year work experience and has the second category of professional qualification.

The action algorithm

Pharmacist manager			Pharmacist		
1. Analyzes	(what?)	1.	Sends	(what?)	
2. Organize	(what?)	2.	Pass	(what?)	
3. Decides to engage		3.	Get a positiv	re response	
4. Analyzes the submitted documents:			4. Presents the following documents		
-		-			
-		_			
_		_			
_		_			
-		-			

Pharmacist manager	Pharmacist
5. Gets(what?)	5. Completes(what?)
6. Concludes and signs in two copies	6. Completes and signs:
	-
(what document?)	-
	7. Signs(what?)
7. Issues	
(what document?)	
8. Forwards the copy of the order to the ac-	8. Receives a copy of the individual labor con-
countancy for opening your personal account.	tract.
9. perfects your personal file	9.Provides the necessary documents and com-
	pletes the Personal Record Sheet.
10. Spends general and primary introductory	10. After passing the general and primary train-
training on health and safety at work.	ing on health and safety at work, it proceeds to
	the fulfillment of the functional duties.
	Indicate the document


Exercise 9. Case study: Students are divided into 2 groups. Perform conflict analysis: between pharmacies; pharmacist-patient. Find the best possibilities to solve the conflict situation with or without the pharmacist manager involvement in solving the problem. Analyze the conflict situation through the Ishikawa diagram. Indicate the normative and legislative acts that will form the basis for solving these conflicts.

Case study no.1

In the evening, an excited, middle-aged lady, presents to the pharmacist a note in which is written "Alprazolam" - 3 packages. The pharmacist tries to explain to the lady how to dispense the "Alprazolam" tablets from the pharmacy, and the lady wishes to hear no argument, she says that without this medicine she will not leave the pharmacy. The pharmacist declined to dispense this medicine. The woman asked the Complaints Register, indicating the pharmacist's incompetence to dispense drugs and consult patients, and left the pharmacy dissatisfied. The next day, the pharmacist manager examining the Complaint Register penalized the pharmacist, canceling his prize for the current month. There was a conflict between a pharmacist and a pharmacist.

Case study no.2

In the pharmacy, an old lady, who received the "Vinpocetine" recipe, said, "Dear, you gave me a fake medicine, I'm sure because I have received this preparation, and he was in a package in blue letters, and it is in green letters! Give me, please, another one, that will be not spurious!" The man, sitting near the old woman, also engaged in dialogue: "Why do you ask? She is required to release you a qualitative medicine! We will bring to light all the scams that they make with us in the pharmacy!". The scandal includes all visitors to the pharmacy, accusing the pharmacist of incompetence, robbery, insanity and scam. The pharmacist did not resist, got out of office and went to the staff room, waiting to calm the spirits of the visitors. The pharmacist manager went out and solved the conflict. The next day, between the pharmacist and the pharmacist manager, there was an open conflict, because information appeared in the media, such as in the "X" pharmacy, falsified medicines being released.



Exercise 10. Get acquainted with the content and fill in a copy of the employment contract between the pharmacist manager and a specialist in the pharmacy. Missing data is arbitrary.

EMPLOYMENT CONTRACT no.____ (model)

""20	
	(locality)
(the name of company or name and surname of empl hereinafter referred to as "Employer", in person of	
(name, surname, workplace)	
on the one hand, and Mr. (Mrs)(name, surname)	
hereinafter referred to as "Employee", on the other hand, pursuant to t 94 of the Labor Code, approved by the Law no.154-XV of 28 March 20 ployment contract by agreeing on the following: 1. The employee is employed as a	=
(function, profession, specialty, qualification) 2. Workplace	
(the name of department, unity)	
3. Work is: a) basic; b) by cumulation.	
4. The duration of the Contract is: a) indefinite; b) determined	
	(the exact period)
5. Probation period (if agreed by the parties)	
	ct period)
6. This employment contract has its effects in:	
a) day of signing; b)	
(date agreed by the parties) 7. Function specific risks	
(work in harmful and / or dangerous of	conditions etc)
8. Employee has the following rights:	
a) rights provided under paragraph (1) of art.9 of the Labor Code;	
b) other rights	
(specify the additional rights agreed by the partie	s)
9. Employee is required:	
a) to fulfill the obligations stipulated in paragraph (2) of art.9 of the	Labor Code;
b) to fulfill other obligations	
(specify the additional obligations agreed by the par	ties)
10. The employer has the following rights:	
a) rights provided in paragraph (1) of Article 10 of the Labor Code;	
b) other rights(specify additional rights negotiated by the partie	
(specify additional rights negotiated by the partie	
11. The employer is obliged:	
a) to fulfill the obligations stipulated in paragraph (2) of art.10 of the	e Labor Code;
b) to fulfill other obligations laid down in the Labor Code, other norm	native acts, collective agree
ments, collective labor agreement and this employment contract, inc	cluding
(additional obligations are specified)	
radundonal Obligations are specified)	

12. Conditions for the remuneration of the employee's work
(salary function or tariff, supplements, bonuses, additions, prizes, material aids and
allowances, including for work performed under
harmful and / or dangerous, labor conditions etc.)
13. Work Regime
(normal or reduced working time, weekly type of work, daily working time)
working time, part-time work, shift work, night work, etc.)
14. Rest regime
(daily rest, weekly rest, etc.)
15. Holiday leave: a) Annual leave:
(duration)
b) additional annual leave(duration)
16. The social insurance of the employee is carried out in the manner and the size provided by the legislation in force.
17. The medical insurance of the employee is carried out in the manner and the size provided by the legislation in force.
18. Specific clauses (if the parties have agreed)
(mobility, confidentiality, other clauses that do not violate applicable law)
19. Benefits that the Employee will receive in return for compliance with the specific clauses set forth in paragraph 18
20. This employment contract may be amended only by an additional agreement signed by the parties, which is attached to the contract and is an integral part thereof.
21. It will be considered as a modification of this employment contract any change that relates to:a) the duration of the contract;b) the place of work;
 c) the specific nature of the work (difficult, harmful and / or dangerous conditions, the introduction of specific clauses according to Art.51 of the Labor Code, etc.); d) the amount of the work remuneration;
e) work and rest regime; f) specialty, profession, qualification, function;
g) the nature of the facilities and the way they are granted.

22. By way of exception, the unilateral amendment by the employer of this employment contract is possible only in the cases and under the conditions provided by the Labor Code. In these cases, the

employee will be prevented from changing the employment contract 2 months before.

- 23. The employee's place of work may be temporarily changed by the employer by moving in the interests of the service or posting to another job in accordance with Articles 70 and 71 of the Labor Code.
- 24. In the event of the occurrence of a situation provided by art.104 paragraph (2) a) and b) of the Labor Code, the employer may temporarily change the place and the specificity of the work of the employee without his consent for a maximum period of one month and without operating the respective modifications in this individual labor contract.
- 25. The transfer of the employee to another work and his / her permutation may take place in strict accordance with the provisions of Articles 68 and 74 of the Labor Code and points 20 to 21 of this employment contract.
- 26. Suspension of this employment contract may occur:
 - a) in circumstances beyond the will of the parties (art. 76 of the Labor Code);
 - b) by agreement of the parties (art.77 of the Labor Code);
 - c) at the initiative of one of the parties (art. 78 of the Labor Code).
- 27. This employment contract may terminate:
 - a) in circumstances not dependent on the will of the parties (art. 82, 305 and 310 of the Labor Code);
 - b) at the initiative of one of the parties (art.85 and 86 of the Labor Code).
- 28. The individual labor disputes that will arise during the duration of this employment contract will be settled in the manner established by the Labor Code and other normative acts.
- 29. This employment contract is drawn up in two copies of the same legal power, one of which is kept by the Employer, and the second by the Employee.

Data identifying the parties to the Contract:

The employer	The employee	
Address	Address	
Tax code	Identity card	
	Released by	
Signature	Personal code	
	Signature	
	Personal Social Insurance Code	

Exercise 11. Legalize the individual material responsibility of a manager in the pharmacy. Missing data is arbitrary.

Annex no. 2 to the RM Government Decision Nr. 449 of 29.04.2004

Full individual material liability contract

No.	""
In order to ensure integrity	
	the transmitted values) aw no.154-XV of March 28, 2003),
hereinafter referred to as Employer, in person	nme of unity) of
acting on behalf of the unit, on the one hand, a	urname, function) nd the employee
acting on behan of the unit, on the one hand, a	(name, surname, function)
hereinafter r	eferred to as the Employee, on the other hand, have
concluded this contract regarding to the follow	
1. Employee assumes full personal liability f by the Employer and undertakes:	for not ensuring the integrity of the values transmitted
a) to have a correct attitude to the transmitted	l values and to take measures to prevent the damage;
b) to inform the employer in time about all ci passed to him;	rcumstances that threaten the integrity of the values
c) to keep in evidence, to prepare and present	, in the established manner, the financial-material re-
to him;	ment and balances of the values that have been passed
him.	ther controls on the integrity of the values passed to
	e integrity of the values that have been passed to him,
the Employer undertakes:	
	ployee and to ensure the integrity of the values passed
to him;	force we good in a the emetarial liability of employees for
, ,	force regarding the material liability of employees for as the internal regulations regarding the way of keep-
· · ·	g), transporting, using in the process of work and car-
	ventory, revision, other controls on the integrity and
status of the values passed to the Employee.	
	npensation for the damage caused to the Employer by
the Employee is carried out in the manner pro	
4. The employee does not bear material liab as in the circumstances provided by art.334 of	pility if the damage was not caused by his fault as well f the Labor Code.
5. This contract commences on the date of i	
	the entire period during which the Employee works
with the values transmitted to him by the Emp	
	n two copies of the same legal power, one of which is
kept by the Employer, and the second by the E	
	ct, its completion or termination shall be effected by
form an integral part thereof.	ne parties, which shall be annexed to the Contract and
Employer	Employee
Address	Address
Signature	Signature
DISHULUIC	DIEHUUUC

PSH

Exercise 12. Legalize the collective material responsibility of a pharmacy department's staff. Missing data is arbitrary.

Annex no. 4 to the RM Government Decision Nr. 449 of 29.04.2004

Full collective material liability contract

No	<u>"</u>
In order to ensure integrity	
(the name o	of the transmitted values)
and according to art.339 of the Labor Code (Law no.154-XV of March 28, 2003),
	name of unity)
(nume of unity)
hereinafter referred to as Employer, in person	on of,
	(name, surname, function)
acting on behalf of the unit, on the one hand,	, and the members of collective,
(name	, surname, function)
(name of section, direc	tion, department, other subdivision)
referred to as the Collective, in person of	
	(name, surname, function)
on the other hand have concluded this conti	ract regarding to the following:

I. Subject of the contract

The Collective undertakes full collective material liability for failure to ensure the integrity of the values transmitted by the Employer, and the Employer undertakes to create normal conditions for work and to ensure the integrity of the values that have been passed to him.

II. General dispositions

- 1. The Employer's decision on the establishment of full collective material liability is made by order (provision, decision) and communicated to the Collective.
 - The order (provision, decision) of the Employer regarding the establishment of collective redemption is attached to this Agreement.
- 2. The team is completed by the principle of free consent. The inclusion of the newly employed employees in the Workforce is taken by considering the opinion of the Collective.
- 3. Team Leadership is exercised by the Leader of Collective.
 - The Leader of the Collective is appointed by the order (the order, decision) of the Employer, after prior consultation with the Collective.
 - In the event that the Leader of Collective is temporarily absent, the Employer shall perform the duties of one of the members of the Collective.
- 4. In the event of a change the Collective Leader or the exit of the Collective by more than 50% of his members, this contract is to be re-opened.
- 5. This Contract shall not be terminated in the event of leaving out of the Group of some of

the employees or of receiving new employees in the Collective. In these cases, the member of the Collective who left the post indicates the date of his departure and the employee who has been received signs the Contract and indicates the date of entry into the Collective.

III. Rights and Obligations of the Collective and the Employer

6. The team has the right:

- a) to participate in the reception of the transmitted values and to carry out the mutual control over the storage, processing, sale (delivery), transportation or use in the labor process of the values that have been transmitted to it;
- b) to participate in the inventory, revision, other controls on the integrity and status of the values passed to him;
- c) to take note of the reports on the movement and balances of the transmitted values;
- d) to ask the Employer, if necessary, to perform the inventory of the transmitted values;
- e) to submit to the Employer proposals for recusal of the Team Leader as well as members of the Collective who, in his opinion, can not ensure the integrity of the transmitted values.

7. The Collective is obliged to:

- a) have a correct attitude to the transmitted values and to take measures to prevent the damage;
- b) keep in evidence, to prepare and present, in the established manner, the financial-material reports and other reports regarding the movement and balances of the values that have been passed to him;
- c) inform the employer in time about all circumstances that threaten the integrity of the values passed to him;
- 8. The Employer is obliged to:
- a) to create the normal conditions for the Collective and to ensure the integrity of the values passed to him;
- b) to take timely measures to detect and eliminate the causes that prevent the Collective from ensuring the integrity of the values passed to him, identify the persons guilty of causing the damage and hold them accountable according to the legislation in force;
- c) to inform the Collective of the legislation in force regarding the material liability of employees for the damage caused to the Collective, as well as the internal regulations regarding the way of keeping, receiving, processing, selling (delivering), transporting, using in the process of work and carrying out other operations with the values passed to the Collective;
- d) to create the necessary conditions for the record keeping and timely reporting on the circulation and balances of the transmitted values;
- e) to examine the question of the merits of the Collective's request to make an inventory of the values passed to him;
- f) to examine, in the presence of the employee, the appeal lodged with him and, if he is motivated, to exclude the respective employee from the members of the staff and to decide, in accordance with the legislation in force, on his / her subsequent activity;
- g) to examine the Collective communications on the circumstances that threaten the integrity of the values passed to him and to take action to remove them.

IV. How to keep records and present reports

- 9. Receiving the transmitted values, keeping records and presenting reports on the movement of these values is done in the established way by the team leader.
- 10. The planned inventory of the values transmitted to the Collective shall be carried out within the time limits provided by the legislation in force.

 The unplanned inventory shall be carried out in the event of a change in the manager of the Collective, in the case of leaving the Collective of more than 50% of its members, and at the request of at least 1/3 of the members of the Collective (brigade).
- 11. Reports on the circulation and balances of the values transmitted to the Collective are signed by the Head of the Collective and, in the order of succession, by a member of the Collective.

The content of the report is brought to the attention of all members of the Collective.

V. Repair of injury

- 12. Reason for material liability of the members of the Collective serves the damage caused to the Employer directly by the Collective.
- 13. The collective and / or a member of the Collective shall be relieved of material responsibility if it is established that the damage has not been caused by the members (member) of the Collective and in the circumstances provided in Article 334 of the Labor Code.
- 14. Determining the amount of damage caused to the Employer by the Collective and its repair is done in the manner established by the applicable law.
- 15. This contract takes effect from the date of signature and its action extends over the entire period in which the Collective works with the values transmitted by the Employer.
- 16. This Contract is drawn up in two copies, having the same legal power, one of which is held by the Employer, and the other by the Head of the Collective.
- 17. Modification of the terms of this contract, its completion or termination shall be affected by a written agreement signed by the parties, which is an integral part of this contract.

Employer	Collective	
Address	Address	
Signature	Signature	
PSH		
Addresses of the members of Collective	Signatures of the members of Collective	

Exercise 13. Indicate the purpose, principles and conditions of certification of pharmaceutical personnel.
Exercise 14. List the documents submitted to the Attestation Commission on the basis of which the certification of pharmacists takes place.
Conclusions and suggestions of the student:
The teacher's signature

TOTALIZATION no. 1 ON HOMEWORK 1 - 5.

The intermediary assessment is organized in writing and in the form of a test to verify the level of studying of the material during the previous laboratory works. All students who have completed all laboratory work and presented the minutes for each work are admitted.

To summarize the material, use the questions from the laboratory work for self-learning, the basic literature, examples of exercises solved during the laboratory work.

PHARMACEUTICAL SYSTEM. COORDINATION OF THE PHARMACEUTICAL SYSTEM.

The purpose of the work: To know the structure, purpose and tasks of the public health and pharmaceutical assistance systems in the Republic of Moldova and the coordination system and the main directions of development of the pharmaceutical system.

Form of training: Seminar and laboratory practical work.

Duration: 4 hours.

Questions for self-learning:

- 1. General notions about system and coordination.
- 2. General features of the pharmaceutical system.
- 3. Coordination of the pharmaceutical system.
- 4. National and international organizations in the pharmaceutical field.
- 5. The pharmaceutical system. Reform of the pharmaceutical system. Development directions.

Exercises for self-solving:

oub	xercise 1. Draw up the g ıblic of Moldova. Highlig gulation and administra	ht the public auth	orities involved in	
	<u> </u>			

	Everaige 2. List the mission and besis tools of intermedianal pharmacoutical everan
	Exercise 2. List the mission and basic tasks of international pharmaceutical organi-
Z	ations (see official websites: https://www.who.int/; https://www.ema.eu-
r	opa.eu/en/about-us; https://www.fda.gov/about-fda/what-we-do;
h	ttps://www.fip.org/who-we-are, etc.).

	2.5	1 .6			Col. Nat.	CII	1.1 6.1
Republic of	Moldova	rate the fu	unctions and attrik pharmaceutical	outions of field.	f the Minist (see the	try of Hea	lth of the
Exercise Republic of https://ms.gov	Moldova	rate the fu in the	inctions and attrik pharmaceutical	outions of field.	f the Minist (see the	cry of Hea official	lth of the website
Republic of	Moldova	rate the fu in the	inctions and attrib pharmaceutical	outions of field.	f the Minist (see the	cry of Hea official	lth of the website
Republic of	Moldova	rate the fu in the	unctions and attrik pharmaceutical	outions of field.	f the Minist (see the	cry of Hea official	lth of the website
Republic of	Moldova	rate the fu in the	inctions and attrik pharmaceutical	outions of field.	f the Minist (see the	cry of Hea official	lth of the website
Republic of	Moldova	rate the fu in the	inctions and attrib pharmaceutical	outions of field.	f the Minist (see the	cry of Hea official	lth of the website
Republic of	Moldova	rate the fu in the	inctions and attrik pharmaceutical	outions of field.	f the Minist (see the	cry of Hea official	lth of the website
Republic of	Moldova	rate the fu	nctions and attrik pharmaceutical	outions of field.	f the Minist (see the	cry of Hea official	lth of the website
Republic of	Moldova	rate the fu	nctions and attrik pharmaceutical	outions of field.	f the Minist (see the	cry of Hea official	lth of the
Republic of	Moldova	rate the fu in the	nctions and attrik pharmaceutical	outions of field.	the Minist (see the	cry of Hea official	lth of the

	. List the basic fund official website htt				dical Devi
ory insurance in	. Indicate the basion medicine. List the	e types of healt	thcare and the	range of servi	ces to wh
1051					

Г

Exercise 6. Study the National Health Strategy 2022-2031 (Drugs and Medical Devices section) and list the proposed development directions in the pharmaceutical field.
Conclusions and suggestions of the student:
deficitions and suggestions of the student.
The teacher's signature

PHARMACEUTICAL ACTIVITY AND ITS AUTHORIZATION. ACCREDITATION OF PHARMACEUTICAL COMPANIES.

The purpose of the work: To learn basically notions about pharmaceutical legislation, the content of pharmaceutical activity and conditions of authorization the exercise of pharmaceutical activity.

Form of training: Laboratory practical work.

Duration: 4 hours.

Questions for self-learning:

- 1. The pharmaceutical system. Reform of the pharmaceutical system. Development directions.
- 2. The law on pharmaceutical activity. Characteristics of pharmaceutical activity.
- 3. Enterprises and pharmaceutical institutions and property types on them.
- 4. Authorization of pharmaceutical activity
- 5. Exercising pharmaceutical activity.
- 6. Basic licensing principles.
- 7. Conditions to obtain the license.
- 8. Updating and issuance of license duplicate.
- 9. Temporary license suspension and withdrawal.
- 10. General notions regarding the evaluation and accreditation of pharmaceutical companies.

Exercises for self-solving:

Exercise 1. Make an Application to the Medicines and Medical Devices Agency to obtain the Pharmaceutical License. Indicate the necessary documents to be attached to the Application.

Exercise 2. Write a Statement to the Medicines and Medical Devices Agency that is attached to the License Application for Pharmaceutical Activity.

	Exercise 3. Indicate the cases and conditions under which the License for exercising
p	harmaceutical activity may be suspended.

р	Exercise 4. Indicate the cases and conditions under which the License for exercising charmaceutical activity may be withdrawn.

No	from

APPLICATION for license issuance

	ioi ncei	iise issualice
	64 License for pha	armaceutical activities
Name and legal form of en	nterprise organizatio	on
Legal address		
	Compa	any tax code
name, su	rname, identification	number of the requesting person;
Phone	Fax	e-mail
Type of activity		
J1 J	in whole or in	part, for which a license is requested
□ pharmacy		- -
□ pharmacy subsidiary		
□ pharmaceutical wareho	ouse	
$\ \square$ within the industrial ph	narmaceutical enterp	orise
□ with the right to work w	with the substances [□ narcotics □ psychotropics □ precursors
$\Box\Box$ without the right to w	vork with the narcoti	cs, psychotropics and precursors
The address of the license	ed activity	
To the application are a	nnexed the next do	cuments:
□ the copy of the propert	ty act of the building	where the licensed activity will take place (Copy of
the extract from the Real I	Estate Register or the	building lease agreement);
□ copies of graduation dip	plomas of the higher	institution or of college in the pharmaceutical field;
□ a copy of the certificate	confirming the contir	nuous education; continuing medical education cer-
tificate;		
□ copies of the employme	nt orders of the head	ds of the pharmaceutical company and their subsid-
iaries.		
I confirm on my own resp	onsibility the observ	vance of the licensing conditions for carrying out
the type of activity for wh	ich I am applying and	d the veracity of the documents attached to the ap-
plication		
Name, surname of the m	nanager of	
organization or person	authorized to	
submit documents (with	n indication of funct	tion)

signature

Annex no. 1 to the Order of MMDA no. A 07 PS - 01. Rg- 04- 240 from 27.11.2017

STATEMENT ON OWN RESPONSIBILITY

By th	STATEMENT ON OWN RESPONSIB	ILIIY		
,	(applicant's name, tax code, address)			
thro	ugh the representative person			
	(name , surname , function	n , no. of o	dentity co	ard)
(mar	ndate) declar	res the t	ruthful	ness of the
subn	nitted information, according to the questionnaire, in ord	er to co	onfirm	compliance with th
	irements of the in force legislation for the exercising of pha			
-				•
		Confor	mable	Comments with
No.	Requirements	YES	NO	reference to- documents prov- ing the answer
1.	Compliance with the location regulations according to point (4) art. 19 of the Law no. 1456 of 25.05.1993 on pharmaceutical activity			
2.	Compliance with demographic norms according to point (5) art. 19 of the Law no. 1456 of 25.05.1993 on pharmaceutical activity			
3.	Assuring the pharmaceutical company with specialists according to the mandatory qualification requirements provided by art.22 of the Law no. 1456 of 25.05.1993 on the pharmaceutical activity and Order no. 553 of 29.12.2006 regarding the approval of the qualification requirements for the pharmaceutical staff.			
4.	Compliance of the pharmacy surface with the norms provided by the Government Decision no. 504 of 12.07.2012 about the approval of the Health Regulation regarding the endowment and exploitation of pharmacies and pharmaceutical warehouse.			
5.	Providing the pharmacy with appropriate equipment and pharmaceutical equipment provided by the Government Decision no. 504 of 12.07.2012 about the approval of the Health Regulation regarding the endowment and exploitation of pharmacies and pharmaceutical warehouse.			
6.	The pharmacy has facilities and equipment specific to the production function, according to the requirements of the Government Decision no. 504 of 12.07.2012 about the approval of the Health Regulation regarding the endowment and exploitation of pharmacies and pharmaceutical warehouse and the requirements of point 2.3 of the Health Ministry Order no. 10 of 06.01.2006 on the supervision of pharmaceutical preparations.			

Date	C'
11214	Signature
Date	orginalui C

Exercise 5. The manager of a pharmaceutical company wrote an Application for Licensing and attached the following documents:

- 1. Copy of State Enterprise Registration Certificate.
- 2. Copy of the extract from the real estate register.
- 3. The copy of the sanitary authorization for the operation of the pharmaceutical enterprise, issued by the territorial sanitary-epidemiological service
- 4. Copy of the authorization of the Permanent Drug Control Committee of the Republic of Moldova for the use of buildings and rooms for activities related to the circulation of narcotic and psychotropic substances and precursors
- 5. The copy of the graduation diploma of the specialized pharmaceutical college
- 6. The copy of the registration for employment as a pharmacist manager

The Medicines and Medical Devices Agency has studied the Application and attached documents and within the time limit set by the law, rejected the Application for the License.

1.	Indicate	how	long	the	decision	to	reject	the	Application	should	be	adopted
2.	Indicate	the re	asons l	behin	d the deci	sior	ı to reje	ct the	Application			
	oviders f	or thei	ir evalı	uation					medical and p er II, Law No.			
Ī												

Exercise 7. Li	ist the criteria of the e	valuation and accreditation s	tandards and describe
the method of asses	ssing the results (Chap	oter II, art. 44 and art. 49 of th	e Order of the Ministry
of Health No. 1289	regarding the approv	al of the Regulation on the e	valuation and accredi-
tation procedure in	n health of 12.11.2018	3).	
		-	
Exercise 8 B	Based on the renort or	n the evaluation of the pharn	naceutical activity of a
	_	he teacher, fill in the tables	_
		e total. Present the accreditat	
_	centage (see exercise		ion decision according
to the obtained per	Appreciation of	The organization's com-	Expert commentary
Chapter	correspondence	ment (points accumu-	(points accumu-
(standards)	•	•	~*
Chartan I	(points)	lated)	lated)
Chapter I			
Chapter II			
Chapter III			
Chapter IV			
Chapter V			
Total points ac-			
cumulated			
<u>r</u>			
		esponsible for health assessn	
2	ities (refer to the WEI	B page of the assessment and	l accreditation author-
ity).			
Canalasiana			
Conclusions a	and suggestions of the	e student:	
		The decelerate	_
		The teacher's signature	9

THE MEDICINES AND OTHER PHARMACEUTI-CAL PRODUCTS AS A STUDY OBJECT OF PHARMACEUTICAL ASSISTANCE. THE MAR-KETING AUTHORIZATION OF MEDICINAL RO-

The purpose of the work: To learn the characteristics of medicines as a study object of pharmaceutical assistance, classifications, development stages, conditions of production, the need, criteria and principles of medicinal products authorization for using them in the medical practice.

Form of training: Laboratory practical work.

Duration: 4 hours.

Questions for self-learning:

- 1. General views on the importance of drugs and their specific features.
- 2. The law on medicines. The main notions and requirements towards medicines.
- 3. Main stages of medicines development.
- 4. Quality assurance standards for medicines: *Good Laboratory Practice (GLP), Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), Good Distribution Practice (GDP), Good Pharmacy Practice (GPP).*
- 5. Names and classifications of medicinal products. Essential medicines.
- 6. Marketing authorization of medicinal products and its goal.
- 7. Stages, principles and criteria for authorization of medicines.
- 8. Registration documentation.
- 9. The Medicines Commission.
- 10. The marketing authorization.
- 11. State Nomenclature of Medicines.

Exercises for self-solving:

Exercise 1. Analyze the State Nomenclature of Medicines (SNM):

- indicate the information relating to the medicines included in SNM;
- select from SNM 2 International Nonproprietary Names of Rx and OTC medicines. Justify the decision of the Medicines Commission on the statutory status.

Exercise 2. Basing on International Nonproprietary Names of medicines determine the assortment of pharmaceutical products (trade names of medicines) authorized in the Republic of Moldova.

Vari-	International Nonproprietary Names	Vari-	International Nonproprietary Names of medi-
ant	of medicines	ant	cines
1	Diclofenac, Ibuprofen, Indometacin	7	Piracetam, Vinpocetin, Gingko Biloba
2	Ciprofloxacin, Norfloxacin, Ofloxacin	8	Terbinafil, Fluconazol, Ornidazol
3	Omeprazol, Famotidin, Lansoprazol	9	Enalapril, Lisonopril, Ramipril
4	Ampicilin, Azitromicin, Cefalexin	10	Simvastatin, Atorvastatin,
			Rosuvastatin
5	Carbamazepin, Acid valproic,	11	Metoprolol, Atenolol, Bisoprolol
	Clonazepam		
6	Diazepam, Alprazolam, Zopilclonum	12	Loratadin, Cetirizin, Desloratadin

4	Ampicilin,Azitromicin,Cefalexin	10	Simvastatin, Atorvastatin,
		11	Rosuvastatin
5	Carbamazepin, Acid valproic, Clonazepam	11	Metoprolol, Atenolol, Bisoprolol
6	Diazepam, Alprazolam, Zopilclonum	12	Loratadin, Cetirizin, Desloratadin
	Exercise 3. Indicate the main areas	of use	of the List of Essential Medicines and specify
			s development (see Order of the Ministry of
	=	_	ation and the List of Essential Medicines of
	2.2007).	J	
	Evension 4 List the wights and attail	h.,.+: a -	as of the Medicines Commission (see the Or
	9		ns of the Medicines Commission (see the Or-
	Commission No. Rg04-000006 of 12		the organization and operation of the Medi-
CITIES	Commission No. Ng04-000000 01 12	01.2	022).

Exercise 5. Look the structure and complete the Report on the Assessment of the Medicinal Product File presented for primary authorization. Evaluation report of quality (Modules 2.3, 3) For the authorization of medicine (trade name, dosage form, dose, packaging) 3.2.S. Active substance 1. Origin of active substance (manufacturer, presence of GMP certificate or CPP, notarial authenticated) 2. Quality of active substance (presence of specification, quality documents) 3. Stability (according with the norms of specification, conclusions) Period of validity of active substance **Storage conditions**

3.2.P. The pharmaceutical product
 Composition (active substance and excipients), the batch size
1.1. The medicines contains or is obtained from genetically modified organ-
isms (module 1.6.1)
2. The manufacturer/manufacturers responsible for production (GMP certifi-
cate for each manufacturer, manufacturing authorization, notarial authenticated)
3. The quality control (specification, certificates of batches analyses)
3.1. The agreement between the holder and the manufacturer (when the holder and the manufacturer are not the same person)
noider and the mandiacturer are not the same person)
3.2. Letter of compliance attesting the ownership of the holder and the man-
ufacturer to the same group of companies (when both the holder and man-
ufacturer are members of the same group of companies)
4. Packing (the type of primary and secondary packaging)

5. Stability (according with the norms of specification for all manufacturers, conclusions)
5.1. Tested batches (industrials, pilot)
5.2. In real time (period)
5.3. In accelerated time (period)
5.4. After the first opening (when is the case)
Davis de Caraliditas e Caratina ambatana
Period of validity of active substance
Storage conditions
5.5. Objections
5.6. Conclusions
The expert:

Exercise 6. Complete the Marketing Authorization of Medicinal Product. Indicate the documents on which the MA is issued.

MINISTERUL SĂNĂTĂȚII AL REPUBLICII MOLDOVA



MINISTRY OF HEALTH REPUBLIC OF MOLDOVA

AGENȚIA MEDICAMENTULUI ȘI DISPOZITIVELOR MEDICALE

MEDICINES AND MEDICAL DEVICES AGENCY

CERTIFICAT DE ÎNREGISTRARE A MEDICAMENTULUI MARKETING AUTHORIZATION OF MEDICINAL PRODUCT

În baza ordinului MS RM (nr. din "	"20)
In accordance with order of MoH RM (nr. from	""20)
se decide autorizarea produsului:	
has been decided the registration of product	

Denumire comercială:	
Name:	
Formă farmaceutică, doză, mărimea amba-	
lajului:	
Dosage form, strength and package size:	
Compoziția:	
Composition:	
Deținător al Certificatului de Înregistrare:	
Marketing Authorization Holder: Producător:	
Manufacturer:	
Clasificarea ATC:	
ATC classification: Termen de valabilitate:	
Shelf life:	
Număr de înregistrare, data emiterii:	
Registration number, and date of issue: Anexa1	Anexa 2
Rezumatul caracteristicilor produsului și prospect sau	
Instrucțiunea pentru administrare	Information on the labeling
Summary of the product and patient information leaf-	injoi mation on the labeling
let	
Instructions for administration	
Parametrii de calitate ai produsului sunt cei prevăzuți îi	n documentatia care a stat la baza eliberării prezentului
Certificat de Înregistrare.	,
The quality of the product is that which is stipulated by	the documentations which were the basis for giving
this	
particular Marketing Authorization.	Ŷ
Orice modificare a datelor specificate în Certificatul de raportată și aprobată de Agenția Medicamentului.	inregistrare sau in documentația de autorizare trebuie
	ng Authorization or documentation must be reported to
the	ig fluction in a documentation must be reported to
Medicines Agency and have its approval.	
Prezentul Certificat de Înregistrare are o valabilitate de	
	mission and doesn't guarantee the import of the medici-
nal product.	
6 IV	
General Manager	
Conclusions and suggestions of the stud-	ent·
gonerations and suggestions of the state	

The teacher's signature

QUALITY ASSURANCE OF MEDICINAL PRO-DUCTS. STATE CONTROL OF THE QUALITY OF DRUGS. PHARMACOVIGILANCE SYSTEM.

The purpose of the work: To study the basic principles regarding the state quality control of different groups of medicines, the working procedures on documenting the organization of state control, the basic principles regarding the assurance of the pharmacovigilance service.

Form of training: Seminar and laboratory practical work.

Duration: 8 hours.

Questions for self-learning:

- 1. Pharmaceutical legislation on the protection of rights of medicines consumers.
- 2. General characteristic of medicines quality assurance system.
- 3. Task and functions of the Laboratory for Quality Control of Medicines.
- 4. State Quality Control of Medicines.
- 5. Types of State Control and their feature.
- 6. Documentation for the quality of medicines.
- 7. Surveillance and pharmacovigilance of medicinal products. Method of organizing the monitoring of adverse effects of medicines.

Exercises for self-solving:

Exercise 1. Indicate the authorities of the central public administration with attribu-
tions in the field of consumer protection (see the Consumer Protection Law No. 105 of
13.03.2003) and specify the state bodies of public health supervision.
Exercise 2. Indicate the safety information reported to the Medicines and Medical Devices Agency and how to submit petitions online as a consumer of medicines.
vices rigerity and now to submit petitions online as a consumer of medicines.

drawals a	nd falsifica	ation of medicines, subs	stitution with similar p	complaints, returns, with- products of pharmaceutical,
paraphar 	maceutica	l and medical devices a	t each stage of their c	irculation.
		-		ample and performing state
		apling Act for the state	control of medicinal	products manufactured by
an muige	iious iiiaiii	macturing company.		Annex no 4
NI -	C		to the Regulation on S	tate Quality Control of Medicines
No	from _			Medicines Agency Laboratory for Medicines
		.	уром рож	Quality Control
		for taking the average san	REQUEST upple and performing state	control
		of manufactured medicine		
			_ requests sampling and p	performing
		(the name of enterprise		
	state c	ontrol of manufactured me	dicines / raw materials, at	the enterprise.
Attached:				
1. 2		quality certificate from the customs declaration -1 cop		
3.	copy of the	completed customs invoice	e (in the case of import) - 1	1 copy or invoice for shipping
* forther		oort in the case of procurem materials used in the manu		
- joi the co		- manetinis usea in ine manii		
	nici oi oj ruw	materials asea in the mana,	<i>ματίατε απά γ οι φτερατάτι</i> ο	on of medicaments

	fo	r the sta	ite cor	ntrol of r		al produ		ufacture	d in the	Repub	lic of N	Moldova	1
		member manage											
				r the qua					_				
Repr	esenta	tive of M	[A						_				
							e contro	within th	_ 1e c				
pany													
No	Code of MP	Trade name of MP	INN	Dosage form	Dose, package	Stored quan- tity	Manu- facturer	Registra- tion no in SMN	Analyti- cal doc- ument	Batch	Ex- piry date	Sam- pling quan- tity	Returned quantity
	1	2	3	4	5	6	7	8	9	10	11	12	13
Dhom	magiat	managa											
		manage respons		r the qua	lity								
		tive of M											
Joine	_			ending o									
, .				•			, .	iality cer			_		
							•	iality cer and c) Ai				nufacti	arer and
orga	потер	Juc Con	iti Oi, j	packagi	iig aiiu	tile illa	ai Kilig,		•				Annex no
				Minictr	v of Ho	alth fro	ım tha I	to the Republic	-		te Qualit	y Control (of Medicines
				MIIIISCI	y of fie			ES AGE		uova			
				Lal	borator	v for M	edicines	Quality	Contro	l		•	
					_			/1 str., pho					
				Quality	certific	ate no.	fror	n		z			
Nan	ne							Bat	ch	z			
Prod	lucer:												
	ented a		,	by	-			1		1			
		pac cording to	_	sampied i	rom	stored	ı раскаде:	s, used	, returne	ea	•		
N	_			riteria				AD limits			Re	esults	
1.													
2.													
3.													
4.													
Conc	clusion	•											
30110		-											

Chief of Laboratory for Medicines Quality Control

Ministry of Health from the Republic of Moldova MEDICINES AGENCY

Laboratory for Medicines Quality Control

MD 2028 Chişinău, Korolenko 2/1 str., phone.727203

REGISTER

of medicines, which distribution is authorized on the basis of quality certificates of the manufacturer and organoleptic control, packaging and the marking

no.	Regis- tration no	The name of medicine	Batch	Quantity	Producer	Certificate from the producer	Expiry date	Analytical document
1.								
2.								
3.								
4.								

The aspect, packaging and marking of the samples correspond to the analytical document

Chief of Laboratory for Medicines Quality Control

 $\label{eq:Annex} Annex\,no\,3$ to the Regulation on State Quality Control of Medicines

Ministry of Health from the Republic of Moldova

MEDICINES AGENCY

Laboratory for Medicines Quality Control

MD 2028 Chişinău, Korolenko 2/1 str., phone.727203

	Analysis bulletin no. fro	m	,
Name		Batch	,
Producer:			
Presented at	by		
Recieved	packages, sampled from stored pack	ages, used, returned	·
Analysis accord	ding to AD:		
No	Criteria	AD limits	Results
1.			
2.			
3.			
4.			
<u> </u>		1	1
·			

Chief of Laboratory for Medicines Quality Control

		_			rees with LM				
ate quality of th		• •	ious pr	oble	em). Specify t	the documer	nts require	ed to per-	
form the State A	Arbitration	Control.							
								ļ	
F	7. Caralata		- C 1 l	UC A E	PERV NORICE	A DOUTE CLD		C / 11	
of effectiveness	•				FETY NOTICE			,	
ON SIDE EFFEC									
tional Drug Enl									
https://amdm.g	_	_			•	•		10110 (000	
. ,,	, ,					,		Annex no. 2	
						to the Order o	of the Ministi no. 358 of M		
SAFETY NOTICE	ABOUT SIDE	EFFECTS /	or lack	of eff	ectiveness of r				
	cal produ	cts (underl	ined / c	heck	solution accep	otable answer	.)		
			The sr	confid ected	lentiality of the ider	ntity data mention	ed in this form	will be re-	
PATIENT INFORM	ATION				The side effect c	ougod.			
Name or initials:					atient's death, to		me / date / n	nonth /	
* Date/ month / yea	ar of birth /Age	<u></u>			r)	oo maroacoa (c.	/ uute /	1011011 /	
* Sex: □ M □ F					endangering the p		: ::::::::::-		
* Weight (kg)	_ * Height (c	cm)		☐ hospitalization or prolongation of hospitalization; ☐ important or lasting disability / disability					
* Allergy (to indicat				☐ Developmental anomaly / congenital malformation					
, , , , , , , , , , , , , , , , , , , ,	□ Not			☐ healing without sequelae (consequences);					
The diagnosis:				☐ state without dynamics ☐ unknown					
					ther, indicate				
Treatment: □Outpa	itient UStation	ary ⊔ Self-m	edication						
№ ambulatory card	or the observa	tion form			he lack of efficac	cy of the drug (LE)		
* Description of si	de effect (SE):	:		•	ne of initiation SE	•			
					_ :_				
			Date /	time/	of healing SE	// : _			
			* Dur	ation:					
* MEDICINAL P	RODUCT (PM)	suspected (of having	a sid	e effect (SE) / La	ick of efficacy o	of the given d	rug (LE)	
Commercial		<u>-</u>		Interr	national Joint	-	_		
Name (DC)				Nam	e (ICC)	C : N /	T		
The manufacturer			Count	ry		Series No. / date of man- ufacture			
Cause of using the			Dose /	dav	The beginningt	End of PM			
remedy	The admin-	Single dose	(nicte	-	of PM admin- istration	administra- tion	Date of de-	The dose that pro-	
(disease or pathological conditions)	istration	omgre dose	eral])	date / month /	date / month	tection SE	duced SE	
1 - Brown containing					vear	/ vear		1	

year

/ year

	1							1		
					/ /		/ /	/ /		
OTHER MEDICINES	Sadminister	ed concomita	ntly (at th	e sa	me time) 🗆	no [⊐ yes			
Commercial Name (DC)	Interna- tional The ad- Loint ministra- Single			Dose / day (nictemeral)		ne beginningt of I administration late / month / year	End of PM administra- tion date / month / year	Cause of using the remedy (disease or pathologi- cal condi- tions)		
							/ /	/ /		
							/ /	/ /		
							/ /	/ /		
					1		/ /	/ /		
Measures taken ☐ Suspected dru	_				lowed by re	gre	e suspected med ssion of the adv seen stopped			
☐ The dose of th	e suspected d	lrug was reduc	ed				or worsening of nistration of the			
☐ Drug administ	tration has be	on discontinu	nd concur		been determined? ☐ yes ☐ no ☐ PM not administered					
rently	ration has be	en discontinue	eu concur-		repeatedly RA improving drug therapy (if it was necessary)					
☐ Received treat treated for (if										
□ without treatr □ Other, to be in										
RELEVANT ADD	ITIONAL INF	ORMATION								
	dney or liver						ditions, past dru regimens, harr			
	t, to indicate a						the administrat lso the date of tl			
 Additional data on the adverse effect (clinical examinations, paraclinical examinations, radiological examinations, relevant laboratory tests (if possible) concentration of the drug in the blood and tissues in case of death of the patient (cause of death, if the death is related to the administration of the suspected medicinal product RA, autopsy data) Describe the pathological changes, indicating the norms in brackets. 										
 Relevant data t 	to justify the l	ack of efficacy	of the susp	ecte	d medicinal p	rod	uct (when is ap	plicable).		
* Physician or othe	er person wh	o has registe	red SE							
*NS:										
* Specialization: * Workplace:										
* Address of the ins	titution:									
** Phone:		'*Fax:			*e-mail:					
* Date of filing:		- 0.11			c mun.					
							ance and ratio		dicines	

Phone: 88-43-38, 73-70-02; Fax: 88-43-38; e-mail: farmacovigilenta@amed.md

Fields marked with * are mandatory. To the extent that you have availability please fill in the other fields as they are important in themselves!

** Fill in at least one contact information

Please fill in the fields that request information about your specialty, job, e-mail address, telephone, fax. These data are requested so that you can be contacted if additional information is needed about the adverse reaction or the evolution of the patient's condition.

A confirmation of receipt followed by the evaluation of the adverse reaction will be sent to you by e-mail or fax.

The patient communicates

$\begin{array}{c} \textbf{COMMUNICATION ON SIDE EFFECTS OF MEDICINES AND OTHER} \\ \textbf{PHARMACEUTICAL PRODUCTS} \end{array}$

The confidentiality of the identity data mentioned in this form will be respected !!!

The connu	entianty	of the identity data in	lentioned	1 111 (1115 10	orm will be respected :::		
PATIENT INFORMATION							
* Name or initials:	* C	- DM - DF * Maia	المد (المد)	* 1	Letalet (com)		
* Date/ month / year of birth /Age_ City (District) The villag	sex	n ⊔r weig Phone numbe	nt (kg) ₋ er	" F	leight (cm)		
Habits: □ smoking □ Drinking	Other:		Pregnai	ncy □			
* Allergy (to indicate): ☐ Yes _			□	l Not			
Diseases suffered by the person:							
* Description of side effect		/ hour of occurence SE			us do you consider this SE _:		
(symptoms, how it occured):		_/ : hour of curing SE:		Light			
		nour of curing SE: _/ :_			it, but did not affect physical activity fect physical activity		
		_, Duration:	□ S	erious to	see a doctor		
				equired h aused de	ospitalization		
SUSPECTED MEDICINE(S):			100	auseu ue	atii		
* Medicine Trade Name							
Manufacturer / Country / № series /	/ data of	manufacturo (if you h	avo infor	mation			
			ave IIII0I	mationj			
* Dose frequency, duration, route (eg: 1 tab	olet, 3 dly, by mouth)					
Cause of using the remedy (disease or pathological conditions)							
Start of administration M (date / mo				Duratio	on of administration M (days)		
year)// * The medicine was previously use		nonth / year)// _ Tyes (specify if it was					
* OTHER MEDICINES administer			-	□ no □	ves		
If Yes, please specify which							
medicines							
* Measures taken to improve SE			* How	does the	person feel at the time of complet-		
☐ Suspected drug was discontinu☐ The dose of the suspected drug		ducad	ing the card:				
☐ Drug administration has been			8				
☐ Received treatment for SE sym			☐ Does not have the symptoms described				
for (if you have any information			□It still has symptoms, but it feels better				
without treatment					otoms, the condition has not im-		
☐ Other, to be indicated			proved		n has worsened		
* Measures to improve SE were u		,	 ☐ The condition has worsened ☐ The person died 				
□ physician □nurse□pharmacist□		ighthers					
* The person who fulfills the form	n:	Communicated the	adverse	reaction	1:		
Patient or drug userThe patient's relative		Name:					
□ Physician		Address :					
pharmacist		** Phone:					
□ Nurse		**e-mail:					
Other specification		* Filling date:					
		t at: Department phar 0-02; Fax: 88-43-38; e			nd rational use of medicines gilenta@amed.md		
Fields marked with* are mandatory. To the turn! ** Fill out at least one of your contact			, please fi	ll in the ot	her fields as they are important in their		
Conclusions and sugge	estions	s of the student:					
		The	teache	er's sign	nature		

INDUSTRIAL PRODUCTION OF MEDICINES. SUPPLY OF MEDICINES. THE PHARMACEUTICAL WAREHOUSE, ITS TASKS AND FUNCTIONS.

The purpose of the work: To acquire the conditions of industrial production of medicines, the development and approval of the Analytical Normative Documentation, the content of the supply cycle of medicines, the order of import, the task, the functions and the structure of the pharmaceutical warehouse.

Form of training: laboratory practical work

Duration: 8 hours.

Questions for self-learning:

- 1. General requirements for medicines production.
- 2. Rules of Good Manufacturing Practice (GMP).
- 3. The organizational structure of the industrial pharmaceutical enterprise.
- 4. Nomenclature of technological documentation for the manufacture of medicinal products.
- 5. The general feature of the drug delivery system. Supply cycle.
- 6. Characteristics of medicines import in Republic of Moldova.
- 7. Authorization and order of import of medicines in the Republic of Moldova.
- 8. Contracts of supplying and delivering of medicines.
- 9. Pharmaceutical warehouse, tasks and functions. The organizational structure.
- 10. Space, endowment and requirements for the pharmaceutical warehouse. Rules of Good Distribution Practice GDP.
- 11. General principles of storage of medicines at the pharmaceutical warehouse.
- 12. Receiving pharmaceutical products from suppliers.
- 13. Order of delivery of pharmaceutical products from the warehouse.

Exercises for self-solving:

Exercise 1. List the necessary means for applying the GMP rules (see the Order of the MMDA No. 24 regarding the approval of the guide on the Good Manufacturing Practice (GMP) of medicines for human use from 04.04.2013).

Exercise 2. Specify the component parts of the standard dossier of the place of manufacture provided for in the Regulation on the authorization of the manufacture of medicinal
facture provided for in the Regulation on the authorization of the manufacture of medicinal products.
products.
Exercise 3. List the manufacturers of medicines for human use in the Republic of Mol-
dova GMP certified by MMDA.
Exercise 4. List the documents required for the industrial production of medicines
specifying for each the order of elaboration (obtaining) and their content.

Exercise 5. Specify the		equired by	the ec	onomic a	gent it	receive the in
port authorization for med	icai products.					
	.1	.1 .		6.1		. 11
Exercise 6. Complete	the request for	the impor	t transa	action (th	e requ	ired data will b
arbitrarily taken).						
				to the Regu	lation or	Annex no. n Authorization Mod
		.1	,	of th	e import	e-export of medicine
1.Importer, address		8. REQUES				rmaceutical product
Importer, address		O. REQUE		ORDINAR		
2. Reg. No. on _/	/_/_	0.0.11		0	n/_	_/
3. Manufacturer, address		9. Seller, a	iaaress			
				T		Seller country
4. Country of destination Mo	oldova MD	11.Expiry	date date	Request		According to
				cording t	o tne	the authoriza-
5. Manufacturing country				_/_/_		//
6. Custom 7. Code of		12. Transa				
custom ∟		Buying /	Selling	3	L	
		13. Curen	cv of pa	vment		
14.Name and characteris-	15.Code of	16. Unit	17.	18.	19.Va	lue
tics of goods	goods	of the	Quan-		Thou	sand curency
		measure	tity			
20. Grounds for the applicat	ion for authori-	22.				
zation						
		DO NOTIO	COMPLE	- mp		
Agreement no on Specification (annex) no		DO NOT (JOMPLI	ETE		
21. Director of importer con	npanv	23.				
	y					
T I DIRECTOR						
Function DIRECTOR		DO NOT (COMPLE	ETE		
Signed and authorized Date	/_/_					

rehouse and a	Make a Pharmaceutical Supply Agreement between a pharmace manufacturer of medicines from abroad.	ut
_		

Exercise 8. Complete the specification of the imported products with the indication of the manufacturer, the country of origin, the number and the date of registration of the product (collect necessary information from the State Nomenclature of Medicines).

	Denumirea Comună Internațională International Nonproprietary Name	15												
Anexa m.2. la Regulamentuli on privire la modali de auforizare a importuli aregordului de medicamente, alle produsa s'armanestine, partifarma estri co	Cod ATC	14												
ia Regulamer autorizare medicamente, al	Data inregistrare in RM date of registration	13												
	Nr. înregistrare în RM number of registration	12												
	Firma producătoare Manufacturing company	11												
	Ţara producătoare Country of origin	10								←			N.P.P., semnatura/ sign	
200	Suma, valuta Value, currency	6							00,00	Cumpărător /Buyer	a)			
	Prețul, valuta Price, currency	8							EURO	Cumpăr	Denumirea Name	Adresa / Adress	Director	stamp
din from din from	Cantitatea Quantity	7							al to be paic					
	Divizare Package	9							chitare/ Tot					
	Dozage Dosage	5							otal pentru achitare/ Total to be paid EURO					
nexa) nr. lendum)nr. cul nr. ict nr.	Forma medicamentoasă Pharmaceutical form	4							T0(
Specificația (anexa) nr. Specification(addendum)nr. la contractul nr. to the contract nr.	Denumirea comercială a medicamentului Trade name of drug	3							***************************************					
	Codul vamal Customs code	2								k			NPP, semnatura/ sign	
	Codul medicamentului Medisines code	1								Vînzător / Seller	Denumirea/Name	Adresa / Adress	Director	gramp
	Nr.		1	2	3	4	5	9						



MINISTRY OF HEALTH FROM REPUBLIC OF MOLDOVA MEDICINES AND MEDICAL DEVICES AGENCY

IMPORT AUTHORIZATION

1.Importer, address				8. REQUEST for IMPORT Authorization ORDINARY						
2. Reg. N	No on//									
3. Manufacturer, addres	9. Selle	r, addre	ess							
			10. Sell	ler coun	itry					
4. Country of destination	n Moldova MD		11.Exp					_		
			date			ding to	the	the authori- zation		
5. Manufacturing countr	У					uest _/_		//		
6. Custom 7. Code of		12. Trans			ı					
custom		Buying /	' Selling	3			L			
		13. Curen	cy of pa	yment						
14.Name and charac-	15.Code of	16. Unit		17. Qua	an-	18.	-	Value		
teristics of goods	goods	of the m	easure tity				Th	Thousand curency		
20. Grounds for the applie	cation for authoriz	zation	22. THE MEDICINES AGENCY							
Agreement no on			N.S.							
Specification (annex) no			Function General Manager							
			Data / /							
21. Director of importer of	company		23. Import-Export Section of Medicines, Other Pharmaceuticals and Parapharmaceuticals							
Function DIRECTOR			N.S.							
Tunction DIRECTOR		-		n Head	Secti	ion				
Signed and authorized D	ate//					_	_	,		
						_ 1	Date	/		
24. Terms and condition	ns To be reviewe	d at 00.00.2	200X							
		ımanian				11.11				
	tne Stai	te Nome	encia	ture o	тме	alcines.				

Exercise 10. Complete the Request for taking the average sample and performing state control and the Sampling Act for the state control of imported medicinal products

 $\begin{array}{c} Annex\ no.4\\ to\ the\ Regulation\ on\ State\ Quality\ Control\ of\ Medicines\\ \textbf{Medicines}\ \textbf{Agency} \end{array}$

				ting the a	0	ge sai f imp	orted	and per medicir	formin nes	g stat	e cor	itrol	edici	nes Q	uality	Conf	crol
	(t	he na	ame of enterprise		quest	s sain	piiiig	anu per	10111111	ig Sta	te co	1111 01	01 1111	porte	u iiie	uiciii	53
No		fr	e import authori om														
2. c 3. p	copy o projec	of Inv	customs declara oice – 2 copies; he Sampling Act Il document of th	for the s	tate c	ontro									ıcts		
Ma	nage	r															
			for t	he state		rol o	f imp		ıedicir				e Qual	ity Cor		nex n	
Com	mitte	e me	mbers:		11 0111				_20								
			nager														
_			e of MA oles of medicina				_		(depe	nding	g on t	he ca	se)				
									•								
No	Code of MP	Custom code	ade name of MP	Dosage form	Dose	Package	Stored quantity	Price, currency	Total, currency	oducing country	oducing company	mport authorization	custom declaration	Batch	Expiry date	mpling quantity	Returned quantity
)	Tra				St	Ā	Ţ	Pro	Pro	No. of ir	No. of			Sar	Ret
								m · •									
_			import-export o				_							ıtical:	S		
			e of MA														

Exercise 11. Following the control of the pharmaceutical products received on a medicinal product (at the teacher's indication) from the imported ones, quantitative divergences were found. Draw the appropriate act.

	Appro	ved by M	inistry of	Health from the Rep	ublic of M	Moldova order r		1 F- 01
				s Department from th				
	C 1 1							
Name	e of pharmaceutical unit _					"ADDD OLID	D.//	
						"APPROVE		
						rmacist ma "		
		ח	ocumo	ent No			_ 20	
		from "	"	20				
	to detect qualitative	or qua	— —— ntitativ	e divergences in	the re	eceipt of goo	ods	
	4	_				P - C		
Comr	nittee members							
In the	e presence of representati	ive						
(auth	orization No. from "	") received	goods	and establi	ished:	
ì. Sı	upplier and addressupplier invoice No from "_ greement of supply No fi							
2. Sı	applier invoice No from "_	"	_20	-				
3. A	greement of supply No fi	com ""	2	0	c			
4. D	elivered goods "_" 2	0 in	wagon,	containers, auto,	from			_ units
5 G	goods, brut to weight oods arrived at "_	"	20	transported to t	he nha	rmacv" "	2	20
o. a.	_ units of goods.		_ 20		ine pina	- Indey		,
		ritten "	"	20				
7. R	rade document no we ceiving the goods: beginnir	ıg: hour	_ min.	"_" 200	end:	$hour _ min$	"_" _	
20		_						
	ondition and contents of sea							
	corage conditions until recei			ada				
10. Մ	escription of the exterior ap cate of external marking of g	pearand oods	te or go	ous				
	eweighted goods (where) _							
	etailed description of the da							
	onclusions of committee:							
	_			ent of committee				
				ers				
		present					-	
15. R	esult of receiving / the value	of the	goods is	s indicated in pur	chase p	rices Divergences (incuffi	
				Quantity		ciency, rebut, o		
No	Name	M.U.	Price	According to the in-		etc.)	Amou	Note
				voice	Real	Quantity	nt	
							-	
	Conclusions and suggesti	ons of	the stu	dent:				
				The teacher's	signati	ure		

TOTALIZATION no. 2 ON HOMEWORK 6 - 10.

THE OUTPATIENT PHARMACEUTICAL CARE SYSTEM. THE COMMUNITY PHARMACY, ITS TASK AND FUNCTIONS.

The purpose of the work: Studying, analyzing of the existing situation and acquiring the basic principles of the pharmaceutical assistance organization, the principles and norms of extending the pharmacy chain and the location of pharmacies and their subsidiaries.

Form of training: laboratory practical work

Duration: 8 hours.

Questions for self-learning:

- 1. Characteristics of the population's pharmaceutical assistance system.
- 2. Basic principles of organizing the activity of community pharmacies.
- 3. Location and expansion of the pharmacy chain in the Republic of Moldova. Principles and enlargement rules.
- 4. Types of pharmacies.
- 5. The community pharmacy. The foundation of the pharmacy, its task and functions.
- 6. Requirements for the space of the pharmacy rooms and their location plan. The endowment of pharmacy.
- 7. Sanitary regime in pharmacy:
 - a) sanitary requirements for rooms and equipment;
 - b) sanitary requirements for the cleaning of the rooms and the pharmaceutical equipment;
 - c) requirements for the personal hygiene of pharmacy workers;
 - d) sanitary rules for preparing, transporting and storaging purified water and water for injection;
 - e) sanitary requirements for the preparation of medicines under aseptic conditions and non-sterile medicinal forms.
- 8. Organizational structure of community pharmacies. Subsidiaries of pharmacies.
- 9. Principles of organizing the storage of medicines and other pharmaceuticals in the community pharmacy.
- 10. Classification of products released from the pharmacy.

Exercises for self-solving:

Exercise 1. Select:

- a) Care factors that serve as a basis for the rational placement of community pharmacies.
- b) Additional factors to be taken into account in the planning, expansion and location of community pharmacies.
- c) Other (nonessential) factors in the expansion and location of pharmacies.

,	, ,	<u> </u>
	Variant 1.	Variant 2.
	1. Number of patients with diabetes	1. Density of the population
	2. Economic significance of the locality	2. Number of residents related to a pharmacy
	3. Presence of medical institutions	3. Number of preschool children
	4. Number of residents related to a pharmacy	4. Existence of the shopping center
	5. Tourist significance of the locality	5. Number of patients with oncological diseases
	6. Density of the population	6. Presence of medical institutions

Variant 3.	Variant 4.
1. Social-economic significance of the locality	1. Average age of district residents
2. Number of pharmacists per 100 thousands resi-	2. The number of people related to a pharmacy
dents	3. Social-economic significance of the locality
3. Presence of medical institutions	4. Number of pharmacists per 100 thousands resi-
4. Number of retired people from the locality	dents
5. Tourist significance of the locality	5. Distance and accessibility to the district center
6. Density of the population	6. Number of pre-school institutions
Variant 5.	Variant 6.
1. Tourist significance of the locality	1. Number of pharmacists per 100 thousands resi-
2. The number of people related to a pharmacy	dents
3. Density of the population	2. Presence of medical institutions
4. Average age of district residents	3. Tourist significance of the locality
5. Economic significance of the locality	4. Density of the population
6. Number of medical institutions	5. Number of the shopping centers
	6. Number of retired people
Variant. 7.	Variant 8.
1.Number of newborns	1. Number of children up to 7 years old
2. Density of the population	2. Density of the population
3. Number of pharmacists per 100 thousands resi-	3. Number of pharmacists per 100 thousands resi-
dents	dents
4. Presence of medical institutions	4. Tourist significance of the locality
	5. Presence of medical institutions
5. The number of people related to a pharmacy	
6. Distance to the nearest pharmacy	6. The number of people related to a pharmacy
Variant 9.	Variant 10.
1. Average age of district residents	1. Presence of medical institutions
2. Economic significance of the locality	2. Density of the population
3. The number of people related to a pharmacy	3. Number of patients with oncological diseases
4. Tourist significance of the locality	4. Number of pharmacists per 100 thousands resi-
5. Density of the population	dents
6. Number of pharmacists per 100 thousands resi-	5. Economic and geographic significance
dents	6. Distance and accessibility to the district center
Variant 11.	Variant 12.
1. Density of the population	1. Number of patients with hypertension
2. Number of medical institutions	2. The number of people related to a pharmacy
3. The number of people related to a pharmacy	3. Density of the population
4. Number of tuberculosis patients	4. Number of pharmacists per 100 thousands resi-
5. The distance between the planned pharmacy	dents
and the pharmacy with the production section	5. Tourist significance of the locality
6. The presence of shopping centers	6. Number of educational institutions
6. The presence of shopping centers	6. Number of educational institutions
a)	
-	
b)	
°)	
c)	·····

Exercise 2. Determine the average pharmacy serving radius at the following distances

from nearby pharmacies: __ km; ___ km; ___ km; ___ km.

Variant		Distance								
varialit	I	II	III	IV						
1	0,5	0,8	0,3	0,6						
2	0,65	0,7	0,4	0,8						
3	0,7	0,25	0,5	0,7						
4	0,3	0,5	0,6	1,0						
5	0,8	0,3	0,8	0,5						
6	0,4	0,6	0,3	0,3						
7	0,25	0,8	0,5	0,5						
8	0,5	0,7	0,3	0,65						
9	0,5	1,0	0,75	0,7						
10	0,8	0,5	1,2	0,3						
11	0,7	0,3	1,0	0,8						
12	0,3	0,9	0,8	0,4						

Exercise 3. The population of a city is ______ thousands of residents. Determine the number of pharmacies that need to work in this city.

Variant Number of residents Variant Number of residents

	110111201 0110010100		
1	26,3 thousands	7	25,1 thousands
2	39,6 thousands	8	28,6 thousands
3	21,3 thousands	9	22,6 thousands
4	29,8 thousands	10	24,3 thousands
5	37,5 thousands	11	20,3 thousands
6	36,4 thousands	12	26,2 thousands

Exercise 4. The	_ population is	thousands resid	dents, in-
cluding thousands of rural populati	on. In	there are	phar-
macies, including in rural areas. Pe	erform the analysis	of population assura	ince with
pharmacies and make the respective concl	usions.		

- 1. Population of Edinet district is 25,4 thousands residents, including 13,9 thousands in rural areas. In Edinet district there are 28 pharmacies, including 7 in rural areas.
- 2. Population of Cahul district is 36,8 thousands residents, including 12,8 thousands in rural areas. In Cahul district there are 20 pharmacies, including 14 in rural areas.
- 3. Population of Drochia district is 75,5 thousands residents, including 37,2 thousands in rural areas. In Drochia district there are 13 pharmacies, including 17 in rural areas.
- 4. Population of Cantemir district is 53,4 thousands residents, including 47,1 thousands in rural areas. In Cantemir district there are 8 pharmacies, including 5 in rural areas.
- 5. Population of Floresti district is 21,5 thousands residents, including 16,3 thousands in rural areas. In Floresti district there are 22 pharmacies, including 15 in rural areas.
- 6. Population of Briceni district is 71,5 thousands residents, including 51,2 thousands in rural areas. In Briceni district there are 23 pharmacies, including 17 in rural areas.
- 7. Population of Soroca district is 77,5 thousands residents, including 54,5 thousands in rural areas. In Soroca district there are 20 pharmacies, including 14 in rural areas.
- 8. Population of Falesti district is 78,6 thousands residents, including 53,4 thousands in rural areas. In Falesti district there are 18 pharmacies, including 10 in rural areas.
- 9. Population of Anenii-Noi district is 79,6 thousands residents, including 64,5 thousands in rural areas. In Anenii-Noi district there are 16 pharmacies, including 11 in rural areas.
- 10. Population of Calarasi district is 64,6 thousands residents, including 43,6 thousands in rural areas. In Calarasi district there are 13 pharmacies, including 8 in rural areas.
- 11. Population of Cimislia district is 49,3 thousands residents, including 38,8 thousands in rural areas. In Cimislia district there are 13 pharmacies, including 8 in rural areas.

eas. In Ca	on or Cause auseni dist	rict there a	is 81,5 thou are 23 phar	usanas resi macies, incl	dents, inclu luding 17 ii	n rural area	inousands i as.	n rura

Exercise 5. Nearby the pharmacy there is a center of family doctors, that works hours from 8:00 to 18:00. Set the work schedule and propose the organizational structure of this pharmacy. Justify the conclusions.				
pharmacy and indicate its a	the results of Exercise 5, list the functions of the community activities for each of these functions. Argument planning strate-			
gies to satisfy consumer der Functions	mand. Activities			

Functions	Functions Activities			
	the results of the exercise 5, determine the rooms and minimum nmunity pharmacy. Make a scheme of the technological location he equipment.			
Fyercise 8 Argue the	e rationality of the location of this pharmacy rooms.			
Exercise 6. Airgue the	rationality of the location of this pharmacy rooms.			
Conclusions and sugg	estions of the student:			
The teacher's signature				

THE LEGAL PRESCRIBING RULES FOR MEDICINES.

The purpose of the work: To acquire the rules and procedures for prescribing different drug groups for outpatient patients, completing prescription forms in accordance with the provisions in force and principles of rational prescription of medicines.

Form of training: Seminar and laboratory practical work.

Duration: 4 hours.

Questions for self-learning:

- 1. General prescribing rules for patients under ambulatory conditions.
- 2. Peculiarities of prescription drugs containing toxic, narcotics and psychotropic substances.
- 3. The specifics of prescribing for different categories of the population and the sick.
- 4. Drug prescribing rules, offset from mandatory health insurance funds.
- 5. The concept of rational drug prescribing.

Exercises for self-solving:

Exercise 1. Select from the list of drugs (narcotics) and psychotropic substances (in
cluded in Table 2, Lists 1 and 2, approved by Government Decision of the Republic of Mo
dova Nr. 1088 of 05.10.2004), used for medical purposes registered in the Republic of Mo
dova.

Exercise 2. Select from the list of narcotic and psychotropic substances (included in Table No. 3, Lists 1, 2 and 3, approved by the Government Decision of the Republic of Moldova No. 1088 of 05.10.2004) used for medical purposes registered in the Republic of Moldova.

Exercise 3. Prescribe prescriptions for drugs from the proposed list, respecting the

rules and peculiarities prescribing requirements.				
List No. 1.	List No. 2.	List No. 3.		
1. Morphinum hidrochl.	1. Omnopon neo	1. Trihexifenidylum		
2. Zopiclonum	2. Diazepamum	2. Fenobarbitalum		
3. Alprozalamum	3. Aminazinum	3. Sotalolum		
4. Ketaminum	4. Cabergolinum	4. Dipiridamolum		
5. Atropini sulf.	5. Prozerinum	5. Plathyphyllini h/t		
6. lorazepamum	6. Streptomycinum	6. Mebendazolum		
7. Amlodipinum	7. Ketoconasolum	7. Captoprilum		
8. Lidocainum	8. Extraveral	8. Caffeinum		
9. Amitriptilinum	9. Piracetamum	9. Doxicyclinum		
10. Tetraciclynum	10. Tinidazolum	10. Actovegin		
11. Nitroglycerinum	11. Ibuprofenum	11. Streptomicinum		
12. Digoxinum	12. Fluconazolum	12. Omnopon neo		
13. Diclofenacum	13. Caffeinum	13. Betamethasonum		
14. Pilocarpinum	14. Varfarinum	14. Zolpidemum		
15. Diazepamum	15. Dexametazonum	15. Clindamicynum		
16. Cefepimum	16. Metronidazolum	16. Oxycort		
17. Metoprololum	17. Amitriptilinum	17. Lisinoprilum		
18. Amoxicillinum	18. Propranololum	18. Rexetinum		
19. Ketoprofenum	19. Glucosaminum	19. Bendazolum		
20. Meloxicamum	20. Pentoxifilinum	20. Inosinum pranobex		
List No. 4.	List No. 5	List No. 6		
1. Trimeperidinum	1. Fentanylum	1. Codeinum fosfas		
2. Metandrostenolonum	2. Propranololulum	2. Ephedrinum h/c		
3. Bromazepamum	3. Bromazepamum	3. Lisinoprilum		
4. Azitromicynum	4. Clonazepamum	4. Pilocarpinum h/c		
5. Argentum nitras	5. Spiritus aethylic	5. Nandrolonum		
6. Nystatinum	6. Metoprololum	6. Cianocobalaminum		
7. Platifilinum h/t	7. Atorvastatinum	7. Clonazepamum		
8. Trimebutinum	8. Sulfat de magneziu	8. Sertralinum		
9. Metoclopramidum	9. Pentoxifilinum	9. Trimeperidinum		
10. Glibenclamidum	10. Metiluracilum	10. Atenololum		
11. Trihexifenidilum	11. Etambutolum	11. Imipraminum		
12. Amlodipinum	12. Oxazepamum	12. Carbamazepinum		
13. Metildopaminum	13. Risperidonum	13. Lizinoprilum		

mesulidum hidroergotamin racetamum deinum ph. drocortizonum motriginum List No.8 azepamum rimeperidinum drocortizonum drocortizonum oxicyclinum romocriptinum	14. Cinarizinum 15. Bromazepamum 16. Fenazepamum 17. Indometacinum 18. Azitromicinum 19. Ciprofloxacinum 20. Acenocoumarolum List No.9 1. Amfetaminum 2. Chlordiazepoxide 3. Droperidolum 4. Tramadolum 5. Cyclodolum
hidroergotamin racetamum odeinum ph. drocortizonum motriginum List No.8 azepamum rimeperidinum drocortizonum drocortizonum oxicyclinum	16. Fenazepamum 17. Indometacinum 18. Azitromicinum 19. Ciprofloxacinum 20. Acenocoumarolum List No.9 1. Amfetaminum 2. Chlordiazepoxide 3. Droperidolum 4. Tramadolum 5. Cyclodolum
racetamum odeinum ph. drocortizonum motriginum List No.8 azepamum rimeperidinum copentalum drocortizonum oxicyclinum comocriptinum	17. Indometacinum 18. Azitromicinum 19. Ciprofloxacinum 20. Acenocoumarolum List No.9 1. Amfetaminum 2. Chlordiazepoxide 3. Droperidolum 4. Tramadolum 5. Cyclodolum
deinum ph. drocortizonum motriginum List No.8 azepamum imeperidinum copentalum drocortizonum oxicyclinum comocriptinum	18. Azitromicinum 19. Ciprofloxacinum 20. Acenocoumarolum List No.9 1. Amfetaminum 2. Chlordiazepoxide 3. Droperidolum 4. Tramadolum 5. Cyclodolum
drocortizonum motriginum List No.8 azepamum imeperidinum copentalum drocortizonum oxicyclinum comocriptinum	19. Ciprofloxacinum 20. Acenocoumarolum List No.9 1. Amfetaminum 2. Chlordiazepoxide 3. Droperidolum 4. Tramadolum 5. Cyclodolum
List No.8 azepamum rimeperidinum eopentalum drocortizonum oxicyclinum romocriptinum	List No.9 1. Amfetaminum 2. Chlordiazepoxide 3. Droperidolum 4. Tramadolum 5. Cyclodolum
List No.8 azepamum rimeperidinum copentalum drocortizonum oxicyclinum comocriptinum	List No.9 1. Amfetaminum 2. Chlordiazepoxide 3. Droperidolum 4. Tramadolum 5. Cyclodolum
azepamum rimeperidinum copentalum drocortizonum oxicyclinum romocriptinum	 Amfetaminum Chlordiazepoxide Droperidolum Tramadolum Cyclodolum
rimeperidinum 2 eopentalum 3 drocortizonum 4 exicyclinum 5 eomocriptinum 6	 Chlordiazepoxide Droperidolum Tramadolum Cyclodolum
copentalum : drocortizonum : exicyclinum : exicyclinum :	3. Droperidolum 4. Tramadolum 5. Cyclodolum
drocortizonum / exicyclinum !	4. Tramadolum 5. Cyclodolum
oxicyclinum !	5. Cyclodolum
omocriptinum	7
	/ Uananain
	6. Panangin 7. Rosuvastatinum
*	8. Sulfocamfocainum
	9. Amlodipinum
	10. Bromazepamum
	11. Trimeperidinum
	12. Oxitocinum
	13. Ofloxacinum
	14. Methotrexatum
	15. Ciclosporinum
_	16. Clozapinum
	17. Losartanum
·	18. Mebendazolum
	19. Ciprofloxacinum
otrimazolum 2	20. Betamethasonum
List No.11	List No. 12.
prazolamum	1. Etilmorfinum clorhidrat
ilamfetaminum Z	2. Barbitalum natrium
profloxacinum :	3. Tofisopamum
phenhydraminum	4. Nandrolonum
nkristinum !	5. Azothyoprinum
rihexifenidilum	6. Chlorpromazinum
sinoprilum '	7. Loratadinum
clofenacum	8. Heparinum
operidolum	9. Indapamidum
onazepamum	10. Izoniazidum
intoprazolum	11. Strofantin K
imeperidinum	12. Haloperidolum
	13. Tamoxifen
kprenololum :	14. Zolpidemum
	15. Ofloxacynum
	16. Thrimeperidinum
_	17. Gentamycinum
	18. Metoprololum
	19. Tramadolum
<u> </u>	20. Imipraminum
	anitidinum mlodipinum emodez neo orphinum phenhydraminum etformin ridoxinum oludexan rotininum sulfas amiprilum ropranololum atifilinum h/t ciclovirum otrimazolum List No.11 prazolamum profloxacinum phenhydraminum nkristinum rihexifenidilum sinoprilum clofenacum roperidolum onazepamum antoprazolum rimeperidinum profloxacinum condinum arbamazepin sprenololum oxicyclinum cropinum sulfas racetamum onidipinum mlodipinum

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions 100mm x 200mm)

	denvery of medicines (dimensions roomin a zoomin)	
	Header stamp of healthcare unit	
Doc	tor phone	
	Prescription	
	Date of prescribing 20	
	(name and surname of the patient)	
	Age years	
Pric e	Rp.:	
	L.P.	
	Signature and stamp of Doctor	
Th	e prescription is valid for 30 days, 2 months (specify)	

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions 100mm x 200mm)

	Header stamp of healthcare unit
Doc	tor phone
	Prescription
	Date of prescribing " 20
	(name and surname of the patient)
	Age years
Pric e	Rp.:
TI	L.P. Signature and stamp of Doctor
111	ne prescription is valid for 30 days, 2 months

Recipe Form No. 2 for prescribing and delivery of medicines (dimensions 100mm x 200mm)

DOCUMENT OF STRICT RECORD Header stamp of healthcare unit (enterprise) Phone Prescription Series Nr Date of prescribing " 20 (name and surname of the patient) Age years. Medical Sheet No Pric e Rp.: L.P. Signature and stamp of Doctor The prescription is valid for 10 days	tenvery of medicines (dimensions roomin x 200mm)					
Prescription]					
SeriesNr						
Series Nr	Doct	tor Phone				
Date of prescribing " 20 (name and surname of the patient) Age years. Medical Sheet No Pric e Rp.: L.P. Signature and stamp of Doctor		Prescription				
Comparison Com	,					
Age years. Medical Sheet No Pric e Rp.: L.P. Signature and stamp of Doctor	Do	ate of prescribing "				
Age years. Medical Sheet No Pric e Rp.: L.P. Signature and stamp of Doctor						
Pric e Rp.: L.P. Signature and stamp of Doctor		(name and surname of the patient)				
L.P. Signature and stamp of Doctor	Age	years. Medical Sheet No				
L.P. Signature and stamp of Doctor	Pric	Rp.:				
	e	r··				
The prescription is valid for 10 days		L.P. Signature and stamp of Doctor				

Recipe Form No. 3 for free prescription and delivery of

medicines (size 100 X 200)					
	Header stamp of helthcare unit				
		(1)			
	ootor	(1)			
ا ا	octor Phone	(2)			
	Prescription	n			
,	_				
	Date of prescribing	20			
P A T I E N T	(name and surname of patient) Age years. Medical File N Address	(3)			
Pric e	Rp.:	L.P.			
	Signature and stamp of Doctor	7-1			
T	The prescription is valid for 10,, 30 days or 2 mounth (specificare)				

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions $100 mm \ x \ 200 mm)$

	Header stamp of healthcare u	nit	
Doc	Doctor phone		
	Prescription	n	
	Date of prescribing		
)	
	(name and surname of the patien	t)	
	Age years		
Pric e	Rp.:		
		L.P.	
	Signature and stamp of Doctor		
Th	he prescription is valid for 30 days, 2 (specify)	months	

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions $100 mm \ x \ 200 mm)$

Header stamp of healthcare unit			
Doc	tor phone		
	Prescription		
	Date of prescribing		
	" " 20		
		_	
	(name and surname of the patient)		
	Age years		
Pric	Rp.:		
e			
		. D	
		L.P.	
	Signature and stamp of Doctor		
Th	The prescription is valid for 30 days, 2 months		
	(specify)		

Recipe Form No. 2 for prescribing and delivery of medicines (dimensions 100mm x 200mm)

Prescription SeriesNr]	DOCUMENT OF STRICT RECORD Header stamp of healthcare unit (enterprise)		
Series Nr . Date of prescribing " 20 (name and surname of the patient) Age years. Medical Sheet No. Pric Rp.:	Doct	or Phone		
Date of prescribing " " 20		Prescription		
	,			
Age years. Medical Sheet No Pric Rp.:	Do	ate of prescribing "20		
Kp		years. Medical Sheet No		
		Τφ		
L.P. Signature and stamp of Doctor The prescription is valid for 10 days				

Recipe Form No. 3 for free prescription and delivery of medicines (size 100 X 200)

medicines (size 100 11 200)			
Header stamp of helthcare unit			
		(1)	
	ctor		
	Phone	(2)	
	Prescription	n	
Se	eria Nr		
	Date of prescribing		
	<i>"</i>	20	
P			
A		(3)	
T	(name and summans of nations)	, ,	
I	(name and surname of patient)		
E Age years. Medical File No			
N			
T	Address		
Price	Rp.:		
	тр		
		L.P.	
	Signature and stamp of Docto	r	
The prescription is valid for 10,, 30 days or 2			
mounth (specificare)			
mounin (specificare)			

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions 100mm x 200mm)

uenv	very of medicines (dimensions 100m	m x 200mm)	
	Header stamp of healthcare	unit	
Doc	Doctor phone		
	Prescriptio	n	
	Date of prescribing		
	" " 	20	
	(name and surname of the pati		
	Ageyear	'S	
Pric e	Rp.:		
Th	Signature and stamp of Doctor ne prescription is valid for 30 days,	L.P.	

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions 100mm x 200mm)

Header stamp of healthcare unit		
Doc	etor phone	
	Prescription	
	Date of prescribing	
	""	
		-
	(name and surname of the patient)	
	Age years	
Pric e	Rp.:	
	Singular and drawn of Dodge	L.P.
	Signature and stamp of Doctor	
Th	ne prescription is valid for 30 days, 2 mon (specify)	nths

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions 100mm x 200mm)

	Header stamp of healthcare unit		
Doc	Doctor phone		
	Prescription		
	Date of prescribing		
	<i>" 20</i>		
	(name and surname of the patient)		
	Age years		
Pric e	Rp.:		
Th	Signature and stamp of Doctore prescription is valid for 30 days, 2 mont (specify)	L.P.	

uciiv	cry of medicines (difficusions roomin x 200min)
	Header stamp of healthcare unit
Doc	tor phone
	Prescription
	Date of prescribing
	" " 20
	(name and surname of the patient)
	Age years
Pric e	Rp.:
	L.P.
	Signature and stamp of Doctor
The prescription is valid for 30 days, 2 months	
(specify)	

$\label{eq:Recipe Form No. 1 for prescribing and} Recipe Form No. 1 for prescribing and delivery of medicines (dimensions 100mm x 200mm)$

	Header stamp of healthcare unit	
Doc	tor phone	
	Prescription	
	Date of prescribing	
	<u>""</u> 20	
	(name and surname of the patient)	
	Age years	
Pric e	Rp.:	
	Signature and stamp of Doctor	L.P.
Th	e prescription is valid for 30 days, 2 m (specify)	onths

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions 100mm x 200mm)

	Header stamp of he	ealthcare unit
Doc	tor	phone
	Prescri	ption
	Date of pres	cribing
	<i>""</i>	20
	(1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2,	of the particust
	(name and surname of Age	-
	Agc	years
Pric	Rp.:	
e		
		L.P.
	Signature and stamp of D	
Th	e prescription is valid fo	•

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions 100mm x 200mm)

	Header stamp of healthcare unit
Doc	tor phone
	Prescription
	Date of prescribing
	" <u> </u>
	(name and surname of the patient)
	Age years
Pric e	Rp.:
Th	L.P. Signature and stamp of Doctor the prescription is valid for 30 days, 2 months (specify)

Header stamp of healthcare unit				
Doc	Doctor phone			
	Prescription			
	Date of prescribing " 20			
	(name and surname of the patient) Age years			
Pric e	Rp.:	I D		
	Signature and stamp of Doctor	L.P.		
Th	The prescription is valid for 30 days, 2 months (specify)			

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions 100mm x 200mm)

Header stamp of healthcare unit			
Doc	Doctor phone		
	Prescription		
	Date of prescribing		
	<u>""</u>		
	(name and surname of the patient)		
	Age years		
Pric e	Rp.:		
Th	L.P. Signature and stamp of Doctor e prescription is valid for 30 days, 2 months (specify)		

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions 100mm x 200mm)

	Header stamp of healthcare unit	
Doc	torphone	
	Prescription	
	Date of prescribing	
	" " 20	
	(name and surname of the patient) Ageyears	
Pric e	Rp.:	
	L.P. Signature and stamp of Doctor	
Th	The prescription is valid for 30 days, 2 months (specify)	

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions 100mm x 200mm)

Header stamp of healthcare unit		
Doc	etor phone	
	Prescription	
	Date of prescribing	
	<u>""</u>	
	(name and sumame of the nations)	
	(name and surname of the patient)	
	Age years	
Pric e	Rp.:	
TI.	L.P. Signature and stamp of Doctor	
Th	ne prescription is valid for 30 days, 2 months (specify)	

denvery of medicines (dimensions footim a 200mm)		
Header stamp of healthcare unit		
Doctor phone		
Prescription		
Date of prescribing		
" " 20		
(name and surname of the patient)		
Age years		
Pric e Rp.:		
L.P. Signature and stamp of Doctor The prescription is valid for 30 days, 2 months (specify)		

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions 100mm x 200mm

delivery of medicines (dimensions 100mm x 200mm)					
	Header stamp of healthcare unit				
Doc	etorphone_				
	Prescription	h			
	Date of prescribing " 20)			
	(name and surname of the patient Age years				
Pric e	Rp.: Signature and stamp of Doctor	L.P.			
Th	ne prescription is valid for 30 days, 2	months			

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions 100mm x 200mm)

	Header stamp of healthcare unit
Doc	tor phone
	Prescription
	Date of prescribing " 20
	20
	(name and surname of the patient)
	Age years
Pric e	Rp.:
Th	L.P. Signature and stamp of Doctor e prescription is valid for 30 days, 2 months (specify)

Recipe Form No. 1 for prescribing and delivery of medicines (dimensions 100mm x 200mm)

uchv	ery of medicines (dimensions 100mm x 200mm)					
	Header stamp of healthcare unit					
es fron	n the proposed list, the cost of which					
Doct	Doctor phone					
	Prescription					
	Date of prescribing					
	<u>""</u>					
	(name and surname of the patient)					
	Age years					
Pric e	Rp.:					
	L.P.					
	Signature and stamp of Doctor					
The	e prescription is valid for 30 days, 2 months (specify)					

Header stamp of healthcare unit						
Doctorphone						
	Prescription					
	Date of prescribing					
	<i>" " 20</i>					
	(a gara and garanger of the mation)					
	(name and surname of the patient)					
	Age years					
Pric e	Rp.:					
	L.P. Signature and stamp of Doctor					
The prescription is valid for 30 days, 2 months (specify)						

Prescription-model for compensated drugs offset by compulsory health insurance funds

Prescription-model for compensated drugs offset by compulsory health insurance funds

Prescription seria 000 nr. 0000000 for compensated drugs of set by compulsory health insurance funds Prescription seria 000 nr. 0000000 for compensated drugs of set by compulsory health insurance funds One of the results of Moldova For No. 3/C Approved by the Common Order Order Ministry of Health for the Republic of Moldova For No. 3/C Approved by the Common Order Order Order Order	Prescription seria 000 nr. 0000000 for compensated drugs offset by compulsory health insurance funds Ministry of Health of the Republic of Moldova Perr. No. 3 / C Ap proved by the Common Order MS and NMIC. No.
1	1
4	4
S. R.D.:	S. Rus:
9 name surname GP L.S. 10. IDNP GP GFs signature The prescription is valid for 10 days, 30 days or 2 mouths from the date of prescribing (underline) 12. Drag code 13. Number of tablets	9
14. Retail trice. lei bani lei bani 16. Amount offset lei bani 16. Amount paid by patient bani	14. Retail price. lei beni 16. Amount officet beni 16. Amount paid by patient lei beni
17	17
Prescription-model for compensated drugs offset by compulsory health insurance funds	Prescription-model for compensated drugs offset by compulsory health insurance funds
for compensated drugs offset by compulsory health insurance funds Prescription seria 000 nr. 0000000 for compensated drugs offset by compulsory health insurance funds Order 1	for compensated drugs offset by compulsory health insurance funds Prescription seria 000 nr. 0000000 for compensated drugs ofset by compulsory health insurance funds Prescription seria 000 nr. 0000000 for compensated drugs ofset by compulsory health insurance funds 1
for compensated drugs offset by compulsory health insurance funds Prescription seria 000 nr. 0000000 for compensated drugs offset by compulsory health insurance funds 1. Ministry of Realth fittle Republic of Moldova For No. 3/C Approved by the Common Order MS and SMIC. No	for compensated drugs offset by compulsory health insurance funds Prescription seria 000 nr. 0000000 for compensated drugs offset by compulsory health insurance funds Prescription seria 000 nr. 0000000 for compensated drugs offset by compulsory health insurance funds Ministry of Health fries Republic of Moldova Form No. 3/C Approved by the Common Order MS and MHIC No. 1.
for compensated drugs offset by compulsory health insurance funds Prescription seria 000 nr. 0000000 for compensated drugs offset by compulsory health insurance funds Prescription seria 000 nr. 0000000 for compensated drugs offset by compulsory health insurance funds 1.	Prescription seria 000 nr. 0000000 for compensated drugs offset by compulsory health insurance funds Prescription seria 000 nr. 0000000 for compensated drugs offset by compulsory health insurance funds 1
for compensated drugs offset by compulsory health insurance funds Prescription seria 000 nr. 0000000 for compensated drugs offset by compulsory health insurance funds Prescription seria 000 nr. 0000000 of the Republic of Moldora Form No. 3 / C Approved by the Common Order Ministry of Health of the Republic of Moldora Form No. 3 / C Approved by the Common Order Mis and NMIC. No. To Approve by the Common Order Mis and NMIC. No. To Approve the No. 1	for compensated drugs offset by compulsory health insurance funds Prescription seria 000 nr. 0000000 of the Republic of Molotura for Compensated drugs of set by compulsory health insurance funds 1.
for compensated drugs offset by compulsory health insurance funds Prescription seria 000 nr. 0000000 for compensated drugs offset by compulsory health insurance funds Prescription seria 000 nr. 0000000 for compensated drugs offset by compulsory health insurance funds 1	Prescription seria 000 nr. 0000000 Prescription seria 000 nr. 0000000 for compensated drugs offset by compulsory health insurance funds Prescription seria 000 nr. 0000000 for compensated drugs offset by compulsory health insurance funds 1

Variants to solve the problem no. 4.

1. Bîrcă Elena, 50 years old

Rp.: Tab.Amlodipin 0.05 N 30 DS. One pill each day.

2. Pitman Marian, 55 years old.

Rp.: Tab.Acid acetylsalicylicum 0.075 N. 30

DS. One pill each day.

3. Arseni Alina, 58 years old.

Rp.: Tab.Enalaprilum 0.01 N 20 DS. One pill 2 times per day.

4. Deget Dumitru, 49 years old.

Rp:Tab.Lisinoprilum 0.020 N 28 DS. One pill each day.

1. Lungu Ion, 63 years old.

Rp.: Tab.Indapamidum 0.0015 N 30 DS. One pill a day in the morning

2. Budu Lavrentie, 49 years old.

Rp.: Tab.Isosorbidi mononitras 0.02 N 30

DS. One pill a day.

3. Bou Adelina, 66 years old.

Rp.: Tab.Enalaprilum 0.01 N 30 DS. One pill 2 times per day.

4. Dontu Iurie, 72 years old.

Rp.: Tab.Losartanum 0.05 N30 DS. One pill a day in the morning

1. Gîncu Lilia, 67 years old.

Rp.: Tab.Ramiprilumum 0.01 N 30 DS. One pill a day.

2. Postolache Ludmila, 58 years old.

Rp.: Tab. Spirolactonum 0.025 N 20 DS. One pill a day.

3. Russu Larisa, 83 years old

Rp.: Tab.Indapamidum 0.0025 N 20 DS. One pill a day in the morning.

4. Forov Dorin, 47 years old.

Rp.:Tab.Verapamilum 0.04 N 30 DS. One pill a day.

1. Tuică Arsenie, 54 years old.

Rp.: Tab.Claritromycinum 0.5 N 14 DS One pill 2 times per day.

2. Rîcun Igor, 57 years old.

Rp.:Tab.Famotidinum 0.02 N 20 DS. One pill 2 times per day.

3. Bujac Constantin, 68 years old.

Rp.: Tab.Omeprazolum 0.02 N 14 DS. One pill a day.

4. Poderioghin Aliona, 58 years old.

Rp.: Tab.Amoxicilinum 0.025 N 20 DS. One pill 3 times per day.

1. Rudenco Livia, 68 years old.

Rp.: Tab.Digoxinum 0.0025 N 25 DS. One pill 2 times per day.

2. Gaibu Oleg, 67 years old.

Rp.: Tab.Amiodaronum 0.2 N 30

DS. One pill a day.

3. Fusu Elena, 60 years old.

Rp.: Tab.Torasemidum 0.005 N 20 DS. One pill 2 times per day.

4. Constantinov Ana-Maria, 49 years old.

Rp.:Tab. Enalapril 0.02 N 30 DS. One pill 2 times per day.

1. Dodonov Ecaterina, 46 years old.

Rp.: Tab. Amlodipinum 0.05 N 30 DS. One pill a day.

2. Gutenco Dragos, 67 years old.

Rp.: Tab.Bisoprololum 0.005 N 30 DS. One pill a day.

3. Furom Raisa, 58 years old.

Rp.: Tab. Ramiprilum 0.005 N 30 DS. One pill a day.

4.Pop Alina, 59 years old.

Rp.:Tab. Verapamilum 0.08 N 30 DS One pill 2 times per day.

1. Racov Andrei, 59 years old.

Rp.: Tab. Indapamidum 0.0015 N 20 DS. One pill a day.

2. Tucanov Liubovi, 49 years old.

Rp.: Tab.Digoxinum 0.00025 N 50 DS. One pill 2 times per day.

3. Golovin Alexandru. 58 years old.

Rp.: Tab.Amlodipinum 0.05 N 56 DS. One pill a day.

4. Ciupearcă Vladimir, 23 years old.

Rp.: Tab. Acidi folicum 0.001 N 30 DS. One pill 2 times per day.

1.Duru Ion, 49 years old.

Rp.:Supp. Paracetamolum 0.1 N 10 DS. One supp. in case of fever.

2. Voroniuc Larisa, 48 years old.

Rp.: Tab.Acidum valproicum 0.2 N 50 DS. One pill 2 times per day.

3.Ciupa Galina, 53 years old.

Rp.: Tab.Carbamazepinum 0.01 N 50 DS. One pill 2 times per day.

4. Golovan Alexandru, 66 years old.

Rp.: Tab. Lamotriginum 0.025 N 30 DS. One pill 2 times per day.

1.Hîncu Virginia, 69 years old.	1.Goreanu Elvira, 37 years old.
Rp.: Tab. Trihexyphenidylum 0.002 N 50	Rp.: Tab.Sorbifer Durulex N 30
DS. One pill 2 times per day.	DS. One pill 2 times per day.
2.Rusu Eugenia, 74 years old.	2.Coastă Nicolae, 46 years old.
Rp.: Tab. Clonazepamum 0.002 N 30	Rp.: Tab.Spironolactonum 0.025 N 20
DS. One pill a day.	DS.Cîte 1 past. în zi.
3.Lungu Olga, 47 years old.	3.Frolov Dorin, 58 years old.
Rp.:Tab.Diazepamum 0.05 N 20	Rp.: Supp. Paracetamolum 0.25 N 10
DS. One pill a day in the morning.	DS. One pill 2 times per day.
4.Laptea Sergiu, 63 years old.	4.Cot Radu, 39 years old.
Rp.: Tab. Losartanum 0.05 N 30	Rp.:Sol. Ergocalciferolum 0.125% 10 ml
DS. One pill a day.	DS. 5 drops 2 times a day.
1. Talbot Nicolae, 17 years old.	1.Iahneva Ecaterina, 70 years old.
Rp.: Tab. Pancreatinum 10000 N 20	Rp.:Tab.Metforminum 0.5 N 60
DS. One pill at mealtime.	DS. One pill 2 times per day.
2.Chircă Anatol, 69 years old.	2.Cozacevscaia Ana, 61 years old.
Rp.: Tab.Desloratadinum 0.005 N 10	Rp.: Tab.Glibenclamidum 0.0035 N 60
DS. One pill a day.	DS. One pill 2 times per day.
3.Gagiu Andrei, 52 years old.	3.Guzun Maria, 48 years old.
Rp.:Tab.Clemastinum 0.001 N 20	Rp.: Tab.Sulpiridum 0.05 N 30
DS. One pill 2 times per day.	DS. One pill a day.
4. Juc Ana, 58 years old.	4. Iațco Oleg, 60 years old.
Rp.: Tab.Theophyllinum 0.02 N 10	Rp.: Tab. Risperidonum 0.002 N 30
DS. One pill a day.	DS. One pill a day in the morning.
Exercise 5. List the principles (content)	of the concept of rational use of medicines.
Conclusions and suggestions of the stud	ent·
conclusions and suggestions of the stud	CIIC

Theme 13

RECEIVING, PRICING AND REGISTRATION OF PRESCRIPTION FUNCTIONS OF MANAGEMENT.

The purpose of the work: Acquisition of general rules and practical skills of receiving, pricing and registering prescriptions for ambulatory patients.

Form of training: Seminar and laboratory practical work.

Duration: 8 hours.

Questions for self-learning:

- 1. The purpose and functions of production department.
- 2. Functions of the pharmacist at receiving prescriptions and dispensing medications.
- 3. Controlling the veracity of prescribing prescriptions at the stage of their receipt.
- 4. Registration of prescriptions containing errors and prevention measures of prescription.
- 5. Rules for prescriptions charging.
- 6. Methods for regulating the receipt of prescriptions for outpatient patients.
- 7. The formulations. Attribute and record.
- 8. Quantitative evidence of the circulation of medicines.

Exercises for self-solving.

Exercise 1. Verify compliance with prescribing and regulation rules for received prescriptions (each student receives a set of prescriptions):

- a) the term of validity;
- b) the presence of necessary requisites;
- c) maximum doses for one administration and for 24 hours;
- d) single delivery rules for a single prescription.


Exercise 2. Report errors-containing prescriptions. Classify errors found in correctable and uncorrectable. Recipes containing errors that can not be corrected, cancel them by applying the "Invalid Recipe" stamp, record them in the "Registry of invalid recipes".


REGISTRY OF INVALID RECIPES

Date	Nr. d/o	Pre- scrip- tion Nr.	нсі	The name of the doctor	Characteristic of de- tected prescribing er- rors	Taken measures	Pharmacist's name	Signa- ture

Date	Nr. d/o	Pre- scrip- tion Nr.	НСІ	The name of the doctor	Characteristic of de- tected prescribing er- rors	Taken measures	Pharmacist's name	Signa- ture

Correc	tly tran	scribe tl	he contents (of the	prescrip	tion ir	the wo	rkbo	ok.	





List of maximum doses for one administration and for 24 hours

No	Name of the medicinal substance	Maximum dose for one administration	Maximum dose for 24 hours
1.	Aethaminali natrium	0,3 g	0,6 g
2.	Aethylmorphini hydrochloridum	0,03 g	0,1 g
3.	Amidopyrinum	0,5 g	1,5 g
4.	Anaesthezinum	0,5 g	1,5 g
5.	Analginum	1,0 g	3,0 g
6.	Atropini sulfas	0,001g	0,003 g
7.	Barbamylum	0,3 g	0,6 g
8.	Barbitali natrii	0,5 g	1,0 g
9.	Bromizovalum	1,0 g	2,0 g
10.	Codeinum (Codeini phosphatis)	0,05 g	0,2 g
11.	Coffeini-natrii -benzoatis	0,05 g	1,5 g
12.	Dibazolum	0,05 g	0,15 g
13.	Dimedrolum	0,1 g	0,25 g
14.	Ephedrini hydrochloridum	0,05 g	0,15 g
15.	Erythromycinum	0,5 g	2,0 g
16.	Euphyllinum	0,5 g	1,5 g
17.	Extr.Belladonnae 1:2	0,05 g	0,15 g
18.	Laevomicetinum	1,0 g	4,0 g
19.	Morphini hydrochloridum	0,02 g	0,05 g
20.	Natrii bromidum	1,0 g	4,0 g

No	Name of the medicinal substance	Maximum dose for one administration	Maximum dose for 24 hours
21.	Norsulphazolum natrium	2,0 g	7,0 g
22.	Novocainum	0,25 g	0,75 g
23.	Omnoponum	0,03 g	0,1 g
24.	Papaverini hydrochloridum	0,2 g	0,6 g
25.	Paracetamolum	0,5 g	1,5 g
26.	Pentazacinum	0,05 g	0,6 g
27.	Phenadonum	0,01 g	0,03 g
28.	Phenobarbitalum	0,2 g	0,5 g
29.	Plathyphyllini hydrotartratis	0,01 g	0,03 g
30.	Promedolum	0,05 g	0,2 g
31.	Sulfacylum - natrium	2,0 g	7,0 g

Exercise 3. All prescriptions written in the workbooks, charge them according to the regulations in force.

Exercise 4. Record all recipes received during the lab work on the current date in the "Recipe Register". For each recipe, indicate the total price, including the cost of ingredients, purified water, and fares.

EXCERPT from the retail price list of medicines

The name	UM	Price (MDL)	The name	UM	Price (MDL)
Ac. acethylsalic.	1,0	0,33	Extr. rad. Althaeae	1,0	0,73
Ac. aminocapronicum	1,0	0,32	Extr.Belladonnae 1:2	1,0	1,00
Ac. ascorbinicum	1,0	1,07	Extr.Valerianae spir.	1,0	1,30
Ac. boricum	1,0	1,24	Vial 10 ml	1 fl	0,70
Ac. folicum	1,0	0,92	Vial 100 ml	1 fl	1,25
Ac. glutaminicum	1,0	3,00	Vial 250 ml	1 fl	2,50
Ac. hidrochlorid. dil.	1,0	0,80	Vial 50 ml	1 fl	0.85
Ac. nicotinicum	1,0	2,18	Furacilinum	1,0	0,58
Ac. salicylicum	1,0	1,54	Furazolidonum	1,0	1,00
Adonizidum	10 ml	1,90	Glucosum	1,0	0,36
Adrenalini h/c sol.0,1%	1 ml	4,80	Glycerinum	1,0	0,59
Aethaminali natrium	1,0	1,70	Herba Leonuri	1,0	0,95
Aethazolum	1,0	0,90	Hexamethylentetramin	1,0	0,90
Aetheri med.	1 ml	1,83	Ichtiolum	1,0	0,21
Aethylmorphini h/c	1,0	1,70	Iodum	1,0	0,94
Amidopirine	1,0	0,75	Kalii bromidum	1,0	1,01
Anaesthezinum	1,0	0,48	Kalii iodidum	1,0	0,47
Analginum	1,0	0,53	Laevomicetinum	1,0	0,50
Antipyrinum	1,0	1,20	Lanolinum anh.	1,0	0,69
Aq. Menthae	100 ml	1,47	Liquor ammonii anis.	1ml	0,82
Aq. purificata	100 ml	1,25	Magnezii oxydum	1,0	0,77
Atropini sulfas	1,0	2,00	Magnezii sulfas	1,0	0,44
Barbamylum	1,0	3,40	Mentholum	1,0	0,67
Barbitali natrii	1,0	1,70	Methyleni coeruleum	1,0	1,97
Benzylii benzoas	1,0	2,07	Methyluracilum	1,0	0,67
Bismuti subnitras	1,0	1,22	Morphine	1,0	4,00
Jar 50,0	1	1,00	Natrii benzoas	1,0	0,27
Bromizovalum	1,0	1,30	Natrii bromidum	1,0	0,19
Butirum cacao	1,0	0,95	Natrii chloridum 1,0		0,12

The name	UM	Price (MDL)	The name	UM	Price (MDL)	
Calcii chloridum	1,0	1,42	Natrii hidrocarb.	1,0	0,37	
Calcii glycerophosfatis	1,0	1,54	Natrii salicylatis	1,0	0,39	
Calcii lactatis	1,0	0,98	Nitroglycerin.sol.	1 ml	1,00	
Camphora trita	1,0	0,66	Norsulfazolum	1,0	0,89	
Citralum sol. sp. 1%	1,0	0,87	Novocainum	1,0	0,50	
Codeini phosphas	1,0	2,50	Olei olivarum	1,0	0,78	
Codeinum	1,0	2,60	Olei vaselinum	1,0	0,96	
Coffeini natrii-benzoat	1,0	1,41	Oleum Helianthi	1,0	0,84	
Box for powder	1	0,50	Omnopon	1,0	1,23	
Dibazolum	1,0	1,20	Osarsolum	1,0	0,60	
Dicainum	1,0	1,30	Papaverini h/c	1,0	4,81	
Difeninum	1,0	1,40	Paracetamol	1,0	0,57	
Dimedrolum	1,0	0,97	Pentazocine	1,0	1,45	
Dimexydum	1,0	2,02	Pentoxylum	1,0	1,50	
Ephedrini h/c	1,0	2,10	Pepsinum	1,0	0,97	
Eritromicine	1,0	3,06	Perhidrolum	1 ml	0,50	
Euphyllinum	1,0	0,68	Phenadone	1,0	5,03	
Phenili salicylas	1,0	0,71	Sulfacylum - natrium	1,0	0,31	
Phenobarbitalum	1,0	0,33	Sulfadimezinum	1,0	1,00	
Piridoxini h/c	1,0	0,94	Sulfur depuratum	1,0	0,78	
Pix liquida	1,0	2,30	Sulfur praecipitatum	1,0	0,72	
Plathyphyllini h/t	1,0	4,00	Terpini hidratum	1,0	0,78	
Prednizolonum	1,0	1,70	Theophyllini	1,0	1,10	
Promedolum	1,0	1,70	Tiamini bromidum	1,0	0,97	
Protargolum	1,0	6,02	T-rae Belladonnae	1 ml	0,80	
Rezorcinum	1,0	0,50	T-rae Convallarie	1 ml	0,89	
Rhizoma cum rad.Val.	1,0	0,91	T-rae Crataeghi	1 ml	0,60	
Riboflavinum	0,1	1,28	T-rae Leonuri	1 ml	0,79	
Rutinum	1,0	0,66	T-rae Menthae pip.	1 ml	0,70	
Saccharum	1,0	0,52	T-rae Valerianae	1 ml	0,50	
Scopolaminum h/b	1,0	1,02	Trichopol	1,0	1,26	
Sirupus Glicerhyzae	1 ml	0,50	Tripsinum	1,0	1,20	
Sol. Cytrali spir.1% 1 ml		0,89	Ung. Prednisoloni 0,5%	1,0	1,02	
Sp.aethylic. 96%	1,0	0,39	Ung. sulfurat. simpl.	1,0	0,89	
Spasmolytinum	1,0	0,80	Validolum	1 ml	0,67	
Streptocidum album	1,0	0,33	Vaselinum	1,0	0,34	
Streptocidum solubile	1,0	0,90	Xeroformium	1,0	1,62	
Succi Kolanhoae	1,0	0,91	Zincum oxydatum	1,0	1,10	

TAXA LABORUM

for the preparation of medicaments according to the (individual) prescriptions in the pharmacies

Nr.	Drug form, technological operation	U.M.	Price				
1.	Sterile solutions. Preparation of bicomponent prescribing with the vol-						
	ume: 400-500 milliliters						
	200-250 ml	vial	12.95				
	50-100 ml	vial	12.45				
	ad 50 ml	vial	10.20				
2.	Eye drops and ointments, medicinal forms for newborns. Sterile oils. Preparation of bicomponent prescribing.	vial	12.50				

Nr.	Drug form, technological operation	U.M.	Price
3.	Solutions for internal and external use. Prescr. bicomp., including infusions,		
	decoctions, mucilages:	vial	11.25
	Drops:		7.50
4.	Powder and dosed species. Preparation of bicomponent prescription	form	8.75
	no.10	101111	0.73
	dosing of each subsequent powder	doses	0.70
5.	Powders non-endangered species. Preparation of bicomponent pre-	form	7.50
	scription	101111	7.50
6.	Suppositories nr. 10. Preparation of bicomponent prescription.	form	20.00
	dosing of each suppository above 10	doses	0.90
7.	Ointments, pastes, emulsions, liniments, suspensions. Prescr. bicompo-	forms	15.00
	nent to 100.0 ml.	form	15.00
	100,0-200,0 ml.	form	17.50
	200,0-500,0 ml.	form	20.00
8.	The subsequent addition of each component (ingredient) into the drug	onon	2.50
	form.	oper.	2.50
9.	Responsibility for working with toxic and narcotic drugs	oper.	3.75
10.	Work with irritating, smelling and coloring substances	oper.	3.75
11.	Measuring (weighing) medicinal substances in their release without fur-	C	7.50
	ther technological operations	form	7.50

Recipe Register

		Medici	ines prepare	d extempo	raneously				
Date	No. of	The name of pa-	Drug	Release	Inclu	Patients			
	prescrip- tion	tient	form price		Purified Taxa la- water borum		address		

	r work day and for th	e reported period t	the following totals are		
made:	mnarary Farme				
	mporary Forms				
	ase prices				
_	edients				
	purified water				
	laborum				
Exercise 5. Draw	the balance for one da	y in the "Recipe Regi	ster".		
Exercise 6. For 2 to the patient.	registered prescription	ns, draw up the receip	ot, which must be handed		
	Receipt for ord				
Pharmacy	Date				
Nr. Recipe	Time				
The name of patient _					
_					
The pricelei _	Daiii				
Mixture	Ointment	Powder	Ophthalmic		
Solution			Sterile		
Solution	Drops	Suppositories	Sterile		
	Receipt for ord	lering the drug			
Pharmacy	Date				
Nr. Recipe	Time				
The name of patient _					
The pricelei _					
<u> </u>					
Mixture	Ointment	Powder	Ophthalmic		
Solution	Drops	Suppositories	Sterile		
Fyercise 7 Deter	rmine the halance and f	ill in the "Record of D	Orugs and Toxic, Narcotic		
			er month		
			e made: Invoice Nr		
			g. Deliveries according to		
=		eliveries according to	order-delivery vouchers		
of prophylactic curativ	e institutions <u> g</u> .				
1.Etaminal of natrium	m	2.Morphine hydroh	loride		
January		January			
Opening balance	=	Opening balance	=		
-	4 06.01.2315,0g	Inputs OD 269243 07.01.2335,0			
	9. 19.01.20	OD 321262 21.01.2325,			
10,0g		Deliveries Rec.amb.26,5			
Deliveries Rec.an		V MSI 39,0	Closing balance		
V MSI 11,3	Closing balance 7,65g	1,93g			

3.Atropine sulfate	4.Promedol			
January	January			
Opening balance 4,58g	Opening balance 12,5g			
Inputs FB 6292472 10.01.2315,0	Inputs OK 27924263 11.01.2325,0g			
FB 6312003 22.01.2310,0	OK 27993421 24.01.2330,0g			
Deliveries Rec.amb 10,7g	Deliveries Rec.amb. 32,6 g			
V MSI 10,5 g Closing balance	V MSI 31,5 Closing balance 3,1			
8,3g	-			
5.Dicainum	6.Atropine sulfate			
January	January			
Opening balance 23,57g	Opening balance 8,51g			
Inputs BM 02462924 11.01.2330,0	Inputs BM 026425320 6.01.2325,0			
BM 02491920 23.01.2325,0	BM 026429160 21.01.2335,0			
Deliveries Rec.amb.28,4	Deliveries Rec.amb.25,4			
V MSI 34,5 Closing bal-	V MSI 37,5 Closing balance			
ance15,3	6,35			
7.Codeine phosphate	8.Morphine hydrochloride			
January	January			
Opening balance 18,8g	Opening balance 15,4g			
Inputs FB 24962117 5.01.2325,0	Inputs BM 26996432 3.01.2325,0			
FB 24986921 26.01.2330,0	BM 26998967 25.01.2320,0			
Deliveries Rec.amb.28,9	Deliveries Rec.amb.25,5			
V MSI 30,5 Closing balance	V MSI 29,5 Closing balance			
14,10	5,8g			
9.Silver nitrate	10. Codeine phosphate			
January	January			
Opening balance 21,7g	Opening balance 16,7g			
Inputs BM 624000241 4.01.23100,0	Inputs OD 241632721 5.01.2365,0			
BM 624120690 22.01.2365,0	OD 241679342 27.01.23100,0			
Deliveries Rec.amb.96,5	Deliveries Rec.amb.95,5			
V MSI 75,5 Closing balance	V MSI 68,5 Closing balance			
11,4g	16,5g			
11. Morphine hydrohloride	12. Silver nitrate			
January	January			
Opening balance 15,4g	Opening balance 21,8g			
Inputs OK 024162294 9.01.2325,0	Inputs OC 249126727 03.01.2350,0			
OK 024196201 21.01.2330,0	OC 249296792 19.01.2360,0			
Deliveries Rec.amb.20,35	Deliveries Rec.amb.45,5 g			
V MSI 35,5g Closing balance	V MSI 70,5 Closing balance			
14,45	15,1			

Exercise 8. At the end of the month the factual balance of ______ in the production department constituted $_{_{_{_{_{}}}}}$ g (see data exercise 9). By comparing it with the balance registered in the registry (task 13), determine the amount of divergence. Establish the natural perishability and the extent of over-indebtedness. Make the respective conclusions from the name of the pharmacist.

Register of evidence of drugs and toxic, narcotic and psychotropic substances in pharmacies

Name of the medicine	Managed	person

]	Inputs	5				Out	puts		ch	jo			ŗ.
Month	Initial stock	Supplier, Nr. doc. date	The amount	Total Monthly: inputs	Types of outputs	1	2	3	4	 31	Monthly calculation for each type	Total monthly in all kinds of outputs	Recorded stock	Factic stock	Signature of Managing per- son
					The ambulatory pre- scription										
Janu-					Health institutions										
ary					pharmacies' subsidiaries,										
					pharmacies sections										
					The ambulatory pre- scription										
Feb-					Health institutions										
ruary					pharmacies' subsidiaries,										
					pharmacies sections										
					The ambulatory pre- scription										
					Health institutions										
					pharmacies' subsidiaries,										
					pharmacies sections										
					The ambulatory prescription										
					Health institutions										
•••					pharmacies' subsidiaries,										
					pharmacies sections										
					The ambulatory pre- scription										
					Health institutions										
					pharmacies' subsidiaries,										
					pharmacies sections										
					The ambulatory pre- scription										
De-					Health institutions										
cem- ber					pharmacies' subsidiaries,										
					pharmacies sections										

Exercise 9. Based on previously received prescriptions (see topics 11,12) prepare the "The act of destroying prescriptions with expired storage term", according to Annex no. 7 of the MS RM Order no. 960 of 01.10.2012.

Annex 7 of the MS RM order

no. 960 of 01.10.2012 **ACT** no.__ from _ of destroying prescriptions with expired storage term Conclusion of the commission Signatures: President Members of the commission have drafted this act of destroying prescriptions with an expired storage term: The period for which the No. of pre-The amount of No. Name of the medicine medicines were delivered d/o scriptions released drug Ways of destroying prescriptions _____ Signatures: Conclusions and suggestions of the student:

The teachers signature _____

Theme 14

TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING IN PHARMACY AND QUALITY CONTROL OF EXTEMPORANEOUS PREPARATION. PACK LABELING AND DISPENSING MEDICINES FROM PHARMACY

The purpose of the work: Studying the rational organization of workplaces for the preparation of drugs in pharmacies, their equipment and arrangement, the technological process of preparing medicines in the pharmacy according to the prescriptions and organizing the preparation of pharmaceutical elaborations. Acquiring practical skills to document internal pharmaceutical control and the appreciation of the quality of the medicinal forms, the completion of the pharmaceutical forms prepared in the pharmacy.

Form of training: laboratory practical work


Duration: 4 hours.

Questions for self-learning:

- 1. Rational organization, equipping and arranging workplaces for the preparation of medicines in the pharmacy.
- 2. Measures to accelerate the preparation of medicines and insurance their quality.
- 3. Particularities of organizing the work of the pharmacist in the preparation of drugs containing toxic and narcotic substances.
- 4. Requirements for the preparation of medicinal forms under aseptic conditions. Equipment and arrangement of rooms and workplaces.
- 5. Organization of pharmaceutical preparation and their documentation.
- 6. Organization of pharmacist-analyst activity on quality control of medicinal forms.
- 7. Internal Pharmaceutical Control of Medicines. Types of control.
- 8. Chemical and physico-chemical control in the pharmacy.
- 9. Quality assessment and deviations allowed in the preparation of extemporaneous drug forms.
- 10. Drawing up the documents for the quality control of the medicines.
- 11. Unique rules of labeling of medicines prepared in the pharmacy.
- 12. Labeling of drugs containing toxic substances, narcotics, particularly toxic, concentrated solutions of different drug substances etc.
- 13. The terms and conditions of storage of medicines prepared in the pharmacy.
- 14. Order of drug release, prepared in pharmacy.

Exercises for self-solving.

Exercise 1. Draw a layout of the pharmacy preparation rooms in the public pharmacy, indicate the location and specify the equipment at different places of preparation of the medicines.



Exercise 2. Indicate the types of mandatory internal pharmaceutical control. to which	ch
the forms will be subjected according to prescriptions. (see exercise 3, Theme no.s No. 13	3).
For 3-4 forms of medicine, make the "Written Verification Document".	

Exercise 3. Register in the "Register of Pharmaceutical elaborations" the following pharmaceutical elaborations determine the price of the medicated forms obtained as a result of the elaborations.

Variant number	Drug form No. 1	Drug form No. 2
1	Ascorbic acid 0.1 Glucose 0.2 N 20, 20 packs	Sol. Potassium iodide2% -200ml 10 vials
2	Theophylline 0.001 Glucose 0.2 N 20, 20 packs	Sol. Sulfacil sodium 30% -10ml 20 vials
3	Dibazol 0.03 Saccharum 0.2 N 20, 20 packs	Sol.Calcium chloride 10% - 200ml 10 vials
4	Papaverine Hydrochloride 0.1 Glucose 0.2 N 30, 20 packs	Sol.sulfacil sodium 20% - 10ml 30 vials
5	Riboflavin 0.002 Glucose 0.2 N 30, 20 packs	Sol. Protargol 2% - 10 ml 20 vials
6	Pyridoxine hydrochloride 0,001 Glucose 0.2 N 20, 30 packs	Sol. Methylene Blue 2% - 20 ml 20 vials
7	Thiamine hydrochloride 0,001 Glucose 0.2 N 20, 30 packs	Sol. Colargol 2% - 10 ml 30 vials
8	Rutin 0.04 Glucose 0.2 N 30, 30 packs	Sol. Colargol 1% - 10ml 30 vials
9	Phenobarbital 0.005 Glucose 0.2 N 20, 30 packs	Sol. Calcium chloride 5% - 100ml 20 vials
10	Caffeine sodium benzoate 0.03 Glucose 0.2 N 20, 20 packs	Sol.Levomycetine 0.25% - 10ml 20 vials
11	Calcium gluconate 0.2 Glucose 0.2 N 20, 20 packs	Sol. Furaciline 1: 5000 - 500ml 10 vials
12	Folic Acid 0.0003 Glucose 0.2 N 20, 20 packs	Sol. Riboflavin 0.02% - 10ml 20 vials

TAXA LABORUM for preparing pharmaceutical preparations in pharmacies

Nr.	Drug form, technological operation	U.M.	Taxa
1.	Sterile solutions. Preparation of bicomponent with the volume: 400-500 ml	vial	6.40
	200-250 ml	vial	6.25
	până la 100 ml	vial	5.90
2.	Eye drops and ointments, medicinal forms for newborns. Sterile oils. Preparation of bicomponent prescribing.	vial	7.00
3.	Solutions for internal and external use. Preparation of bicomponent prescribing with volume 5000 ml and more	vial	8.75
	1000-5000 ml	vial	5.65
	400-500 ml	vial.	3.30
	până la 250 ml	vial	2.90
4.	Infusions and decoctions. Preparing bicomponent prescribing: more than 1000 ml	vial.	13.30
	400-500 ml	vial	4.25
	till 250 ml	vial	3.75
5.	Powder and dosed species. Preparation of bicomponent prescription no.10	form	3.75
	dosing of each subsequent powder	doses	0.40
6.	Powders non-endangered species.	form	3.75
7.	Ointments, pastes, emulsions, liniments, suspensions. Prescr. Bicomponent.	form	7.50
	dosing of each subsequent suppository	doses	0.70
8.	The subsequent addition of each component (ingredient) into the drug form.	oper.	1.00
9.	Responsibility for working with toxic and narcotic drugs	oper.	3.30
10.	Work with irritating, smelling and coloring substances	oper.	3.30
11.	Division of medical remedies and medical confections	oper.	1.25

Form F-05

Approved by the Ministry of Health of the Republic of Moldova by order no. ___ din_and the Decision of the Department of Statistics of the Republic of Moldova Nr. ___ from ___

Section	EVIDENCE REGISTER OF PHARMACEUTICAL ELABORATIONS
Name of pharmaceutical unit_	

According to this model are printed all sheets.

	ρλ	Controlled	
	ρλ	Prepared	
	rence	Таха Ідрогит	
	The extra difference	Purified water	
	The	Total	
taught		Sum	
ivided,		Pric e	
Prepared, divided, taught		The amount	
		D M	
		The name of the finished production	
		Sum	
		Price	
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		The amou nt	
to wor		NM	
Taken into work		Name of material values	
		Charge	
		Date	

Exercise 4. Prepare internal quality control records for the quality of medicines and appreciate their quality:

- a) Register of quality control results of magisterial forms, drug forms in stock, concentrates, semi-finished products.
- b) Registry of Purified Water Quality Control Results.
- c) Register of Drug Determination Results.
- d) The protocol for the collection of medicinal forms for quality control.

All the data necessary for the preparation of the documents are taken from the minutes of the previous laboratory works.

Annex no. 2 to the Forms Quality Control Regulation medicinal products prepared in pharmacies Register of quality control results of magistral forms,

drug forms in stock, concentrates, semi-finished products

Name and signature of the person who performed the quality control Conclusion: corresponds or does not match Name and surname of the person who prepared, controlled or packaged quantitative, formula, index of Control results refraction **Oualitative** (+) or (-) physical organoleptic The active principle, volume, mass, homogeneity of the mixture Composition of the drug form Nr. series of the industrial producer Nr. recipe (bill); packaging series; Nr. filled stangas Nr. d / o who is and Nr. analysis Date

Registry of Purified Water Quality Control Results

Name and	signature of the person who per- formed the quality con- trol		
Conclusion: corresponds to or does not match			
es	CO ₂		
Results of control of absence of impurities	Reducing sub- stances		
absence o	NH ₄ +		
ontrol of	Ca ²⁺		
esults of c	SO ₄ 2-		
Re	Cl-		
	Nr. collector (workplace)		
7	Nr. d / o who is also Nr. con- trol quality		
	Date of control		
	Date of obtain-ing (water training)		

REGISTER OF DRUG DETERMINATION RESULTS *

	Nr. d /						Sig	natures
Date	o which is also Nr. analy- sis	Name	Nr. series or No. MMDA Quality Cer- tificate **	Nr. filled stangas	Determined substance (ion)	The result of control (+) or (-)	The person who filled it	The person who performed the quality con- trol

 $^{^*\}overline{\it This}$ record also records the results of the solution identity determination for the biuret system

Annex no. 6 to the Regulation for Quality Control of Pharmaceutical Forms in Pharmaciesc

Pharmacy No	
City, rayon	
	MINUTES
	of taking medicinal forms for quality control in pharmacies
	""20

	No nno		The price	Co	ontrol results			Name and sur-
No d/o	No. pre- scrip- tion (bill)	Composition of the drug form	The price of the drug form	Quality (+) or (-)	Quantitative (formula, re- fractive in- dex)	Physi- cal	Conclusion (satisfactory or unsatisfactory)	name of the per- son who pre- pared the medi- cine

The s	ignatur	es:						-		
Name	, surnan	ne, who performed ta	king							
in the	presen	ce of the person to be	sampled							
Head- Pharmacist										

^{**} Medicines and Medical Devices Agency

Exercise 5. For all forms of drugs according to prescriptions received choose and fulfill the finishing labels and warning inscriptions.

Exercise 6. Based on previously received prescriptions, indicate for each drug form the conditions and terms of storage in the pharmacy until release.

Exercise 7. Ased on previously received prescriptions, complete:

- a) "Register of drugs removed due to expiration of the storage term"
- b) "Register of drug delivery without receipt".

REGISTER Of drugs removed due to expiration of the storage term

Date	No. pre- scription	Patients NS	Drug form	Price	Retired (NS)

REGISTER OF DRUG DELIVERY WITHOUT RECEIPT

Date	Nr. of prescription	Pa- tients NS	Patients address	Drug form	Price	NS of physician	Signature

Conclusions and suggestions of the student:

The teachers		
I ha taachare	cianatiira	
THE LEACHELS	Signature	

Theme 15

MANAGEMENT AND LEGISLATION OF PHARMACEUTICAL ASSISTANCE IN HOSPITAL.

The purpose of the work: The study of the medical assistance system for stationary patients, the general principles of organization and operation of pharmacies of medical institutions, their attributions, space, endowment and leadership. Study of the clinician's pharmacist's work, his rights and obligations. Acquiring practical skills in using the Pharmacotherapeutic Formulary in the Sanitary Institutions and calculating the need for the medicines included in the Pharmacotherapeutic Formulary.

Form of training: Seminar and laboratory practical work. **Duration:** 8 hours.

Questions for self-learning:

- 1. The characteristic of the pharmaceutical care system for stationary patients.
- 2. Hospital pharmacy and the peculiarities of its activity.
- 3. Minimal requirements for space, location and endowment of the hospital pharmacy. Organizational structure and organization of work places.
- 4. Drug prescribing rules for stationary patients.
- 5. Control of storage and rational use of medicines in hospital wards.
- 6. Records of medicines and medical articles in health care institutions.
- 7. Clinical pharmacy and its role in the quality of medical treatment of inpatients.
- 8. The Formulary system "Rational Pharmaceutical Management".
- 9. Pharmacotherapeutic Formulary and its feature. Pharmacotherapeutic Formulary.
- 10. The role of the Pharmacotherapeutic Formulary Committee of the medical institution in the rational and efficient use of medicines.
- 11. Calculation of the necessary for the medicines included in the Pharmacotherapeutic Formulary of the medical institution.
- 12. Organizing the pharmaceutical supply of medical institutions through the procedures of centralized purchasing.

Exercises for self-solving.

Exercise 1. Perform the registration of the pharmaceutical products received from the pharmaceutical stores according to the tax invoices. Each student receives a set of invoices.

Exercise 2. Perform the prescription and acceptance (cost determination, registration) of the order for one of the medical institutions, subject to the following conditions:

- a) the order must include industrial and magistral drugs that are subject to quantitative evidence:
- b) all industrial pharmaceutical preparations should be included in the National Pharmaceutic Formulary.
- c) consider that the pharmacy fully satisfies the department's order.

Exercise 3. Record Order-to-Delivery Bills (see task 2) in the Book of Records of Priced Bills.

Exercise 4. Prepare the "Pharmacy Management Report" including the operations performed during the reporting period. (see tasks 1 and 2).

Approved by the Ministry of Health of the Republic of Moldova by order no. _____ din____ and the Decision of the Department of Statistics of the Republic of Moldova Nr. ____ from _____

Register of inputs of material values

Name of the pharmaceutical unit

Note												
		In acquastion prices										
		In realization prices										
Including		In In acquisition realization prices										
Inch		In realization prices	9									
	Medicines	In acquisition prices										
	Medi	In realization prices										
Total amount		In acquisition prices										
Total 3		In realization prices										
Date Provider Accompanying document,												
Provider												
Date				T	T							
No.			\top	\dagger	T	Г			Г			

The standard form F-07

		ed by the Ministry of Hand the Decision of the I						
	_	narmaceutical unit (Fiscal Co	ode	
Secu	VII		 Consignee			Fiscal Code		
			Section (Cabinet)					
				(deputy "	chief physic "	ian signatur 20	e issues cur	rative)
			Through Delegat					
Purc	hase (Order Number				Deliver	y Bonn	et Nr
from '	· " _		fr	rom " "				
No. d/	Drug code	Name of the medi- cine	UM	The amount		The value		For extempora- neous forms, the
				re- quested	deliv- ered	Price	Sum	cost of purified water and "taxa laborum"
	E.	Toulfilled by	otal	Charles	ed by	rolos	acad by	
		hecked by			v allow			

The standard form F-07

		ed by the Ministry of Health cision of the Department of S		_		-			
Nam	e of p	harmaceutical unit (FU)			Fisc	cal Cod	e		
Section	on						Г		
Consignee Fiscal Code Section (Cabinet) (deputy chief physician signature issues curativ "" 20 Through Delegation Nr from									
		Order Number.		-	nnet Nr.				
					mount		value	For extempora- neous forms,	
No. d/o	Drug code	Name of the medicine	UM	re- queste d	deliv- ered	Price	Sum	the cost of purified water and "taxa laborum"	
		Total	<u> </u> 						
		Fulfilled by Checked by			У llow		-		

and the	Decision o	ne Ministry of He of the Departmen	-	-	_			
Pharma	cy	Boo	ok of Record	ls of Priced	Bills			
		in the	month	2	20			
			Section (offic	ce) health unit				
	No.				Including			
Date	bill	Total sum	Medicines	Materials for dressings		cal in- ments		
and the Pharma		of the Departmer	nt of Statistics	of the Repub	lic of Mold	ova Nr (chief doc	"APPR	ROVED
					11	"		20
			MANAGEME		_			20 _
	;	about the circu		ilue values i		ndices		
Type of		document (number	e month r and Drags		Auxiliary Materials	Package		
Initial s	tock la 01			ings	(Utensils)			
			IMP	UTS				
								<u> </u>
								+
								-
Total !	mnuta							
Total in	որուծ						1	1

Verso formulary F - 34

	UUIFU	113			
1. Delivery for sections, cabinets in accordance with "Book of Records of Priced Bills".					
Triceu Bills .					
Total outputs					
2. Losses under settlement (document, settlement).					
Total grassings loss					
Total crossings loss Total outputs					
Final stock la 31					
attached documents	Head	pharmaci	ist _		
Verified	Chief	accounta	nt .		
Exercise 5. Make an analysis of tional Pharmacotherapeutic Formular Medicines are not contained in the Nat	y. What	medicines	s on the Lis	st of Esse	

Exercise 6. The patient was pres	cribed by the doctor Suggest doc-
or generic and therapeutic substitution	on. Justify your decisions.
Tab. Relium 0,005 N20	
Tab. Metrozol 0,5 N20	
Tab. Timonil 0,2 N50	
Tab. Berlipril 0,01 N40	
Tab. Corinfar 0,01 N50	
Sol. Clodifen 75mg/5ml 3ml N5	
Sol. Aminofilin 2,4% -5ml N10	
Sol. Dicloberl 75mg/5ml 3ml N10	
Tab. Movalis 0,015 N10	
Exercise 7. Assume that in the	hospital "X" an "N" quantity of medication is used
	per year, and total cost - each student receives indi-
vidually).	per year, and total cost caen stadent receives mar
a) Make a classification of drugs used	by three key categories for life:
- V (Vital) - vital medicines requ	
- E (Essential) - Essential Medici	
- N (non-essential) - non-essential	
	al expenditure for each drug in relation to the total
	irchasing medicines (ABC Analysis).
Conclusions and suggestions of t	he student:
	The teachers signature

TOTALIZATION no. 3 ON HOMEWORK 11 - 15.

Theme 16

PHARMACEUTICAL RECORDS. THE PRICES FOR DRUGS AND OTHER PHARMACE-UTICAL PRODUCTS.

The purpose of the work: Acquisition of the principles of organizing the record and the peculiarities of the economic activity of the pharmaceutical enterprises, the principles and the way of forming the prices of medicines and other pharmaceuticals.

Form of training: Laboratory practical work.

Duration: 4 hours.

Questions for self-learning:

- 1. General characteristic of the record. Notions. Purpose, tasks and requirements for evidence.
- 2. Types and standards of record. Organizing records in pharmaceutical companies.
- 3. Classification of pharmaceutical companies' funds and their characteristic.
- 4. The objects of record in pharmaceutical companies. Documentary preparation of management operations. Justifying documents. Document requisites.
- 5. Prices and their components. Prices for medicines and other pharmaceuticals.
- 6. The order of price formation of medicines and other pharmaceuticals in Republic of Moldova

Exercises for self-solving:

	c ise 1. Desc	ribe the not	tion of "evi	dence", in	dicate what	are the req	juirements fo
vidence.							
Exerc	c ise 2. Repr	esent in the	e form of a	diagram tl	ne characte	ristic of fun	ds of pharma
eutical ent	_						P

Exercise 3. According to "Pricing regulation for medicines":

a) Determine purchase prices and wholesale drug "A" based on the following data: The cost for a unit of measurement of the drug - ___ \$ US. 2000 units were imported. Custom duty and state fee - 0.25% of the amount. Import duty - 0,1% of the amount. Cost of State Quality Control ___ lei. The warehouse markup will be in accordance with the legal provisions.

b) Determine the maximum retail pharmacy price of the same drug.

b) Determine the maximum retail pharmacy p	rice of the same drug.
Variant 1.	Variant 2.
The price of the medicine "A" UM 9-90 \$ US	The price of the medicine "A" UM 8-50 \$ US
Import 2000 units	Import 2000 units
Cost of State Quality Control 820 lei	Cost of State Quality Control 994 lei
Variant 3.	Variant 4.
The price of the medicine "A" UM 6-25 \$ US	The price of the medicine "A" UM 11-36 \$ US
Import 2000 units	Import 2000 units
Cost of State Quality Control 890 lei	Cost of State Quality Control 985-50 lei
Variant 5.	Variant 6.
The price of the medicine "A" UM 21-78 \$ US	The price of the medicine "A" UM 12-25 \$ US
Import 2000 units	Import 2000 units
Cost of State Quality Control 829-90 lei	Cost of State Quality Control 828-00 lei
Variant 7.	Variant 8.
The price of the medicine "A" UM 29-62 \$ US	The price of the medicine "A" UM 17-43 \$ US
Import 2000 units	Import 2000 units
Cost of State Quality Control 998-50 lei	Cost of State Quality Control 1227-00 lei
Variant 9.	Variant 10.
The price of the medicine "A" UM 8-96 \$ US	The price of the medicine "A" UM 11-64 \$ US
Import 2000 units	Import 2000 units
Cost of State Quality Control 996-00 lei	Cost of State Quality Control 989-00 lei
Variant 11.	Variant 12.
The price of the medicine "A" UM 8-95 \$ US	The price of the medicine "A" UM 11-92 \$ US
Import 2000 units	Import 2000 units
Cost of State Quality Control 972-00 lei	Cost of State Quality Control 997-00 lei

a)	

b)			

Exercise 4. Determine the maximum retail price of the following drugs by the phar-

macy:	
Variant 1.	Variant 2.
a)Drug B → 20 units price 29-80	a) Drug B \rightarrow 5 units price. 62-80
The warehouse markup 15%	The warehouse markup 12,5 %
b)Drug C →5 units price 680-20	b)Drug C →15 units price 199-20
The warehouse markup 4,95%	The warehouse markup 7,9%
Variant 3.	Variant 4.
a)Drug B \rightarrow 5 units price 295-00	a)Drug B \rightarrow 25 units price 25-80
The warehouse markup 4,8 %	The warehouse markup 15 %
b)Drug C →10 units price 52-20	b)Drug C →10 units price 102-50
The warehouse markup 11,4 %	The warehouse markup 10 %
Variant 5.	Variant 6.
a)Drug B \rightarrow 10 units price 101-80	a)Drug B \rightarrow 30 units price 29-80
The warehouse markup 10 %	The warehouse markup 14,9 %
b)Drug C →3 units price. 842-00	c) Drug l C \rightarrow 10 units price 242-50
The warehouse markup 5 %	The warehouse markup 5 %
Variant 7.	Variant 8.
a)Drug B \rightarrow 50 units price 4-80	a)Drug B \rightarrow 20 units price 115-80
The warehouse markup 15 %	The warehouse markup 10 %
b)Drug C →5 units price. 442-20	b)Drug C →10 units price 145-50
The warehouse markup 5 %	The warehouse markup 8 %
Variant 9.	Variant 10.
a)Drug B \rightarrow 40 units price 12-85	a)Drug B \rightarrow 20 units price 11-60
The warehouse markup 14,5 %	The warehouse markup 14,9 %
b)Drug C →10 units price 192-50	B)Drug C \rightarrow 10 units price 142-20
The warehouse markup 8 %	The warehouse markup 7,9 %
Variant 11.	Variant 12.
a)Drug B \rightarrow 5 units price 421-70	a)Drug B \rightarrow 25 units price 21-95
The warehouse markup 4,9 %	The warehouse markup 14,5 %
b)Drug C \rightarrow 10 units price 95-50	b)Drug C →10 units price 119-90
The warehouse markup 10 %	The warehouse markup 10 %

a)		

b)		

Exercise 5. Calculate the purchase price and the maximum wholesale and retail prices for the following import medicines:

nr d/o	N	Jame, dosage, pacl	kaging		Imported Quantity	State control costs (lei)	State fee (%)	Trans- port cost (lei)		Price Invois (in foreign currency)	Import currency	Exchange rate on the day of devotion
1	MIG® pentru copii	Sus. orală	20mg/1ml	100ml	5000	550	1	2300	45,59	2,33	EUR	20,25
2	Lerkamen ®	comp. film.	10 mg	N14x2	6500	590	1	4500	78,26	4,00	EUR	20,25
3	L-Thyroxin 100mcg BCh	comp	100mcg	N25x4	5500	550	1	1250	30,72	1,57	EUR	20,25
4	Prostamol Uno®	capsule moi	320 mg	N25x4	5500	580	1	1250	306,97	15,69	EUR	20,25
5	Bronchipret®	sirop		100ml	7000	650	1	1450	82,17	4,20	EUR	20,25
6	Ampicillin	p. p/u sol. inj	1 g	N50	4000	750	1	1400	193,56	10,05	USD	19,66
7	Diazolin	drajeuri	100mg	N10	6000	500	1	2500	8,86	0,46	USD	19,66
8	Ciprinol®	Com. filmate	750mg	N10	5500	650	1	1250	72,39	2,00	EUR	20,25
9	Siofor ®	Com. filmate	1000 mg	N15x4	7000	750	1	1450	49,69	2,54	EUR	20,25
10	Cyanocobalomina	sol.inject.	0,5mg/1ml	N10	2500	880	1	3000	10,97	0,57	USD	19,66
11	Nixar®	comprimate	20mg	N10	4500	550	1	2500	41,67	2,13	EUR	20,25
12	Fastum® gel	gel	25mg/g	100g n	5000	500	1	2300	81,39	4,16	EUR	20,25

nr d/o	N		Imported Quantity	State control costs (lei)	State tee	Trans- port cost (lei)		Price Invois (in foreign currency)	Import	Exchange rate on the day of devotion		
1	Lioton®	gel	1000UI/g	30g N1	5000	500	1	2300	78,06	3,99	USD	19,66
2	Spasmomen®	comp. film.	40mg	N10x3	3500	600	1	3200	89,80	4,39	USD	19,66
3	Berlipril ®	comp.	10 mg	N10x3	5000	590	1	2300	30,32	1,55	EUR	20,25
4	Flavamed®	comp.	30 mg	N10x2	4000	650	1	1400	27,78	1,42	EUR	20,25
5	Movalis®	Compr.	15 mg	N10x2	5500	650	1	1250	40,11	2,05	EUR	20,25
6	Gentamicina	sol.inject.	80 mg/2ml	2ml N10	7000	750	1	1450	39,48	2,05	USD	19,66
7	Sulfacil	pic.oft. sol	30mg/ml	10mlN1	7000	650	1	1450	11,36	0,59	USD	19.66
8	Quamatel ® mini	comp.film.	10 mg	N14	4000	650	1	1400	25,63	1,31	EUR	20,25
9	Rovaltro	comp. film.	10mg	N10x3	3500	550	1	3200	451,54	23,45	USD	19,66
10	Enap®	comp.	5mg	N10x2	7000	670	1	1450	9,20	0,47	EUR	20,25
11	Fromilid®	comp. film.	250 mg	N7x2	3500	680	1	3000	51,06	2,61	EUR	19,66
12	Finalgel®	gel	5 mg/g	35 g N1	5000	500	1	2300	43,67	2,25	EUR	20,25

nr d/o		Name, dosage, _l		Imported Quantity		State fee (%)	Trans- port cost (lei)	Price from CNPPM (lei)	Price Invois (in foreign currency)	Import	Exchange rate on the day of devotion	
1	Naclofen@duo	capsule	75mg	N10x2	6000	600	1	2500	35,02	1,79	EUR	20,25
2	Gliclada ®	comp.cu elib.prel.	30mg	N15x2	5000	680	1	1240	22,30	1,14	EUR	20,25
3	Roswera®	comp.film	20mg	N10x3	5500	780	1	3000	80,80	4,13	USD	20,25
4	Tenox®	comp.	10mg	N10x3	6500	590	1	4500	25,04	1,60	USD	20,25
5	Fusis®	comp.	50mg	N10	6500	600	1	4500	31,30	0,43	USD	19,66
6	Dexalgin®	comp.film.	25mg	N100	8000	650	1	1400	39,91	2,04	EUR	20,25
7	No-Spa®	comp.	40mg	200 ml N1	5500	680	1	3000	75,13	3,84	USD	20,25
8	Captopril	comp.	50 mg	N10x3	7000	550	1	1450	13,29	0,69	USD	19,66
9	Azitrox®	comp. film.	500 mg	Nx3	4500	630	1	3200	52,04	2,66	USD	19,66
10	Zeloxin®	sol.inj.	15mg/1,5ml	1,5ml N3	5000	570	1	2300	17,69	0,92	EUD	20,25
11	Neohemodez	sol.perf.	60 mg/ml	200ml N1	4500	750	1	2500	54,70	2,84	USD	19,66
12	Niperten®	comp.film	5mg	N10x3	5000	580	1	2300	17,80	0,91	EUR	20,25

Conclusions and suggestions of the student:	
The teachers signature	

Theme 17

CIRCULATION RECORDS OF PHARMACEU-TICAL PRODUCTS.

The purpose of the work: Learning the principles for determining the current demand in the in pharmaceutical products, controls and records the preparation of pharmaceutical products input. The study of the types of realization of pharmaceutical products and acquiring the practical skills of documenting these operations. Study of the classification, characteristics, destination and analysis of pharmaceutical stock indices.

Form of training: Seminar and laboratory practical work **Duration:** 4 hours.

Questions for self-learning:

- 1. Suppliers of medicines and other pharmaceutical products to pharmacies. Determining current needs in medicines and making orders.
- 2. Receiving pharmaceutical products in pharmacy. Record of inputs of pharmaceutical products.
- 3. Summary of the stocks increase sources of pharmaceuticals and their documentation.
- 4. Forms of achievement of pharmaceutical products. Turnover. Types and parts of the turnover balance between them.
- 5. Economic feature of the turnover. Analysis of the turnover indices.
- 6. Pharmaceutical stocks of pharmaceutical companies. Their classification and destination.
- 7. Records of expenses and losses of pharmaceutical products.
- 8. Quantitative evidence of drug circulation.

Exercises for self-solving.

Exercise 1. Determine current pharmacy medicines needs and make an order to the pharmaceutical warehouse based on the following data:

<u> </u>		-8				
No.	Name of the medicine	UM	Consumpt	on in the la	st 3 weeks	De-
d/o	Name of the medicine	UM	I	II	III	mand
1						
2						
3						
4						
5						

No.			Week	S	No.	Name of the medicine, dose, quantity		Week	S	
d/o	quantity	I	II	III	d/o	acso, quarrory	I	I	II	
	Variant 1					Variant 2				
1	Naclofen Duo 75mg N.20	7	5	7	1	Roswera 10mg N.30	15	12	18	
2	Movalis15mg N.20	5	4	5	2	Tenox 5mg N.30	12	15	18	
3	Fastum gel 2,5 %-30,0	5	8	7	3	Fusis 50mg N.10	5	6	7	
4	Spazmomen 40mg N30	6	5	4	4	Dexalgin 25mg n.10	10	12	14	
5	Siofor 1000mg N.60	10	12	9	5	Kaptopril 25mg N.20	13	7	10	
	Variant 3					Variant 4				
1	No-Spa 40mg N.24	16	19	15	1	Neohemodez 200ml	5	6	4	
2	Azitrpox 500mg N.3	11	10	12	2	Niperten 5mg N.30	10	12	19	
3	Panzinorm 20 000N.10	10	12	14	3	Normodipin 10mg N.30	15	24	23	
4	Corvalol 25ml	25	21	26	4	Lioton gel 30.0g	10	11	9	
5	Naftizin 0,1% 10ml	25	27	30	5	Citramon P N.10	96	119	125	
	Variant 5					Variant 6				
1	Cavinton 10mg N.30	5	6	5	1	Fromilid 500mg N.14	5	6	8	
2	Flavamed 30mg N.20	8	10	9	2	Rovaltro 10mg N. 30	2	3	4	
3	Senadexin N.10	45	35	40	3	Gliclada 60mg N.30	8	10	12	
4	Quamatel mini 10mg N.14	6	5	4	4	Nimesil plic.3g N30	5	4	6	
5	Enap 10mg N.20	10	12	18	5	Halixol 30mg N.20	11	10	13	
	Variant 7					Variant 8				
1	Spazz 40mg N.20	12	11	12	1	Nurofen 200mg N.12	12	10	13	
2	Melox Fort 15mg N.30	7	8	6	2	Strepsils N.24	6	8	7	
3	Etol Fort 400mg N.14	5	3	4	3	Famotidin 40mg N.30	10	9	11	
4	Aksef 500mg N.10	7	10	8	4	Piracetam 200mg N.10	60	58	61	
5	Carbo activatis 250mg N.10	58	60	83	5	Dexametazon 4mg N.20	3	5	4	
	Variant 9					Variant 10				
1	Tempalgin N.100	3	4	2	1	Suprastin 25mg N.20	5	7	6	
2	Lagosa 150mgN.100	5	6	7	2	Novocain 2%-2ml N10	4	3	2	
3	Galazolin 0,1% 10ml	15	16	18	3	Terbisil cremă 15g	5	6	8	
4	Ofloxin 200mg N.20	6	4	6	4	Dicloran gel 20g	7	8	10	
5	Inhalipt 30ml aer.	12	18	15	5	Groprinosin 250mg N.50	3	4	5	
	Variant 11					Variant 12				
1	Diroton 10mg N.56	6	5	8	1	Ciprinol 500mgN.10	5	7	4	
2	Atoris 10mg N.30	7	8	8	2	Rawel 1,5 N20	18	21	30	
3	Duovit N.40	5	6	4	3	Diroton 5mg N56	15	10	16	
4	Forsef 1g i/m N1	24	20	28	4	Cameton spray 30ml	10	11	14	
5	Rinzasip N10	8	6	7	5	Enap HL N.20	5	6	7	

Exercise 2. Prepare the act on the re-evaluation of pharmaceutical products. Please note that the following products have been re-evaluated:

Nr. d/o	Name of the medicine, dose, quantity	The amou nt	Price un- til	Price af- ter	No. d/o	d/o quantity		Price until	Price after		
	Varianta 1				Varianta 2						
1	Frontin0,25mg N.30	10	24,20	23,45	1	Cavinton forte 10mg N30	5	69-90	67-80		
2	Anuzol N.10	6	21-50	20-20	2	Alfa-lipon 600mg N.30	3	235-85	233-90		
3	Clemastin 1mg N20	3	18-20	17-10	3	Hartil 10mg N28	10	59-60	53-15		
4	Sol. Papaverin h/h 2% - 2ml N10	4	19-70	18-30	4	Enap 5mg N20	6	28-80	27-20		
5	Diprosalic ung. 15g	3	126-20	103-00	5	Suprastin 25mg N20	10	43-50	42-50		
	Varianta 3					Varian	ita 4				
1	Benevron BF N.N.20	5	108-80	105-50	1	Furagin 50mg N.30	5	42-60	41-50		
2	Mezim forte N20	20	25-10	24-60	2	Aksen Fort 550mg N.10	10	22-10	20-00		
3	Prednizolon 5mg N40	5	14-90	14-20	3	Furacilin 20mg N.10	15	16-75	16-20		
4	Trikaxon 1g i/m N1	20	36-15	35-00	4	Carsil 22,5 N.80	5	105-60	102,-80		
5	Neoanuzol sup.N10	2	22-50	21-90	5	Berlipril 10mg N.30	2	52-50	49-90		
	Varianta 5					Varian	ıta 6				
1	Choliver N100	10	149-00	145-00	1	Galazolin 0,1% 10ml	12	22-50	22-15		
2	Ciprinol 500 N10	8	91-00	89-00	2	Funzol 50 mg N7	3	142-00	125-00		
3	Fastum gel 50g	7	60-00	58-00	3	Diroton 10mg N28	10	71-50	69-90		

118)

Nr. d/o	Name of the medicine, dose, quantity	The amou nt	Price un- til	Price af- ter	No. d/o	Name of the medicine, dose, quantity	The amount	Price until	Price after		
4	Betadine 10% 120ml	7	81-55	113-05	4	Fromilid 500mg N.14	3	120-20	119-00		
5	Cinnarizin 25mg N.50	13	13-00	12-75	5	Forsef 1g i/m N1	30	38-00	37-00		
	Varianta 7				Varianta 8						
1	Ceftinex 300mg N.10	10	137-50	136-00	1	Floxadex pic. oft.10ml	6	55-50	53,80		
2	Mig 400mg N10	12	36-40	35-00	2	Trikaxon 1g i/m N1	25	38-20	34-20		
3	Lucetam 800mg N30	15	39-50	38-50	3	Ciston N100	3	132-50	131-20		
4	Cefecon D sup. N.10	5	12-40	11-60	4	Ostalon N4	5	232-00	229-00		
5	Berlipril 10mg N20	20	49-90	46-35	5	Maxigra 100mg N.4	4	189-55	184-90		
	Varianta 9					Varian	ta 10				
1	Aksef 750mg sol. inj. N.1	3	30-80	29-50	1	Melox 7,5 mg N.30	2	29-50	28-10		
2	Albendazol 200mg N.10	2	85-65	83-00	2	Ketanov 10mg N10	15	21-20	19-50		
3	Cavinton 5mg N.50	4	80-60	78.20	3	Fastum gel 100,0	3	120-95	119-00		
4	Furagin 50mg N.30	5	42-65	41-30	4	ACC 100 N.20	4	49-60	48-10		
5	Gaviscon N.16	2	70-00	67-90	5	Flucinalon N 18g ung	7	34-40	33-50		
	Varianta 11	L				Varian	ta 12				
1	Gabagamma 300mg N.100	2	314-80	309-50	1	Cavinton forte N30	10	79-50	75-00		
2	Carbune activat N10	300	4-90	4-50	2	Cerebrolizin 10ml N.5	5	609-95	598-90		
3	ACC 200 N.20	10	69-00	67-00	3	Adaptol 300mg N.20	4	114-95	113-00		
4	Fokusin 0,4 N.30	6	76-35	74-90	4	Alfa-lipon 600mg N.30	5	235-85	230-00		
5	Senadexin N10	50	14-20	13-50	5	Aciclovir 200mg N.30	3	61-00	59-50		

J	Sei	iduexiii N10	30 14	20 13-30	J = J = I	CICIOVII 2001	ng N.Su	J	01-00	39-30	
	Name of the pharmaceutical unit Tax Code										
	Sec	ction									
				A C T	No.						
			-1		_						
						of goods					
			of "	_''		_ 20	_				
Con	nmi	ssion in composition: cl	nairman								
com	nmit	tee members									
bas	ed o	on	Nr	fi	rom "			_20_			
has	rev	aluated the following g	oods. As	a result o	f invent	ory was re	vealed:				
						Prio	ce		The dif	ference	
N	Vo.	The name	IIM	The	IImell m	eevaluation	After re-	evalua-	THE GIT		
d	l/o	The name	UM	amount	Until re	eevaluation	tio	n	Extra	Less	
					Price	Sum	Price	Sum			
<u> </u>											

					PH		The an	ierence	
No. d/o	The name	UM	The amount	Until reevaluation		After re- tio		Extra	Less
				Price	Price Sum		Sum		
				Total					

Signatures:

Chairman of the commission

Commission members

Managed person

Exercise 3. Register the Fiscal Invoices for Medicines Received from the Pharmaceutical Warehouse "Register of Material Value Entries "(form F-02) (each student receives the set of invoices).

Approved by the Ministry of Health of the Republic of Moldova by order no. din and the Decision of the Department of Statistics of the Republic of Moldova Nr. from

Name of the pharmaceutical unit

Register of inputs of material values

Note											
		In In In In orderstron									
		In realization prices									
Including		In In In In acquisition realization acquisition									
Inch		In realization mores									
	Medicines	In acquisition mices									
	Medi	In realization roices									
Total amount		In In In acquisition realization a									
Total 3		In realization									
41,	document,										
No. Date Provider											
Date											
No.			П								

Exercise 4. On "__" day _____ 20 _ In the pharmacy have been recorded extemporary prescription and the following elaborations have been made: (see the data from the 13 and 14 topics). The amount of the extra difference from the delivery of extemporal forms to the MSI was 1543 lei, including purified water supply 329 lei. Draw the "Note about the extra difference and the difference in the minus" (form F-14). Take arbitrarily the missing data.

	_	f the Republic of Mol	order nofron dova Nrfron	
nit		Tax Code	,	
				
rence a) E		
		The	difference	
		Extra difference	In minu	IS
			X	
			X	
oration	S		T	
			X	
			X	
			X	
			X	
			Jsed for Manag	ging an
Price	No.		dicine form	Price
	,	Varian	t 2	
25-90	1			22-50
13-95	2			21-75
8-20	1		<u>t 4</u>	14-85
	oration Border es. Reme	Price No. d/o	NOTE rence and the difference in the The Extra difference Border of Records of Products Ces. Remember, that were used: Price No. d/o Name of the me Varian 25-90 1 Chlorhexidini biglucon 13-95 2 Antibacterial soap 300 Varian	The difference Extra difference In minu X X Orations Price No. d/o Name of the medicine form Variant 2 25-90 1 Chlorhexidini bigluconati 0,1%-100 ml 13-95 2 Antibacterial soap 300ml Variant 4

	Variant 1			Variant 2	
1	Sol.Ammonii caustici 10% - 25ml	25-90	1	Chlorhexidini bigluconati 0,1%- 100 ml	22-50
2	Wadding 60g	13-95	2	Antibacterial soap 300ml	21-75
	Variant 3			Variant 4	
1	Sol. Hydrogen peroxide 3% - 100ml	8-20	1	Wadding 60,0	14-85
2	Antibacterial soap 300ml	19-20	2	Hydrogen peroxide 40ml	6-50
	Variant 5			Variant 6	
1	Starch 500,0	14-00	1	Sol.ammonii caustici 10% - 25ml	26-90
2	Gauze 5m	26-50	2	Gauze 3m	18-30
	Variant 7			Variant 8	
1	Starch 500g	13-50	1	Gauze 3m	18-65
2	Chlorhexidin bigluconat 0,1%- 100ml	12-30	2	Antibacterial soap 300ml	19-20
F					

No. d/o	Name of the medicine form	Price	No. d/o	Name of the medicine form	Price
	Variant 9	nt 9 Variant 10			
1	Sol. Hydrogen peroxide 3%-100ml	8-20	1	Chlorhexidin bigluconat 0,1%- 100ml	21-90
2	Antibacterial soap 300ml	18-60	2	Antibacterial soap 60g	10-50
	Variant 11			Variant 12	
1	Gauze 10m	38-50	1	Antibacterial soap 500ml	21-70
2	Starch 400g	17-90	2	Gauze 3m	18-50

Form F- 11

N	Name (of the pharm	aceut	ical unit			ŗ	Гах Со	de 「		om
		n				Borde			L		
		of Records	of Pr	oducts U				ınd Fii	rst Medi	cal Aid	
				month	1		20_	_			
No.	_	Name of ma-		The	In the zation		In pur		Pur-	Signa	ature
d/r	Date	terial values	UM	amount	Price	Sum	Price	Sum	poses	Deliv- ered	Re- ceived
					Total						

Exercise 6. Register in the "The Border of Records of Products Used for Managing and First Medical Aid" following medicines. Note, that were used for first aid:

No. d/o	Name of the medicine form	Pricel	No. d/o	Name of the medicine form	Price
	Variant 1			Variant 2	
1	T-ra Leonuri cardiacae 25ml	9-20	1	T-ra Valerianae 25ml	9-80
2	Tab.Validol N10	4-00	2	Sol.Amoniac 10% -25ml	17-20

No. d/o	Name of the medicine form	Pricel	No. d/o	Name of the medicine form	Price			
	Variant 3		Variant 4					
1	Sterile gauze 7×14	10-20	1	Sterile gauze 7×14	8-50			
2	Sol.Iodi 5% -10ml	8-95	2	Sol.Brilliant green 1% -10ml	9-55			
	Variant 5		Variant 6					
1	T-ra Valerianae 25ml	9-30	1	Corvalol 25ml	9-20			
2	Gauze 5m	26-50	2	Tab.Validol N10	4-00			
	Variant 7			Variant 8				
1	T-ra Valerianae 25ml	9-20	1	Picături cardiace 50ml	18-00			
2	Sol.Amoniac 10% -25ml	13-15	2	Tifon steril 5×10	8-75			
	Variant 9			Variant 10				
1	Verde de briliant 1% -10ml	8-95	1	Tab.Validol N10	4-00			
2	Sterile gauze 7×14	8-25	2	T-ra Valerianae 25ml	9-10			
	Variant 11			Variant 123				
1	Sterile gauze 7×14	10-25	1	Cardiac drops 25ml	17-95			
2	Sol. Brilliant green 1% - 10ml	8-95	2	Tab.Validol N10	4-10			

By the end of the month there was no case of first medical aid.

Assistance.".

Ap	prove	a by the Minis and the De				-			e Repub	lic of Mo	
N	lame (of the pharm	aceu	tical uni	t			Tax C	ode		
S	Section	of Records o			The B sed for	Mana			st Medic	al Aid	
No.	D .	Name of ma-	113.4	The	In the zation		In pur		Pur-	Signa	ature
d/r	Date	terial values	UM	amount	Price	Sum	Price	Sum	poses	Deliv- ered	Re- ceived
			I		Total						
Ü	tures:										
Mana	aged p	erson			Α	ccount	ant				

Form F- 11

		ed by the Ministry Decision of the Dep						nofı	
Nai	me of t	he pharmaceutica	l unit .		Т	ax Code			
Sec	ction _								
				ACT	Nr				
0	n the S	ettlement of Medicir	nes and	d Other Ma	iterial Values	s Used for	Household	Purpose	s and for
				First l	Medical Aid				
			mo	onth		_ 20			
cor	nmissi	on composed of: con membersvn up this act, abo							
		s, medical supplies						20	
_								Sum	
	No. d/o	For what pu	rpose	s they we	re consume	ed	Purchas prices		alization prices
	1.	For household pu	ırpose	es					
	2.	For Firs Medical	Aid						
						Total:			
	iount ii nature	n letters: s: Head Members of tl		_					
		Managed pers	son						
<u>13</u>)		rcise 8. Draw up tider that the term				•	•	roducts'	' (Form F-
No.		Name	UM	Series	Term of valid- ity.	Receive	ed (date, supplie	r) Th amo	ou The amount
									I

Variant 1 Maxigra 100mg N.4 00264 04.04.23 Vinamex, 01.09.21 189-55 amb. Postinor N2 amb. 2732 09.04.23 Tetis, 02.06.21 2 99-70 12782 57-35 3 Urolesan 15ml 12.04.23 DitaEstFarm, 02.05.21 1 amb. Alprazolam 0,5mg N30 amb. 064213 21.04.23 Tetis, 02.04.21 1 39-20 Variant 2 012362 Frontin 0,25mg N.30 amb. 10.04.23 Vinamex, 01.06.21 1 24-20 2 06321 01.04.23 Tetis, 02.05.21 76-35 Betagen 15g amb. Siofor 1000 N60 DitaEstFarm, 02.04.21 3 amb. 08213 03.04.23 1 64-90 Prospan 100ml Vinamex 06.09.21 98-30 amb. 02472 19.04.23 Variant 3 Adep 30mg N30 06721 10.04.23 Virim Impex, 06.10.21 62-90 amb. Sinaflan 0,025% -25g amb. 01272 16.04.23 DitaEstFarm, 01.06.21 1 21-30 3 Furagin 50mg N30 amb. 042611 26.04.23 RihPanGalfarma, 12.02.21 1 42-65 RihPanGalfarma, 21.09.21 32-40 4 Pancreatin N60 amb. 039126 11.04.23 1 Variant 4

No.	Name	UM	Series	Term of valid- ity.	Received (date, supplier)	The amou	The amount
1	Imudon N40	amb.	063245	01.04.23	Tetis, 01.02.21	nt 1	124-50
2	Adenuric 120mg N.28	amb.	013216	07.04.23	Tetis, 01.02.21	1	290-80
3	Subtil N20	amb.	003216	11.04.23	DitaEstFarm, 01.02.21	1	89-70
4	Fromilid 250mg N14	amb.	001216	21.04.23	DitaEstFarm, 01.10.21	2	71-90
			Variai	nt 5			
1	Gabagamma 600mg N.100	amb.	03261	20.04.23	Vinamex, 01.02.21	1	314-90
2	Aksef 750mg sol. inj. N.1	amb.	01300	13.04.23	Dita, 02.01.21	1	30-85
3	Suprastin 25mg N20	amb.	04261	10.04.23	Tetis 02.10.11	1	69-80
4	Cefamed 1g sol inj. N.1	amb.	01362	21.04.23	RihPanGalfarma, 03.03.21	3	41-20
			Varia	nt 6			
1	Ketonal 100mg N10	amb.	26421	01.04.23	Tetis, 01.02.21	1	29-60
2	Imodium 2mg N10	amb.	26329	03.04.23	DitaEstFarm, 09.03.21	1	89-70
3	Betamaks 100mg N.30	amb.	26840	09.04.23	Tetis, 02.10.21	1	52-70
4	Ceraxon 100mg/ml 30ml	amb.	7625	10.04.23	RihPanGalfarma, 04.09.21	1	233-65
			Varia	nt 7			
1	Aerius 5mg N10	amb.	26392	02.04.23	DitaEstFarm, 01.02.21	1	78-90
2	Kaptopril 25 mg N20	amb.	32641	09.04.23	Tetis, 01.07.21	3	38-50
3	Amoxicilin 500 mg N10	amb.	42321	10.04.23	Vinamex 01.07.21	10	20-10
4	Alflutop 10mg/ml N10	amb.	61342	12.04.23	DitaEstFarm, 01.03.21	1	453-30
			Varia	nt 8			
1	Furagin 50mg N30	amb.	53267	03.04.23	Vinamex, 09.10.21	1	42-70
2	Maalox 250 ml	amb.	12364	16.04.23	DitaEstFarm, 01.07.21	1	78-20
3	Betamaks 50mg N.30	amb.	67432	21.04.23	Tetis 01.07.21	1	49-95
4	T-ra Propolis 25ml	amb.	12364	13.04.23	DitaEstFarm, 06.02.21	1	49-75
			Varia	nt 9			
1	ACC 200mg N.20	amb.	36241	06.04.23	Tetis, 10.02.21	1	66-90
2	Gaviscon N.16	amb.	76325	05.04.23	Vinamex, 12.01.21	1	70-50
3	Grippgo N10	amb.	3724	12.04.23	RihPangalFarm, 16.01.21	10	19-50
4	Aler-G 10 mg N.20	amb.	37213	14.04.23	DitaEstFarm, 10.01.21	1	55-80
			Varian	t 10			
1	Famotidin 20mg N20	amb.	36241	06.04.23	Tetis, 10.01.21	1	34-50
2	Fokusin 0,4mg N.30	amb.	21734	07.04.23	DitaEstFarm, 17.03.21	1	76-50
3	Dimexid 50ml	amb.	73217	15.04.23	Vinamex 10.12.21	1	53-40
4	Duspatalin 200mg N20	amb.	27112	03.04.23	DitaEstFarm, 12.01.21	1	65-20
			Varian	t 11			
1	Ceftinex 300mg N10	amb.	27213	12.04.23	Vinamex, 01.12.21	1	137-00
2	Cefamed 1.0	amb.	32126	10.04.23	RihPanGalfarma, 02.06.21	1	41-50
3	Klion-D sup.N.10	amb.	74127	06.04.23	DitaEstFarm, 01.06.21	1	78-50
4	Airtal100mg N60	amb.	3253	03.04.23	RihPanGalfarma, 06.05.21	1	172-80
			Varian		,		
1	Diazolin 0,1 N20	amb.	7342	02.04.23	RihPanGalfarma	2	29-60
2	Enalapril 5mg N20	amb.	12342	09.04.23	DitaEstFarm, 13.02.21	1	32-15
3	Airtal cremă 60g	amb.	72132	12.04.23	Tetis, 01.06.21	1	99-60
4	Adaptol 500mg N.20	amb.	27314	14.04.23	DitaEstFarm, 01.10.21	1	163-50

ı

mmissi	ion composed of: chair ion members	airman						
sed on . ering tl	ion members No he material values ro	from " etained ir	_'' 1	20	have d	lrafted t to be se	this act ettled.	about
	person							
No.	N	IIM	The		chase ices		ization rices	Cause of damage No, date of
d/o	Name	UM	amount	Price	Sum	Price	Sum	laboratory analysis
_								
			<u> </u>					<u> </u>
			 	<u> </u>				
			-					
al-vai o	Tota]		_
	on of the commission	_						
_	tures: Head bers of the commiss							
	ged person							
The a	ct approves. Losses	in the am	ount of _			to be pa	assed	
Pharr	macist-Head		.""_		_20_			
	destruction of mater							
Con	clusions and sugges	tions of th	<u>1e studer</u>	1t:				

Theme 18

EVIDENCE OF OTHER STOCK MO-VEMENTS. CASH FLOW IN PHARMACEU-TICAL COMPANIES.

The purpose of the work: Appropriating the operations of recording the circulation of other material values and monetary means in pharmaceutical enterprises and the documentation of these operations and the preparation of the Report on cash flow of the circulation of material values in the pharmaceutical enterprise.

Form of training: Seminar and laboratory practical work

Duration: 4 hours.

Questions for self-learning:

- 1. Evidence of circulation of other material values in pharmaceutical enterprises.
- 2. Fixed assets. Classification. Documentation of fixed assets.
- 3. Determining the efficiency of using fixed assets.
- 4. Objects of small value and short duration.
- 5. Evidence of cash. Purpose and tasks.
- 6. Operations of collecting and spending money and their documentation.
- 7. Cash register and control and Cash register and their compilation.
- 8. Cashier revision and control over the observance of discipline.
- Types of settlements by transfer. Evidence of payments with suppliers and buyers of medicines.
- 10. Report on cash flow in pharmaceutical companies. The structure, periodicity and method of drawing up and presenting the report.

Exercises for self-solving.

Exercise 1. Make a note about transferring subsequent packaging in freight for further realization:

No.	Name of the medicine, dose,	The	Price	No. d/o	Name of the medicine,	The	Price	
d/o	quantity	amount	nt 11166		dose, quantity	amount		
Variant 1					Variant	2		
1	Glass bottles 51	6	39-00	1	Wooden boxes	2	25-00	
2	Metal cans 50l	3	120-00	2	Glass bottles 10l	5	70-00	
3	Glass bottles 20l	5	78-00	3	Metal boxes	2	35-00	
	Variant 3				Variant	4		
1	Metal cans 50l	3	89-00	1	Glass containers 5l	6	35-00	
2	Plastic bag	4	62-15	2	Glass bottles 20l	5	85-00	
3	Glass bottles 20l	3	62-00	3 Metal cans 50l 3 19			195-00	
	Variant 5			Variant 6				
1	Metal cans 50l	5	182-00	1	Glass bottles 10l	10	68-00	
2	Glass bottles 20l	3	69-00	2	Glass bottles 20l	6	75-00	
3	Glass bottles 51	4	32-00	3	Metal cans 50l	3	170-00	
	Variant 7			Variant 8				
1	Metal cans 50l	5	169-00	1	Wooden crate	5	36-00	
2	Glass bottles 20l	10	79-00	2	Metal cake	3	164-00	
3	Glass bottles 51	7	29-00	3	Glass bottles 5l	6	81-00	

No. d/o	Name of the medicine, dose, quantity	The amount	Price	No. d/o	Name of the medicine, dose, quantity	The amount	Price		
Variant 9					Variant 10				
1	Plastic table	5	65-00	1	Glass bottles 5l	10	26-00		
2	Wooden crate	3	38-00	2	Glass bottles 20l	6	58-00		
3	Metal canister	4	158-00	3	Glass bottles 50l	3	102-00		
	Variant 11				Variant	12			
1	Plastic bag	5	78-00	1	Wooden crate	3	37-00		
2	Glass bottles 20l	2	57-00	2	Glass bottles 5l	3	29-00		
3	Metal canister	2	165-00	3	Metal canister	3	167-00		

Exercise 2. Document the collection of the following herbal medicinal product:

No.	Vegetable Product	The	Price	No.	Vegetable Product	The	Price		
d/o	name	amount	TITCC	d/o	name	amount	Trice		
	Varia	ınt 1			Variant 2				
1	Nettle leaves o	10 kg	80 lei/kg	1	Hyperici herbae	10 kg	120 lei/kg		
2	Chamomile flowers	5kg	125 lei/kg	2	Linden flowers	5kg	150 lei/kg		
	Varia	ant 3			Variant	t 4			
1	Marigold Flowers	15 kg	90 lei/kg	1	Hyperici herbae	10 kg	120 lei/kg		
2	Sheepfruit	20 kg	75 lei/kg	2	Hawthorn fruits	15 kg	100 lei/kg		
	Varia	ant 5		Variant 6					
1	Linden flowers	15 kg	125 lei/kg	1 Chamomile flowers 10 kg 125		125 lei/kg			
2	Chamomile flowers	10 kg	135 lei/kg	2	Aerial parts of salvia	15 kg	95 lei/kg		
	Varia	nt 7		Variant 8					
1	Linden flowers	6 kg	120 lei/kg	1	Mint leaves	10 kg	95 lei/kg		
2	Cascara Bark	10 kg	98 lei/kg	2	Cascara Bark	10 kg	90 lei/kg		
	Varia	int 9			Variana	10			
1	Marigold Flowers	7 kg	95 lei/kg	1	Aerial parts knotweed	10 kg	75 lei/kg		
2	Plantain feafs	8 kg	90 lei/kg	2	Mint leaves	10 kg	95 lei/kg		
	Variant 11				Variant	12			
1	Chamomile flowers	10 kg	125 lei/kg	1	Roots of licorice	6 kg	105 lei/kg		
2	Plantain feafs	8 kg	80 lei/kg	2	Leaf-thistle leaves	10 kg	76 lei/kg		

				FOTIII F- U9
Approved by the Mi	nistry of Health of the	e Republic of Mold	lova by order no	from
and the Decision of the	Department of Statis	tics of the Republ	ic of Moldova Nr. ₋	from
Name of the pharmace	utical unit	Tax	Code	
Section				
RE	CIPE RECIPIENT N	IO. of the m	edicinal plant pr	oduct
		"		
Received from		Identity Bulleti	n Series Nr	
Issued by	to P	ersonal code		
าววนนิน มง	iuI	ci sonai coue		

No. d/o	Vegetable Product name	UM	The amount	Collection price	The amount in the col- lection price	Realiza- tion price	Amount in the realization price	The re-sults of the analy-sis

No. d/o	Vegetable Product name	UM	The amount	Collection price	The amount in the col- lection price	Realiza- tion price	Amount in the realization price	The re-sults of the analy-sis			
	Total										
Me	edicinal herbal product										
	nt signature receiv		_								
То	pay	_ Amou	nt in lette	ers							
	(NPP of the supplier)										
Sig	Signatures: Head-Pharmacist Accountant										
	Supplier of herbal pr	oduct _									
" RECII	Exercise 3 . Make a note about transferring of herbal product collected according to the "RECIPE RECIPIENT" (task 2) in pharmaceuticals. The documents required for the operation: he positive results of the analysis of the medicinal plant product, carried out "" 20 _ with Nr										
	of the pharmaceutical unit			Tax	Code						
Section	n	Δ(T No								
	about tran				nt produc	t					
	fro	m ""		20							
	mposition of the commissi										
				Committee members							
on the				20 harro	droum iir		_				
	basis of Nr. of				drawn up	tnis act	-				
about t	the following product trans	sfer me	dicinal p	lant				Analysis			
			dicinal p	lant Collec	tion	Achieven	nent	Analysis Number			
about 1	the following product trans	sfer me	dicinal p The amou	lant	tion	Achieven	nent				
about 1	the following product trans	sfer me	dicinal p The amou	lant Collec	tion	Achieven	nent				
about 1	the following product trans	sfer me	dicinal p The amou	lant Collec	tion	Achieven	nent				
about 1	the following product trans	sfer me	dicinal p The amou	lant Collec	tion	Achieven	nent				
about 1	the following product trans	sfer me	dicinal p The amou	lant Collec	tion	Achieven	nent				
about 1	the following product trans	sfer me	dicinal p The amou	lant Collec	tion	Achieven	nent				
about 1	the following product trans	sfer me	dicinal p The amou	lant Collec	tion	Achieven	nent				
about 1	the following product trans	sfer me	dicinal p The amou	lant Collec	tion	Achieven	nent				
about 1	the following product trans	sfer me	dicinal p The amou	lant Collec	tion	Achieven	nent				
about 1	Vegetable Product trans	sfer me	dicinal p The amou	Collec	tion	Achieven	nent				
about 1	the following product trans	um	dicinal p The amount nt	Collec	tion I	Achievem	nent Sum	Number			

No. Name, No. d/r and date of the Medicines	aterial val-
MANAGING MANAGEMENT REPORT	aterial val-
MANAGING MANAGEMENT REPORT From "_"	aterial val-
From "_"	
No. d/r and date of the document Supplier No. d/r Sum	
No. d/r and date of the document Supplier No. d/r Name, No. d/r and date of the document Supplier Retail price Package Package Auxiliary materials Inputs Inp	
No. d/r and date of the document Supplier No. d/r Name, No. d/r and date of the document Supplier Retail price Package Package Auxiliary materials Inputs Inp	
No. d/r and date of the document Supplier Retail Wholesale price Package Auxiliary materials	
Stock at 01. Inputs Total inputs Retail price price materials price materials	
Inputs	
Total inputs	
Outputs	
Total outputs	
Stock at 01.	
Annex:documents	•
Report and documents received Corrections accept. Stock of goods in the amount	
Verified, confirm	
Accountant signature Managed person signature	

Exercise 4. Based on the documents executed during previous laboratory work draw

Exercise 5. Document one of the below-mentioned cash-in-house transactions: cashing from the execution of the industrial section; cashing from pharmacy branches; cashing from the bank for payment of the salary; reimbursement of the advanced and unused amount by the Head-pharmacist.

	TRANSMISSI				TEND	EIPT ER BET N	
	"—" The correspondence account	Analytic evidenc accoun	cal The	Special destina- tion code			20_
	Received from			Received	d from		
	Based on				1		
	(value i	n letters)			(value in lette		
		lei _	bani	lei	bani		
		ountant		Head Accounta	ınt		
		joint ord	er of the Dep		tistics of the	Republic	c of Molde
ate ompa	Approved by the	joint ordertry of Fina	er of the Dep ance of the R	artment of State epublic of Molo Tax Code Tax	tistics of the lova no. 24- Code	Republic	c of Moldo
ate ompa	Approved by the and the Minis	joint ordertry of Fina	er of the Dep ance of the R dress	artment of State epublic of Molo Tax Code Tax of the beneficiar	tistics of the lova no. 24- Code	Republic	c of Moldo
ate ompa ame (Approved by the and the Minis	add	er of the Dep ance of the R dress Name, Surname	artment of State epublic of Molo Tax Code Tax	tistics of the lova no. 24- Code	Republic	c of Moldorch 25, 19
ate ompa ame (Approved by the and the Minis any name of the beneficiar Name of goods	add	er of the Dep ance of the R dress Name, Surname	artment of State epublic of Mole Tax Code Tax of the beneficiary dress Value exclud-	tistics of the dova no. 24-	Republic 36 of Mar	c of Moldorch 25, 19
ate ompa ame (Approved by the and the Minis any name of the beneficiar Name of goods	add	er of the Dep ance of the R dress Name, Surname	artment of State epublic of Mole Tax Code Tax of the beneficiary dress Value exclud-	tistics of the dova no. 24-	Republic 36 of Mar	c of Moldorch 25, 19
ate ompa ame (Approved by the and the Minis any name of the beneficiar Name of goods	add	er of the Dep ance of the R dress Name, Surname	artment of State epublic of Mole Tax Code Tax of the beneficiary dress Value exclud-	tistics of the dova no. 24-	Republic 36 of Mar	c of Moldorch 25, 19
ate ompa	Approved by the and the Minis any name of the beneficiar Name of goods	add	er of the Dep ance of the R dress Name, Surname	artment of State epublic of Mole Tax Code Tax of the beneficiary dress Value exclud-	tistics of the dova no. 24-	Republic 36 of Mar	c of Moldorch 25, 19

Exercise 6. Document one of the following cash outflows: payment of salaries according to the payment list; payment for collecting the medicinal plant product; handing over money to the bank; advance for delegation expenses of the pharmacist's deputy assistant.

Company name			
	Payment	Nr	
	u n	20	
The correspond- ence account	Analytical evidence account	The value	Special destination code
Racad on	(Name, surna	· ·	
Daseu on		iba	 ani
	(value in l		****
-	Chief accou		
Received			bani
""20	(value in le Signa	etters] ture	
Identity card			
•	(series, number, date a		
Exercise 7. Throceutical products rec	ough the "Payment Order' eived in the pharmacy. (worth of _	document paymen Consider that the p	2
1. Dita EstFarm wo	orth 35760 lei	2. RihPanGalFar	ma worth 98465-00 lei
3. EsculapFarm wo	orth 46620-20 lei	4. Farmina worth	n 65250-20 lei
5. RihPanGalFarma	a worth 52674 lei	6. UniFarm wort	h 33710-55 lei
7. Sanfarmprim wo	orth 49926-60 lei	8. RihPanGalFarı	na worth 85480 -00 lei
9. Vinamex worth	72825-80 lei	10. Lismedfarm w	orth 61340-00 lei
11. Tetis Internatio		12. Becor worth 5	

Pavmen	t order	No.		DATA EMITE	RII	.DOC. TYP. 1
Pay			LEI			
Payer	(R)				IBAN Code	
					CODUL FISCAL	
Paying provi	der					
D						
Benefit	(R)				IBAN Code Tax code	
					1 ax code	
		_				
PRESIATOR	RUL BENEFICIAI	к				
Payment desti	nation				Transfer Type	
					NORMAL/URGENT	
					N	/
						(L. S.)
Transaction co	ode	Date of receipt	Date of exec	cution	Signatures of the Issuer	
L					Signatures of the Issuer	
			Signature	e of the provider	L. S.	
		Reason for refusal			2. 5.	
		Reason for refusar				
Cond	lucione and	l suggestions	of the studen	·+·		
Conc	iusions and	suggestions	or the studen	11.		

The teachers signature_____

Theme 19

LABOR AND WAGES RECORDS. CON-SUMPTION, EXPENSES AND RESULTS OF THE ECONOMIC ACTIVITY OF PHARMACEU-TICAL ENTERPRISES

The purpose of the work: Acquisition of the principles for the determination of the tariffs of pharmacies, staff records and working time, calculation of salary, bonuses, increments and supplements, salary deductions, salary payment order. Determining the results of the economic and financial activity and ways to increase the efficiency of the activity of the pharmaceutical enterprises.

Form of training: Seminar and laboratory practical work **Duration:** 4 hours.

Questions for self-learning:

- 1. The purpose of labor and wages records. Evidence of staff and time sheet.
- 2. Salary systems and forms in pharmaceutical enterprises.
- 3. Basic labor and pay indexes and their characteristics.
- 4. The basic and additional labor remuneration and their characteristics.
- 5. Determination rate of wages of pharmaceutical personnel. Supplements to wages and bonuses.
- 6. Charges from salary.
- 7. Social assistance.
- 8. General concepts of consumption and expenditure. Consumption composition. Composition of expenditure.
- 9. Determination of consumption and expenditure. Record of expenditures in pharmaceutical companies. Analysis of expenditure on items and amount.
- 10. Commercial payment and economic characteristics. Formation of commercial rebate. His destination. Prime cost.
- 11. Determination of realized and unrealized added value.
- 12. Results of financial-economic activity of pharmaceutical companies.
- 13. General considerations on the taxation of pharmaceutical companies. The structure of the balance sheet.

Exercises for self-solving.

Exercise 1. Establish pharmacy staff. In the pharmacy activate the production sections with material stocks and industrial forms. Pharmacy activity program between $8^{\circ\circ}$ and 20^{00} , with no rest days.

Exercise 2. Determine the rate of wages of pharmaceutical personnel.

Company Name	
, ,	Staffing for the year
	8 ,

No.	Name, Surname	Job title	Units	Wage rate or function salary

No.	Name, Surname	Job title	Units	Wage rate or function salary
probler	or work of a pharmacist with years ns.	of service. Use	ine uata	Trom the previou

Exercise 4. Calculate the amount of the insurance subsidy during the temporary working incapacity of a pharmacist with a seniority in work ___ years.

		Maod	Posse de																
		nep	+200)		\vdash	\vdash		Н	Н	$\overline{}$	Н	Н				П			
			mad still			\vdash		Н	Н		Н	Н	Н			Н			
						H	H	Н	Н		Н	Н	Н			Н			
			30			\vdash		Н	Н				Н						
			2			\vdash		Н				Н	Н			Н			
			28 2					\vdash		\vdash		Н			\vdash	Н			
			13			Т		Н	Н		П	П				П		-	Margaret .
			25			Г		П	П	П	П	П				П			
			23																
			- 75																
			8																
			81					\perp											
			- 54										Ш						
			2			L		⊢	L	\vdash			Н		_			-	
Sectia			6			L		H	H				Н			Н			
- 7	HOTE.		90			H	H	Н	H			Н	Н						
	5	Data	5 17			\vdash		Н	Н	Н	Н	Н	Н		\vdash	Н			
	22		91 81			\vdash		Н	Н		Н	Н				Н			
	-		=		\vdash	\vdash		Н	Н	\vdash	Н	Н	Н		\vdash	Н			
	=		13					Н	Н			П				П			
	Foaie colectivă de prezență Luna		23		Г	Т		П	П		П	П				П			
	5		=																
	00		2																
	.≅		01																
	<u> </u>		96																
	_ 3		Pin-					\perp										-	
			49					ш								Ш		de la	
			W)	_		L		⊢	Н	-			Н		_			Æ	
			-			L		Н	H	\vdash		Н	Н			Н			
			2		\vdash	\vdash		Н	\vdash	\vdash		Н	Н		\vdash	Н		Æ	
			- 3					Н	H	\vdash			Н			Н		Ē	=
		\vdash		\vdash		\vdash		Н	Н	\vdash			Н		\vdash	Н			5
			fund;is															Conducătorul întreprinderii	Şef de secție
Ē		"	2.3															0	9>
prind			<u> </u>																
intre		Numela	prenumele																
2		Ž	bud																
Denumirea intreprinderii		- 5	q ₀										Н			П			
		_		_		_	_	_		_					_		ı		

Exercise 5. Calculate the size of the payment for ordinary leave for a worker in pha	ar-
macy. Use the data from previous tasks.	
Exercise 6. Calculate payment for working on holidays. Please note that during to	
holiday days a pharmacist worked within the monthly balance of working hours and t	
second - in addition to the balance sheet with salaries of lei. Two such pharmacis	
were also working under such conditions for a holiday day with a monthly salary of le	<u>:1.</u>

Exercise 7. Transfer all expenses incurred by the pharmacy (see problems of the previous laboratory work) to the appropriate items according to the form proposed in the table below.

Delow.		
Name of the document, (No. of the topic)	Value, lei	Expenditure item

Exercise 8. Based on exercise 7 data, calculate the total cost of the pharmacy spend for the previous (managed) period per item and amount.

No. d/o	Item name	Value, lei	Share (%) to turnover of pharmacy

Pharmacy			

Draft expenditure for the year 20 _.
Turnover in the reporting year 6520750-55 lei.
The project turnover for the year 20__,___lei.

N d/o	Item name	Fulfillin the repo	orted	The profession for the 20	e year
		Sum	%	Sum	%
1.	Auxiliary materials	3000			
2.	Salary				
3.	Contributions for social insurance and social protection				
4.	Maintenance and repair costs of fixed assets for administrative and general economic purposes	16000			
5.	Expenditure on fuel, gas, electricity, water	62000			
6.	Ensuring enterprise assets	10000			
7.	Amortization of intangible assets	15000			
8.	Wear of inventory items (dishes, special sanitary clothing, underwear)	1000			
9.	Expenditure on packaging operations	5000			
10.	Current expenditure on rent of premises and equipment, unrelated to production	12000 0			
11.	Payments for banking, auditing, legal and other services	60000			
12.	Losses due to degradation of values and gaps in the limits and over norms of natural perishability				
13.	Losses due to interruptions	-			
14.	Expenses related to the acquisition of marketing licenses for the appropriate types of activity	5000			
15.	Expenditure on maintenance of security and fire safety assurance	30000			
16.	Judicial and arbitration costs	-			
17.	Office, post, telephone and telegraph charges	20000			
18.	Payments to charity organizations	-			
19.	Expenditure on studies (training of staff)	5000			
20.	Expenses related to development, for research, design and experimentation	-			
21.	Fees, fees, and other mandatory payments except for income tax (profit)	10000			
22.	Expenditure on labor remuneration and security techniques	15000			
23.	Travel expenses	-			
24.	Expenditure on transport employees	-			
25.	Expenditure on environmental protection	10000			
26.	Other administrative and general expenses of the household				

Exercise 9. Calculate the value and amount of the rebate made for the month _____. Please note the data in the table below:

Flease IIO	te the data i		Delow.		
Current situation and	Value	` '	Current situation and circu-	Value	
circulation of pharma- ceuticals	In the realiza- tion prices	In acquisi- tion prices	lation of pharmaceuticals	In the realiza- tion prices	In acquisition prices
Va	riant 1	,	Vai	riant 2	, , , , , , , , , , , , , , , , , , ,
Balance Mar 01.03	650141-80	548275-50	Balance Mar 01.03	766080-35	654755-35
March inputs	680162-50	661052-45	March inputs	800270-25	690150-90
Realization	693599-25	-	Realization	770150-57	-
other outputs	1117-75	947	other outputs	783-45	670-20
Balance 01.04 April			Balance 01.04 April		
Va	riant 3		Vai	riant 4	
Balance Mar 01.03	813352-40	694683-70	Balance Mar 01.03	876342-05	749475-25
March inputs	852090-20	729278-50	March inputs	864200-60	739084-90
Realization	800758-15	-	Realization	621225-16	-
other outputs	2091-80	1807-50	other outputs	982-80	840-60
Balance 01.04 April			Balance 01.04 April		
Va	riant 5		Vai	riant 6	
Balance Mar 01.03	989545-65	859789-55	Balance Mar 01.03	1209780-30	1034143-35
March inputs	961250-45	825725-60	March inputs	1399101-95	1196010-50
Realization	800262-63	-	Realization	1138960-25	-
other outputs	2283-05	1958- 65	other outputs	1597-05	1365-30
Balance 01.04 April			Balance 01.04 April		
Va	riant 7		Vai	riant 8	
Balance Mar 01.03	672712-40	580455-50	Balance Mar 01.03	989854-00	886503-25
March inputs	684053-20	590842-40	March inputs	930520-50	851757-55
Realization	651240-65	-	Realization	919248-25	-
other outputs	952-85	821-65	other outputs	3001-65	2567-05
Balance 01.04 April			Balance 01.04 April		
	riant 9			iant 10	
Balance Mar 01.03	998998-95	882503-65	Balance Mar 01.03	793934-65	689475-35
March inputs	885220-60	869981-50	March inputs	820759-70	706003-40
Realization	864565-50	-	Realization	791330-05	-
other outputs	3119-65	2689-05	other outputs	1109-90	955-85
Balance 01.04 April			Balance 01.04 April		
Vai	riant 11		Var	iant 12	
Balance Mar 01.03	954156-15	819385-35	Balance Mar 01.03	1145769-35	992058-45
March inputs	968256-95	832265-85	March inputs	1142695-75	989705-40
Realization	942617-50	-	Realization	999784-50	-
other outputs	2175-95	1875-85	other outputs	2247-90	1945-30
Balance 01.04 April			Balance 01.04 April		

LACICISC 10. Galt	ulate til	e coefficient an	d the level of p	rime cos	st for the same	periou.
Exercise 11. Dur	ing the	management p	eriod were so	ld medi	cations in the	amoun
of lei. The avera	ge level	of the comme	rcial rebate co	nstitute	ed %. Calcu	ılate the
a <u>mount of the rebate sh</u>			nt and level of p	orime co	ost for this per	iod
1Realizing 925,7 thou-		zing 880,127	3. Realizing 925,	14	4. Realizing	11.
sand lei N RC=19,3%		sand lei =19,3%	thousand lei N RC=18,3%		1329,3 thousa N RC=17,6%	ana iei
5. Realizing 965,16		alizing 795,765	7. Realizing		8. Realizing	
thousand lei		sand lei	1250,92 thous	and lei	896,57 thous	and lei
N RC=18,2%		=19,2%	N RC=16,5%		N RC=17,3%	
9. Realizing 579,58	10. Rea		11. Realizing	968,65	12. Realizing	671,59
thousand lei N RC=18,4%		sand lei =16,8%	thousand lei N RC=18,2%		thousand lei N RC=14,9%	
N KC-10,4%	IN NC-	-10,0%	N NC-10,2%		N NC-14,5%	
Exercise 12. The	volume	e of realization	of pharmaceut	ical pro	ducts (turnov	er of the
Exercise 12. The pharmacy, a legal entity			_	_	-	
	y of 20 _	_ constituting _	le	ei. The a	verage comme	ercial re
pharmacy, a legal entity	y of 20 _ %.	_ constituting _ Pharmacy reve	nue from othe	ei. The a r activit	verage comme ies was	ercial re- _ lei. Op
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharma	y of 20 _ %. basic ac cy's fina	_ constituting _ Pharmacy revectivity ancial and econ	enue from othe lei, other exper omic activity fo	ei. The a r activit nses or this y	verage comme ies was lei. Deter ear (global inc	ercial re _ lei. Op mine the come, in
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharma come before tax, amou	y of 20 _ %. basic ac cy's fina nt of tax	_ constituting _ Pharmacy revectivity ancial and econ xes to be paid,	nue from othe lei, other expenomic activity for benefit, profita	ei. The a r activit nses or this y bility). l	verage comme ies was lei. Detern ear (global inc Draw up the re	ercial re _ lei. Op mine the come, in eport or
pharmacy, a legal entity bate on the same time	y of 20 _ %. basic ac cy's fina nt of tax	_ constituting _ Pharmacy revectivity ancial and econ xes to be paid,	nue from othe lei, other expenomic activity for benefit, profita	ei. The a r activit nses or this y bility). l	verage comme ies was lei. Detern ear (global inc Draw up the re	ercial re- _ lei. Op mine the come, in- eport or
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharma come before tax, amou "The results of the econ	y of 20 _ %. basic ac cy's fina nt of tax nomic ar	_ constituting _ Pharmacy revectivity ancial and econ xes to be paid, and financial acti	enue from othe lei, other exper omic activity fo benefit, profita vity" of the pha	ei. The a r activit nses or this y bility). I armaceu	verage commeries waslei. Determent lei. Deter	ercial re _ lei. Op mine the come, in eport or
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amount The results of the economic of the economic of the volume of realization.	y of 20 _ %. basic ac cy's fina nt of tax nomic ar	_ constituting _ Pharmacy revectivity ancial and econ xes to be paid, and financial acti	enue from othe lei, other experomic activity for benefit, profitativity" of the pharealization -	ei. The ar activith ases or this y bility). I armaceu	verage commeries was lei. Determent lei. Dete	ercial re _ lei. Op mine the come, in eport or on -
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharma come before tax, amou "The results of the econ	y of 20 _ %. basic ac cy's fina nt of tax nomic ar on - evenue	_ constituting _ Pharmacy revectivity ancial and econ xes to be paid, and financial acti	lenue from othe lei, other experomic activity for benefit, profitation - narmacy revenue	ei. The ar activithses or this ybility). In armaceu	verage commeries waslei. Determent lei. Deter	ercial re _ lei. Op mine the come, in eport or on -
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous "The results of the econ" 1. The volume of realization of the econ from other activities 28,2 N RC= 18,4%	y of 20 _ %. basic ac cy's fina nt of tax nomic ar on - evenue 2 th. lei,	_ constituting _ Pharmacy revectivity ancial and economics to be paid, and financial action 2. The volume of 8798,25 th. lei, Pherom other action N RC= 19,6%	enue from other lei, other experomic activity for benefit, profitativity" of the pharealization - parmacy revenue rities.27,2 th lei	ei. The ar activithsesor this y bility). In armaceu	verage commercies waslei. Determent [global incompany] Draw up the restricted company Dlume of realization the lei, Pharmacy ther activities 27, 19,7%	ercial re _ lei. Op mine the come, in eport or on - revenue .6 th. lei
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous "The results of the econ" 1. The volume of realization (6599,6 th. lei, Pharmacy reform other activities 28,2 N RC= 18,4% Operating expenses of the	y of 20 _ %. basic ac cy's fina nt of tax nomic ar on - evenue 2 th. lei,	_ constituting _ Pharmacy revectivity ancial and econexes to be paid, and financial action acti	enue from othe lei, other experomic activity for benefit, profitativity" of the pharmacy revenue rities.27,2 th lei	ei. The ar activithsesor this y bility). If armaceu 4350,55 from of N RC= 10 Operatir	verage commercies waslei. Determent [global incompany] Draw up the restricted company Dlume of realization the lei, Pharmacy ther activities 27, 27,7% ag expenses of the	ercial re _ lei. Op mine the come, in eport or on - revenue .6 th. lei
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous "The results of the econ 1. The volume of realization 6599,6 th. lei, Pharmacy refrom other activities 28,2 N RC= 18,4% Operating expenses of the basic activity. 794,5 th. lei	y of 20 _ %. basic ac cy's fina nt of tan nomic an on - evenue 2 th. lei,	constituting _ Pharmacy reversitivity ancial and economics to be paid, and financial action ac	enue from othe lei, other experomic activity for benefit, profitativity" of the pharmacy revenue rities.27,2 th lei	ei. The ar activithsesor this y bility). If armaceu 3. The vo. 4350,55 from of N RC= 14 Operatir basic act	verage commercies was lei. Determear (global incompany of the lei, Pharmacy the lei, Pharmacy the activities 27, % ag expenses of the lei, very 698,6 th lei	ercial re _ lei. Op mine the come, in eport or on - revenue 6 th. lei
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous "The results of the econs". The volume of realization 6599,6 th. lei, Pharmacy refrom other activities 28,2 N RC= 18,4% Operating expenses of the basic activity. 794,5 th. lei Other expenses. 27,525 th	y of 20 _ %. basic ac cy's fina nt of tan nomic an on - evenue 2 th. lei,	_ constituting _ Pharmacy reversitivity ancial and economics to be paid, and financial action action action with the properties of t	enue from othe lei, other experomic activity for benefit, profitation - narmacy revenue rities.27,2 th lei es of the 1,5 th. lei 2,563th lei	ei. The ar activithses or this y bility). If armaceu 3. The vo 4350,55 from of N RC= 14 Operatir basic act Other ex	verage commercies was lei. Determear (global incompany olume of realization the lei, Pharmacy ther activities 27,9,7% ag expenses of the civity 698,6 th leipenses. 24,563 th	ercial re _ lei. Op mine the come, in eport or on - revenue 6 th. lei
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous "The results of the econ" 1. The volume of realization 6599,6 th. lei, Pharmacy refrom other activities 28,2 N RC= 18,4% Operating expenses of the basic activity. 794,5 th. lei Other expenses. 27,525 th. 4. The volume of realization	y of 20 _ %. basic accy's finant of taxonic and comic and comic and comic and comic at the lei,	_ constituting _ Pharmacy reversitivity ancial and economics to be paid, and financial action a	enue from othe lei, other experomic activity for benefit, profitativity" of the pharmacy revenue rities.27,2 th lei les of the pharmacy from the lei les of the lei les of the pharmacy from the lei les of the lei les of the pharmacy from the lei les of the lei les of the lei les of the lei les of the pharmacy from the lei les of the lei l	ei. The ar activithses or this y bility). In armaceu 3. The voice 4350,55 from of N RC= 10 Operation basic act Other ex 6. The voice 4350,55 from of N RC= 10 The voice 4350,55 from of	verage commercies was lei. Determent [lei. Determent [lei. Determent [lei. Determent [lei. Determent [lei. lei. Pharmacy ther activities 27, 19,7% ag expenses of the divity 698,6 th leit penses. 24,563 the follower of realization.	ercial re _ lei. Op mine the come, in eport or on - revenue 6 th. lei
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amount the results of the economic of the econom	y of 20 _ %. basic ac cy's fina nt of tax nomic ar on - evenue 2 th. lei,	_ constituting _ Pharmacy reversitivity ancial and economics to be paid, and financial action action action with the properties of t	enue from othe lei, other experomic activity for benefit, profitativity" of the pharmacy revenue rities.27,2 th lei les of the	ei. The ar activithses or this y bility). I armaceu 3. The vo 4350,55 from of N RC= 19 Operatir basic act Other ex 4596,9 t	verage commercies was lei. Determear (global incompany olume of realization the lei, Pharmacy ther activities 27,9,7% ag expenses of the civity 698,6 th leipenses. 24,563 th	ercial re _ lei. Op mine the come, in eport or c. on - revenue 6 th. lei e n lei on - evenue
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous "The results of the econ" 1. The volume of realization (6599,6 th. lei, Pharmacy refrom other activities 28,2 N RC= 18,4% Operating expenses of the basic activity. 794,5 th. lei Other expenses. 27,525 th. 4. The volume of realization (3521,2 th lei, Pharmacy refrom other activities 19,3 N RC= 18,1%	y of 20 _ %. basic acy's fina nt of tax nomic ar on - evenue 2 th. lei,	constituting _ Pharmacy reversitivity ancial and economics to be paid, and financial action ac	enue from other lei, other experiomic activity for benefit, profitativity" of the pharmacy revenue rities. 27,2 th lei les of the lei les control of the lei les of the lei les control of the lei les contro	ei. The ar activithses or this y bility). If armaceu 3. The voice 4350,55 from of N RC= 10 Operation basic act Other ex 4596,9 t from of N RC= 18	verage commercies waslei. Determent lei. Pharmacy lei. Lei. Pharmacy lei. Lei. Pharmacy lei. Lei. Pharmacy lei. Phar	ercial re _ lei. Op mine the come, in eport or on - revenue .6 th. lei e n lei on - evenue 6 th lei
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous "The results of the econ" 1. The volume of realization of the econ from other activities 28,2 N RC= 18,4% Operating expenses of the basic activity. 794,5 th. lei Other expenses. 27,525 th. 4. The volume of realization 3521,2 th lei, Pharmacy refrom other activities 19,3 N RC= 18,1% Operating expenses of the	y of 20 _ %. basic acy's fina nt of tax nomic ar on - evenue 2 th. lei,	constituting _ Pharmacy reversitivity ancial and economic exes to be paid, and financial action actio	enue from other lei, other experiomic activity for benefit, profitativity" of the pharmacy revenue rities. 27,2 th lei	ei. The ar activithses or this y bility). If armaceu 3. The voice 4350,55 from of N RC= 10 Operation basic act Other ex 4596,9 t from of N RC= 18 Operation of N RC= 18	verage commercies was lei. Determent lei. Pharmacy ther activities 27,9,7% lei. Determent lei. Pharmacy rether activities. 17,8,3% lei. Repenses of the lei. Pharmacy rether activities. 17,8,3% lei. Repenses of the lei. Pharmacy rether activities. 17,8,3% lei. Repenses of the lei. Pharmacy rether activities. 17,8,3% lei. Repenses of the lei. Pharmacy rether activities. 17,8,3% lei. Repenses of the lei. Pharmacy rether activities. 17,8,3% lei. Repenses of the lei. Pharmacy rether activities. 17,8,3% lei. Repenses of the lei. Pharmacy rether activities. 17,8,3% lei. Repenses of the lei. Repenses lei.	ercial re _ lei. Op mine the come, in eport or on - revenue .6 th. lei e evenue .6 th lei
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous "The results of the econ" 1. The volume of realization of the econ from other activities 28,2 N RC= 18,4% Operating expenses of the basic activity. 794,5 th. lei Other expenses. 27,525 th. 4. The volume of realization 3521,2 th lei, Pharmacy reform other activities 19,3 N RC= 18,1% Operating expenses of the basic activity 491,4 th lei	y of 20 _ %. basic ac cy's fina nt of tax nomic ar on - evenue 2 th. lei,	constituting _ Pharmacy reversitivity ancial and economics to be paid, and financial action ac	enue from other lei, other experiomic activity for benefit, profitativity" of the pharmacy revenue rities. 27,2 th lei les of the lei les of the lei les of the lei les of the lei les of the lei les of the lei les of the lei les of the lei les of the lei les of the lei les of the lei les of the lei les of the lei les of the lei les of the lei les of the lei	ei. The ar activithses or this y bility). If armaceu 3. The voice 4350,55 from of N RC= 10 Operation basic act Other ex 4596,9 the from of N RC= 10 Operation basic act of the sail	verage commercies was lei. Determear (global incompany of the restriction of realization of the lei, Pharmacy from the restriction of realization of the lei, Pharmacy from the reactivities 27, 8,3% ag expenses of the lei, Pharmacy from the ractivities. 17, 8,3% ag expenses of the lei, Pharmacy from the ractivities. 17, 8,3% ag expenses of the lei, Pharmacy from the lei, Pharmacy fr	ercial re _ lei. Op mine the come, in eport or on - revenue 6 th. lei evenue 6 th lei
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous "The results of the econ" 1. The volume of realization (6599,6 th. lei, Pharmacy reform other activities 28,2 N RC= 18,4% Operating expenses of the basic activity. 794,5 th. lei Other expenses. 27,525 th. 4. The volume of realization 3521,2 th lei, Pharmacy reform other activities 19,3 N RC= 18,1% Operating expenses of the basic activity 491,4 th lei Other expenses. 5,795 th lei Other expenses.	y of 20 _ %. basic ac cy's fina nt of tax nomic ar on - evenue 2 th. lei,	constituting _ Pharmacy reversitivity ancial and economics to be paid, and financial action ac	enue from othe lei, other experomic activity for benefit, profitativity" of the pharmacy revenue rities.27,2 th lei realization - range from the lei res of the le	ei. The ar activithses or this y bility). If armaceu 3. The voca 4350,55 from of N RC= 19 Operatir basic act Other ex from of N RC= 18 Operatir basic act Other ex Operatir basic act Other ex Other ex	verage commercies was lei. Determear (global incompany of the restriction of realization of the activities 27, 29,7% ag expenses of the civity 698,6 th leipenses. 24,563 the leipenses of the civity 698,6 the leipenses of the civity 698,6 the leipenses of the civity 698,6 the leipenses of the civity. 683,2 the leipenses. 9,564 the	ercial re _ lei. Op mine the come, in eport or /. on - revenue 6 th. lei e evenue 6 th lei e et hei evenue 6 th lei
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous "The results of the econ" 1. The volume of realization of the econ from other activities 28,2 N RC= 18,4% Operating expenses of the basic activity. 794,5 th. lei Other expenses. 27,525 th. 4. The volume of realization 3521,2 th lei, Pharmacy reform other activities 19,3 N RC= 18,1% Operating expenses of the basic activity 491,4 th lei	y of 20%. basic acy's fina nt of tax nomic ar on - evenue 2 th. lei, lei on - evenue 31 th lei	constituting _ Pharmacy reversitivity ancial and economics to be paid, and financial action ac	enue from other lei, other experiomic activity for benefit, profitativity" of the phase realization - narmacy revenue rities.27,2 th lei realization - macy revenue rities 12,4 th lei res of the 2,3 th lei res of the 2,3 th lei realization - reservenue rities 12,4 th lei realization - reservenue rities 12,4 th lei realization - reservenue rities 12,4 th lei realization - realiza	ei. The ar activit ases or this y bility). I armaceu 3. The vo 4350,55 from of N RC= 10 Operatir basic act Other ex 4596,9 t from of N RC= 18 Operatir basic act Other ex 9. The vo	verage commercies was lei. Determear (global incompany of the restriction of realization of the lei, Pharmacy from the restriction of realization of the lei, Pharmacy from the reactivities 27, 8,3% ag expenses of the lei, Pharmacy from the ractivities. 17, 8,3% ag expenses of the lei, Pharmacy from the ractivities. 17, 8,3% ag expenses of the lei, Pharmacy from the lei, Pharmacy fr	ercial re _ lei. Op mine the come, in eport or come on - revenue 6 th. lei e evenue 6 th lei e evenue 6 th lei e evenue 6 th lei
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous "The results of the econ" 1. The volume of realization (6599,6 th. lei, Pharmacy refrom other activities 28,2 N RC= 18,4% Operating expenses of the basic activity. 794,5 th. lei Other expenses. 27,525 th. 4. The volume of realization 3521,2 th lei, Pharmacy refrom other activities 19,3 N RC= 18,1% Operating expenses of the basic activity 491,4 th lei Other expenses. 5,795 th lei, Pharmacy refrom other activities 15,7 The volume of realization 2351,5 th lei, Pharmacy refrom other activities 15,7	y of 20%. basic acy's fina nt of tax nomic ar on - evenue 2 th. lei, lei on - evenue 31 th lei	constituting _ Pharmacy reversitivity ancial and economics to be paid, and financial action ac	enue from other lei, other experiomic activity for benefit, profitativity" of the phase realization - narmacy revenue rities.27,2 th lei realization - macy revenue rities 12,4 th lei res of the 2,3 th lei res of the 2,3 th lei realization - reservenue rities 12,4 th lei realization - reservenue rities 12,4 th lei realization - reservenue rities 12,4 th lei realization - realiza	ei. The ar activithses or this y bility). If armaceu 3. The voice 4350,55 from of N RC= 10 Operatire basic act Other ex 4596,9 te from of N RC= 18 Operatire basic act Other ex 4528,7 te from of from	verage commercies was lei. Determear (global incompany) Draw up the restrical company Dlume of realization the lei, Pharmacy ther activities 27, 29,7% ag expenses of the divity 698,6 th lei penses. 24,563 the penses. 24,563 the penses of the civity 683,2 the lei penses. 9,564 the penses 9,564 the pen	ercial re _ lei. Op mine the come, in eport or / on - revenue 6 th. lei e evenue 6 th lei e lei on - evenue 6 th lei e
pharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amout The results of the econ The result	y of 20%. basic acy's fina nt of tax nomic ar on - evenue 2 th. lei, lei on - evenue 31 th lei ei on - evenue 74 th lei	constituting _ Pharmacy reversitivity ancial and economics to be paid, and financial action ac	enue from other lei, other experiomic activity for benefit, profitativity" of the pharmacy revenue rities. 27,2 th lei realization remacy revenue rities 12,4 th lei realization remacy revenue rities 12,4 th lei realization remacy revenue rities 28,72 th lei realization remacy revenue rities 28,72 th lei realization remacy revenue rities 28,72 th lei	ei. The ar activithses	verage commercies waslei. Determear (global incompany) Draw up the restricted company Dlume of realization the lei, Pharmacy ther activities 27,97% ag expenses of the divity 698,6 th lei penses. 24,563 the penses. 24,563 the penses of the divity. 683,2 the lei penses. 9,564 the penses 9,564 the pens	ercial re _ lei. Op mine the come, in eport or con - revenue 6 th. lei e evenue 6 th lei e lei on - evenue 18 th lei
coharmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous 'The results of the econ 'The volume of realization (The volume of realization (The expenses of the expenses	y of 20 _ %. basic ac cy's fina nt of tax nomic ar on - evenue 2 th. lei,	constituting _ Pharmacy reversitivity ancial and economic exests be paid, and financial action	enue from other lei, other experiomic activity for benefit, profitativity" of the pharmacy revenue rities. 27,2 th lei realization remacy revenue rities 12,4 th lei res of the 2,3 th lei realization remacy revenue rities 28,72 th lei realization remacy revenue rities 28,72 th lei realization remacy revenue rities 28,72 th lei res of the	ei. The ar activithses	verage commercies was lei. Determear (global incompany) Draw up the restricted company Dlume of realization th. lei, Pharmacy ther activities 27,97% ag expenses of the penses. 24,563 the penses. 24,563 the penses. 24,563 the penses of the penses of the penses of the penses. 9,564 the penses. 9,564 the penses. 9,564 the penses. 9,564 the penses of the pen	ercial re _ lei. Op mine the come, in eport or / on - revenue 6 th. lei e evenue 6 th lei e lei on - evenue 18 th lei
charmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous 'The results of the econ 'The results of the basic activity. 794,5 th. lei Other expenses. 27,525 th. The volume of realization activities 19,3 N RC= 18,1% Operating expenses of the basic activity 491,4 th lei Other expenses. 5,795 th. The volume of realization 2351,5 th lei, Pharmacy refrom other activities 15,7 N RC= 18,4% Operating expenses of the basic activity. 418,97 th lei	y of 20%. basic acy's fina nt of tax nomic ar on - evenue 2 th. lei, lei on - evenue 31 th lei ei on - evenue 74 th lei	constituting _ Pharmacy reversitivity ancial and economic exests be paid, and financial action	enue from other lei, other experiomic activity for benefit, profitativity" of the pharmacy revenue rities. 27,2 th lei realization remacy revenue rities 12,4 th lei res of the 2,3 th lei realization remacy revenue rities 28,74 th lei realization remacy revenue rities 28,72 th lei realization remacy revenue rities 28,72 th lei res of the 28,8 th lei res of the 38,8 th lei	ei. The ar activithses or this y bility). If armaceu 3. The voice 4350,55 from of N RC= 10 Operation basic act Other ex 6. The voice 4596,9 the from of N RC= 10 Operation basic act Other ex 9. The voice 4528,7 the from of N RC= 10 Operation basic act Other ex 9. The voice 4528,7 the from of N RC= 10 Operation basic act Other ex	verage commercies was lei. Determear (global incompany olume of realization th. lei, Pharmacy ther activities 27,97% ag expenses of the civity 698,6 th lei penses. 24,563 the pharmacy rether activities. 17,8,3% ag expenses of the civity. 683,2 th lei penses. 9,564 the pharmacy rether activities 12,8,7% ag expenses of the civity. 683,2 th lei penses. 9,564 the pharmacy rether activities 12,8,7% ag expenses of the civity. 793,2 th lei civity. 793,2 th lei	ercial re _ lei. Op mine the come, in eport or / on - revenue 6 th. lei evenue 6 th lei evenue 18 th lei evenue 18 th lei
charmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous 'The results of the econ 'The results of the basic activity. 794,5 th. lei Other expenses. 27,525 th. 100 (The results of the basic activity 491,4 th. lei Other expenses. 5,795 th. 100 (The results of the econ the activities 15,70 (The volume of realization 2351,5 th. lei, Pharmacy refrom other activities 15,70 (The volume expenses of the basic activity. 418,97 th. lei Other expenses. 14,539 th.	y of 20 _ %. basic acy's fina nt of tax nomic ar on - evenue 2 th. lei, lei on - evenue 31 th lei	constituting _ Pharmacy reversitivity ancial and economics to be paid, and financial action of the second of	enue from other lei, other experomic activity for benefit, profitativity" of the pharmacy revenue rities. 27,2 th lei realization - rancy revenue rities 12,4 th lei realization - rancy revenue rities 28,72 th lei res of the 28,8 th lei 21,275 th lei	ei. The ar activithses or this y bility). If armaceu 3. The voca 4350,55 from of N RC= 19 Operation basic act Other ex 4596,9 the from of N RC= 18 Operation basic act Other ex 4528,7 the from of N RC= 18 Operation basic act Other ex 4528,7 the from of N RC= 18 Operation basic act Other ex Other ex Other ex	verage commercies was lei. Determear (global incompany up the restrical company olume of realization th. lei, Pharmacy ther activities 27, 9,7% ag expenses of the civity 698,6 th lei penses. 24,563 ther activities.17, 8,3% ag expenses of the civity. 683,2 th lei penses. 9,564 the olume of realization lei, Pharmacy restricts a lei, Pharmacy restricts 12,8,7% ag expenses of the civity. 793,2 th lei penses. 23,720 there activities 12,8,7% ag expenses of the civity. 793,2 th lei penses. 23,720 there activities 23,7% ag expenses of the civity. 793,2 th lei penses. 23,720 there activities 23,7% ag expenses of the civity. 793,2 th lei penses. 23,720 there activities 24,720 there activities 24,	ercial re _ lei. Op mine the come, in eport or / on - revenue 6 th. lei evenue 6 th lei evenue 18 th lei evenue 18 th lei
charmacy, a legal entity bate on the same time erating expenses of the results of your pharmacome before tax, amous 'The results of the econ 'The results of the basic activity. 794,5 th. lei Other expenses. 27,525 th. The volume of realization activities 19,3 N RC= 18,1% Operating expenses of the basic activity 491,4 th lei Other expenses. 5,795 th. The volume of realization 2351,5 th lei, Pharmacy refrom other activities 15,7 N RC= 18,4% Operating expenses of the basic activity. 418,97 th lei	y of 20%. basic acy's fina nt of tax nomic ar on - evenue 2 th. lei, on - evenue 31 th lei ei on - evenue 74 th lei i lei cion -	constituting _ Pharmacy reversitivity ancial and economic exests be paid, and financial action	enue from othe lei, other experomic activity for benefit, profitativity" of the pharmacy revenue rities. 27,2 th lei realization - racy revenue rities 12,4 th lei realization - racy revenue rities 28,72 th lei resofthe 1,275 th lei realization - racy revenue rities 28,72 th lei racy	ei. The ar activithses or this y bility). If armaceu 3. The voca 4350,55 from of N RC= 14 Operatir basic act Other ex 6. The voca 4596,9 the from of N RC= 18 Operatir basic act Other ex 9. The voca 4528,7 the from of N RC= 18 Operatir basic act Other ex 12. The voca 12. The voca 12. The voca 13.	verage commercies was lei. Determear (global incompany olume of realization th. lei, Pharmacy ther activities 27,97% ag expenses of the civity 698,6 th lei penses. 24,563 the pharmacy rether activities. 17,8,3% ag expenses of the civity. 683,2 th lei penses. 9,564 the pharmacy rether activities 12,8,7% ag expenses of the civity. 683,2 th lei penses. 9,564 the pharmacy rether activities 12,8,7% ag expenses of the civity. 793,2 th lei civity. 793,2 th lei	ercial re _ lei. Op mine the come, in eport or /. on - revenue 6 th. lei e 1 lei on - evenue 6 th lei e 1 lei e

RC= 18,	9%	N RC= 20,7%	N RC= 19,05%	
	ng expenses of the	Operating expenses of the	Operating expenses of the	ne .
	tivity 997,3 th lei	basic activity 1498,5 th lei	basic activity. 1257,9 th	
	xpenses. 12,7 th lei	Other expenses. 24,9 th lei	Other expenses. 24,65 th	
	ne of pharmaceutical comp Results of the e	conomic and financial activi	ity for the year 20	Value
Nr.	Results of the e	conomic and financial activi	ity for the year 20	Value
Nr. 1.	Results of the e	conomic and financial activi Name of indexes olume)	ity for the year 20	Value
Nr. 1. 2.	Results of the e Net sales (turnover v Cost of sales (prime c	Name of indexes	ity for the year 20	Value
Nr. 1. 2.	Results of the e Net sales (turnover v Cost of sales (prime of Gross Profit (Total Lo	conomic and financial activi Name of indexes olume)		Value
Nr. 1. 2. 3.	Results of the e Net sales (turnover v Cost of sales (prime of Gross Profit (Total Lo	Name of indexes olume) cost) oss) - (Commercial Refund) value difference of the indices in rov		Value
Nr.	Net sales (turnover v Cost of sales (prime of Gross Profit (Total Lotis determined as the Other operating incompared to the control of the co	Name of indexes olume) ost) oss) - (Commercial Refund) value difference of the indices in rov		Value
Nr. 1. 2. 3. 4. 5.	Net sales (turnover v Cost of sales (prime of Gross Profit (Total Lo is determined as the	Name of indexes olume) oost) oss) - (Commercial Refund) value difference of the indices in roveme		Value
Nr. 1. 2. 3.	Results of the e Net sales (turnover v Cost of sales (prime of Gross Profit (Total Lo is determined as the Other operating incor Commercial expenses General and administ	Name of indexes colume) cost) cost) cost) cost) cost) cost) cost (Commercial Refund) value difference of the indices in row me cost		Value
Nr. 1. 2. 3. 4. 5. 6.	Net sales (turnover v Cost of sales (prime of Gross Profit (Total Lo is determined as the Other operating inco Commercial expenses	Name of indexes olume) oss) - (Commercial Refund) value difference of the indices in rov me s crative expenses inses		Value
Nr. 1. 2. 3. 4. 5. 6. 7.	Results of the e Net sales (turnover v Cost of sales (prime of Gross Profit (Total Lo is determined as the Other operating inco Commercial expenses General and administ Other operating expe The result of the open	Name of indexes olume) oss) - (Commercial Refund) value difference of the indices in rov me s crative expenses inses	v 1 and 2	Value
Nr. 1. 2. 3. 4. 5. 6. 7. 8.	Results of the e Net sales (turnover v Cost of sales (prime of Gross Profit (Total Lo is determined as the Other operating inco Commercial expenses General and administ Other operating expe The result of the open	Name of indexes olume) ost) oss) - (Commercial Refund) value difference of the indices in rov me s crative expenses nses rational activity ing to the expression from the indice	v 1 and 2	Value
Nr. 1. 2. 3. 4. 5. 6. 7.	Results of the e Net sales (turnover v Cost of sales (prime of Gross Profit (Total Lo is determined as the Other operating inco Commercial expenses General and administ Other operating expe The result of the oper is determined accord	Name of indexes olume) oost) oss) - (Commercial Refund) value difference of the indices in rov me s crative expenses rational activity ing to the expression from the indices stment activity	v 1 and 2	Value
Nr. 1. 2. 3. 4. 5. 6. 7. 8.	Results of the e Net sales (turnover v Cost of sales (prime of Gross Profit (Total Lo is determined as the Other operating inco Commercial expenses General and administ Other operating expe The result of the oper is determined accord The result of the inve	Name of indexes olume) oost) oss) - (Commercial Refund) value difference of the indices in rov me s crative expenses rational activity ing to the expression from the indices stment activity	v 1 and 2	Value
Nr. 1. 2. 3. 4. 5. 6. 7. 8.	Results of the e Net sales (turnover v Cost of sales (prime of Gross Profit (Total Lo is determined as the Other operating incor Commercial expenses General and administ Other operating expe The result of the oper is determined accord The result of the inve The result from finan The result of econom	Name of indexes olume) oost) oss) - (Commercial Refund) value difference of the indices in rov me s crative expenses nses rational activity ing to the expression from the indices strent activity cing activities	es in the rows (3 + 4-5-6-7)	Value
Nr. 1. 2. 3. 4. 5. 6. 7. 8.	Results of the e Net sales (turnover v Cost of sales (prime of Gross Profit (Total Lo is determined as the Other operating incor Commercial expenses General and administ Other operating expe The result of the oper is determined accord The result of the inve The result from finan The result of econom	Name of indexes olume) oost) oss) - (Commercial Refund) value difference of the indices in rov me s crative expenses rational activity ing to the expression from the indices stment activity cing activities ic and financial activity	es in the rows (3 + 4-5-6-7)	Value

Conclusions and suggestions of the student:

Net profit (benefit) is determined as the value difference of indices in lines 13 and 14

is determined according to the expression in the lines (11 + 12)

14.

15.

Income tax expense

The teachers signature _____

Theme 20

MONITORING MANAGEMENT OF PHAR-MACEUTICAL ACTIVITY. INVENTORY OF MATERIAL ASSETS IN PHARMACEUTICAL COMPANIES

The purpose of the work.: Study of the principles and conditions for the accreditation of pharmaceutical companies, the state control system for the exercise of pharmaceutical activity, the organization of the inspection activity in the pharmaceutical enterprises, the legal provisions and the acquisition of practical skills regarding the inventory of the material values of the pharmaceutical enterprises.

Form of training: Seminar and laboratory practical work

Duration: 4 hours.


Questions for self-learning:

- 1. General terms of pharmaceutical control function.
- 2. Characteristic of the state control system over pharmaceutical activity.
- 3. Organization of pharmaceutical inspection.
- 4. Legal provisions on the inventory of material values in pharmaceutical companies.
- 5. Commission of inventory.
- 6. The inventory overview mode
- 7. Inventory particularities of different types of material values.
- 8. Determination of inventory results. Natural perishability
- 9. Notes on forms used in the inventory.

Exercises for self-solving.

Exercise 1. Indicate the content of the control of the following domains in relation to the reference normative acts:

- a) Legality of pharmaceutical activity;
- b) Assortment of medicines, other pharmaceutical and parapharmaceutical products;
- c) Prices of medicines and other pharmaceutical products.



form an inventory of a group of medicines, as instructed by the professor Head of Section of the University Pharmacy and on the basis of the data obtained will perfect the documents below.

pharmaceutical company name **Inventory decision (Order)** *No.* _____from _____20__ In order to perform inventory at _____ (the name of the compartment) inventory committee is established in the following composition: President (position, name, surname) Commission members (position, name, surname) 1. ______ 2. ______ (indicated divisions, goods to be inventoried) Inventory begins at ______ and ends at _____ Reason for inventory _____ (the reason is given: control, delivery-receipt, reassessment, etc.) The inventory shall be carried out in accordance with the Inventory Regulation in force. Control of inventory results and drafting of the report is carried out by _____ funcțion _____ until the _____ Head pharmacist _____ pharmaceutical company name INVENTORY DECLARATION The undersigned ______ manager of ______

Name surname the name of the subdivision
appointed by decision no. _____ from _____, in the presence of the committee I declare: 1. All goods under the management of the undersigned are located in the warehouses 2. Posed (not posed) goods belonging to _____ 3. I have (I do not have) knowledge of the existence of pluses worth (quantity) of 4. I have (I do not have) released goods without legal documents. Beneficiary ___ 5. I have (I do not have) goods not accepted or to be dispatched, for which the related documents have been prepared in the amount of 6. have (I do not have) receipt / surrender documents that have not been taught in account-7. I own (do not own) cash from the sale of the goods under management lei. 8. The last entry documents are: type _____ no. ____ from _____ type _____ no. ____ from _____ 9. Latest exit documents: type _____ no. ____ from _____ type _____ no. ____ from _____ 10. The last management report was drawn up on _____ for the period . 11. Other mentions _ Taught in our presence Signatures Manager Date _____ Hour ____

Entity			
Subdivision			
about invents	Minutes No	nancial documents	
about invento	ory of filotiey and fi om	20	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
	Statement		
At the start of inventory all payment and cash rec and issued are recorded.	eipts were taught in th	e general ledger and all fi	ınds received in my liabilit
Manager			
(Name, surname)	(function)	(Signal	ture)
5 1 4 1 7 2 2 3 1 1 1	. 37		H
Based on the order (disposition) on making inven	tory No Irom "	_" 20_	_ the inventory of funds wa
carried out according to the situation at "" Following the inventory were established:	20		
1. Cash:			
in national currencylei	bani		
In the currency Foreign			
In foreign currency ()		
2. Postal markslei 3. Travel ticketslei	bani		
3. Travel tickets lei	bani		
4. Excise Stampslei	bani		
5le	ei bani		
(Monetary document name)			
TOTAL actual:			
in national currencylei	bani		
In foreign currency ()			
According to the accounting data:			
in national currency lei	bani		
In foreign currency ()			
Inventory results:			
Pluses lei bani			
Pluses			
Shortcomings lei	_ bani		
Last numbers of the provisions:	20		
Collection Nofrom			
Payment No from	20		
nventory Commission:			
Theirman of the Inventory Commission	-		
Chairman of the Inventory Commission:	(Name, surname)	(Signature)	(function)
Members of the Inventory Commission:			
	(Name, surname)	(Signature)	(function)

nharmaceutical	company name

MINUTES OF SIGILATION	UN
-----------------------	----

N	o from	20	
In order to execute the inventor, member of the, and the assistant deposits for keeping the money a	inventory commi	ssion, in the pwe proceeded	presence of the manager to sealing the following
streetnr.			
A seal was applied			
			of the seal applied)
Sealing was also done when hand man of the sealed access doors in	•	to the second	row of locks to the chair-
Inventory Commission	Manager	Assista	nts
Today, hour, the following the applied seal, which was found		re unsealed	_ after prior checking of
Inventory Commission	Managor	Accieta	nte

										Forn	n INV-1		
	erprise				Page								
Sub	division		from20							1 480			
	-t		/	T	۲-	p	le Ie		Depr	eciation			
No. d/	Name goods inven- toried	Code or inventory number	Ме	Effective quantity	Amount recorded in accounting	0°u	Unit price recorded in accounting	Balance sheet value	Inventory Value	Value	Reason (code)		
Α	1	2	3	4	5	6=4-5	7	8=4x7	9	10	11		
	Total on the nage	X	X				X				X		
			bers of the Inventory Commission				Manager Man			ager *	Ac- count- ant		
Sign	ature												

^{*}To be signed by the receiver of the goods, in the case of handing over-receipt of management.

Verso Form INV-1

	ne and surname	1.10		missi			Ivialia	igei	lviaii *	agti	coun
	Total on the page	X Mei	X mbers	of the I	ventory (Com-	X Mana	ıσer	Man	ager	X Ac-
No. d/ o	Name goods inventoried	Code or inventory number	Measure units	Effective quantity	Amount recorded in accounting	Quantitative difference	Unit price recorded in accounting	Balance sheet value	Inventory Value		recia- ion

Last page of the form INV-1 Total on the list: ordinary numbers. in figures in letters Total actual units in figures in letters Chairman of the commission function name, surname signature Members of the commission function name, surname signature function name, surname signature function name, surname signature All goods registered in this list at no. _____ to no. _____ have been effectively verified by the commission, as well as the fact that prices, quantities, qualities and units of measurement have been established in my (our) presence for which we have no objections to the inventory committee. The goods listed in this list are kept under my responsibility (ours). Manager (s):

name, surname

name, surname

signature

signature

function

function

20_

Ente	erprise					Page
Sect	ion	1				
			LIST OF INVE	NTORY		
			from	_20		
No. cr		Code or name	Characteristic	UM	Effective inventory	Inventory recorded in accounting
Α		1	2	3	4	5
	Total on the page		X	Х		
		Inventory Commission	Signature	Ma	ınager (i)	Signature
Nan	ne and					
sur	name					_
				Ac	countant	Signature

INV-2 Management related records in quantitative expression

		Last _I	page of the form INV-2
Total on the list: ordinary numbers.			
J	in figures	in letters	;
Total actual units			
Chairman of the commission	in figures 1	in letter	'S
	function	name, surname	signature
Members of the commission	function	name, surname	signature
	function	name, surname	signature
	function	name, surname	signature
All goods registered in this li commission, as well as the f have been established in my tory committee.	fact that prices, quant	ities, qualities and ı	units of measurement
The goods listed in this list a	are kept under my resp	oonsibility (ours).	
Manager (s):			
	function nar	ne, surname signat	ure
"	function na	me, surname signa	ture

REGISTER

		nces,	Short- com- ings	12=9- 10										
		Differences, (Ici)	Pluses	11=10- 9										
	Its	Actual value,	(lei)	10=5×8										
	Inventory resultsInventory results	Value reg- istred in	General Ledger, (lei)	9=4×8										
esults	y results	Unit Price,	(lei)	80										×
entory r	nventor	Differences	Short- com- ings	7										
of inve	I	Diffe	Pluses	9										
ation			Actu- ally	9										
of verification of inventory results		Sold	Registered General Ledger	4										
	Unit of	meas- ure-	men	3										×
	Code	or In- ventory	ber ber	2										
	Name of	inventoried goods		1										\$L:
	ó	o/p		4										TOTAL

THE INVENTORY COMMITTEE:

Commission:	Commission:
Inventory	Inventory
of the	of the
Chairman	Members

(signature)	(signature)
surname)	aurmame)
(name,	(name.

mings	Value		58												
Final Shortcomings	Quantity		52											2	
_ =	Value		2											THE PARTY	
Final	Quantity Value		23											The manager (I have no objection to the results	(New, suman)
	ming ed uses	Value	22											90	
Officts between aprons	Shortcoming covered from Pluses	Quantity Value	71											nger (I hav	
its betw	d Plus the sing	Ville	2												(Charleston)
ouge	Distributed Plus To cover the Shortcoming	Quantity	19											F	FA
	55 000	Account	18										×		
iling sr	Shortcomings	Value	13												(Company)
Adjusted based on the finding Records in General Ledger	Sho	Quantity	16												(Vent, sensor) (i)
sted based ords in Ge		Account	15										×		Service Co.
Adju Rec	Pluses	Value	14											¥	
	_	Quantity	13											Accountant	

Conclusions and suggestions of the student:

The teachers signature_____

TOTALIZATION no. 4 ON HOMEWORK 16 - 20.

THE CONTENT OF THE INDIVIDUAL WORK FOR STUDENTS DURING THE STUDY OF THE DISCIPLINE "MANAGEMENT AND LEGISLATION FARMACEUTICĂ"

IWS

Student's individual work is a complex and varied activity of independent, free, personal learning, both for the achievement of the objectives of the educational process and for the extradidactic activity within the time he has at its disposal. It is the kind of independent academic activity of the student included in the curricular discipline, assumed by the teacher's instructions, carried out with or without the methodical support offered by him, but realized without his direct involvement. Thus, during each semester, each student must complete at least two assignments from the recommended fields of activity, or as indicated by the teacher, and from other fields related to the topics of the analytical plan of the discipline. Assignments must be completed in the recommended form and submitted for assessment at least two weeks before the end of the semester. The student's individual activities are assessed with a grade, which is a component of the annual (semester) average grade.

The aim of student's individual work:

- establishing the objectives of the activity, designing the activity, distributing the time budget, identifying the database and materials, etc.
- studying course notes, completing and expanding them
- extensive documentation from different sources
- consultation and / or study based on textbooks / course materials, dictionaries, scientific articles
- preparing communications, essays, reports, syntheses, abstracts, articles, etc.
- identifying and solving case studies, specific professional situations, the labor market
- initiating, designing, organizing and conducting on-the-spot investigations preparing for mid-term and final evaluations.

GLOSSARY FOR THE STUDENT'S INDIVIDUAL WORK

Report. The report is an individual work of the student, which must reflect his / her knowledge of self-study of the proposed topic. The report must include the following compartments:

- 1. The introduction, where the actuality of the theme is argued, the objective of the work and the tasks, objects and methods of research.
- 2. Content, main part:
 - 2.1. Analysis of existing materials in printed and electronic editions (sources) on the proposed theme
 - 2.2. The actual research, in which the student must propose his hypothesis in the analysis of the question, with arguments
- 3. Conclusion, including the most important results in the report.

The paper will be displayed on a minimum of 10 pages (A4, Times New Roman, character size 12, space between intervals 1.5) and is completed during the semester. The report is sent to the email address indicated by the teacher.

Evaluation criteria: The quality of the systematization of the information material obtained through own activity; Concordance of the information with the proposed theme; The degree of argumentation of the conclusions; Ingenuity of presentation, creativity.

Essay. The essay is a form of task that represents one or several questions the student answers in free form. The essay is evaluated according to rules or criteria designed to identify skills for using creativity and acquired knowledge. The student's independent work consists of a creative, professional response on the theme of the essay. The themes are individually recommended by the teacher.

Essay Preparation:

- 1. From the sources of selected information, the materials in which the subject is being discussed are taken;
- 2. The materials are analyzed, comparing different points of view on this issue.
- 3. In form of theses, the theory, the evidence and the opinions of the specialists, which the student needs to know to understand this problem (question), are exposed.
- 4. The author's (student's) position on the subject is formulated and exposed in the main part of the written paper.

Paper size – 3-5 pages, (A4, Times New Roman, character size 12, space between intervals 1.5). The essay is sent to the email address indicated by the teacher.

Evaluation criteria: The quality of the systematization of the information material obtained through own activity; The ability to analyze and understand the topic under discussion; The ability to formulate and present one's own position on this topic; Ability to use creativity and acquired knowledge.

Case study analysis. In order to adopt the action plan proposed in the case study, the student must understand that he will have to use rationally the time to prepare qualitatively a report on the analysis of the proposed situation. First, the student needs to understand and analyze the proposed situation. To do this, he needs to work with the text, making notes and extracts. At the same time, it is useful to create their own "logical" schemes. Then it will be well thought out how to present the results of the analysis.

The general structure of the report on the proposed case may be as follows:

- context of events and facts:
- formulation of the problem;
- direct analysis;
- their decisions and implementation;
- figures, charts and tables;
- conclusions with the student's position on the subject.

Paper size - 2-3 pages, (A4, Times New Roman, character size 12, space between intervals 1.5). The results of the case study analysis are sent to the email address indicated by the teacher.

Evaluation criteria: The ability to identify topical issues; The ability to think and approach problems and situations; Analysis, synthesis, generalization of data obtained through own investigation; Formation of a knowledge algorithm based on the obtained conclusions.

THE CONTENT OF THE INDIVIDUAL WORK FOR SEMESTER I

<u>Field I.</u> MANAGEMENT AND APPLICATION OF ITS ELEMENTS (COMPONENTS) IN THE PHARMACEUTICAL FIELD.

The general management features. Functions of management. General characteristic of management Elements of management in pharmaceutical activity. Management of the leading process. Decisions in the process of leading. Organization management. Human resources management of the pharmaceutical system.

Tasks of individual study: integration, search and self-assessment;

Expected product: *individually identified case study and resolved, personal investigations.*

Exercises for self-solving

Exercise 1. Case study

The student should analyze the situation below, then complete the Control System Matrix and answer the questions.

You work (theoretically) for a small but growing pharmacies network (a company). The organization grew very fast, and managers did not have time to assess and monitor activity control. The manager asked you to develop an action plan to optimize the quality control system. You have decided to start work by completing the Control Matrix that requires identification of the necessary control for the three categories of resources - human, material, and informational.

There are three categories of control. The first category is the Preliminary Control that controls the entries in the organization system. The second category is the Examination Control that controls the transformation processes. The third category is Posterior Control that controls the outputs of the organization system.

Your task is to complete the Control Matrix by identifying different controls that can be set for the three resources at each stage of the control.

Questions:

- a. Which of the 3 resources (material, human and informational) is the most importan for the control system? Why?
- b. Which of the 3 resources is the least subject to control? Why?

Control System Matrix

Phases	Material resources	Human resources	Information resources
Preliminary			
control			
Examination			
control			
Subsequent			
control			

Exercise 2. Essay

Topic: The role of control in directing the activity of the organization and for each employee.

Exercise 3. Case study

Complete the "Theory X - Theory Y" questionnaire and calculate the score according to the guidelines. Develop the answers to the questions proposed below.

"Theory X - Theory Y" questionnaire

Afirmații	Acord total	Acord parțial	Nu sunt sigur	Dezaco rd parțial	Deza cord total
1. Most people do not like to work.	5	4	3	2	1
2. When people are given the chance to think for themselves, most of them are brilliant.	5	4	3	2	1
3. Individuals are motivated to achieve the goals they have assumed.	5	4	3	2	1
4. Managers must control their employees, in order to do their work.	5	4	3	2	1
5. Above all employees need security.	5	4	3	2	1
6. If people are treated seriously, they will accept responsibility.	5	4	3	2	1
7. People prefer someone else to tell them what to do.	5	4	3	2	1
8. People could be forced to do the right thing.	5	4	3	2	1
9. Work is as natural as playing.	5	4	3	2	1
10. Employees can be creative at work.	5	4	3	2	1
11. At work people show their ambitions.	5	4	3	2	1
12. Some people will not work until they are threatened.	5	4	3	2	1
13. Some people will follow their goals if they are rewarded.	5	4	3	2	1
14. Most employees try to avoid as much work as possible.	5	4	3	2	1
15. Most employers do not use the full potential of their employees.	5	4	3	2	1
16. If they were given the chance, some employees would propose innovative solutions to solve the problems.	5	4	3	2	1
17. People usually avoid responsibility.	5	4	3	2	1
18. To achieve the goals, managers must supervise the activity of subordinates.	5	4	3	2	1
19. Under favorable conditions, people will take responsibility.	5	4	3	2	1
20. It is not natural for people not to like the work.	5	4	3	2	1

The score for Theory X - Theory Y

Transfer the points corresponding to each answer in this scoring sheet. Calculate the score for both theories in the following way:

Questions for Theory X							
Number	Score						
1							
4							
5							
7							
8							
11							
12							
14							
17							
18							
Total							

Questions for Theory Y								
Number		Score						
2								
3								
6								
9								
10								
13								
15								
16								
19								
20								
Total								

Questions:


- 1. What determines differences in individual scores?
- 2. It is possible for a person to correspond less to Theory X and more to Theory Y and vice versa?
- 3. Indicate the types of effective motivation depending on the obtained result and argue the answer.

Exercise 4. Case study

The student should study the figure "The Systemic Concept of Organizations" and consult the literature on the systemic approach to management, then apply these concepts to creating a Systemic Organizational Model for 3 specified organizations (pharmaceutical factory, pharmaceutical warehouse, community pharmacy).

The systemic concept of organizations.

Reverse link from the environment



Systemic organizational model

Organizations	Inputs	The transformation process	Outputs
Pharmaceutical factory			
Pharmaceutical warehouse			
Community pharmacy			

Questions:

- 1. There are common inputs for these organizations?
- 2. There are processes of transformation of inputs used by these organizations?
- 3. There are common outputs for these organizations?

Exercise 5. Report

Topic: Managerial leadership style and its impact on work team activity.

Exercise 6. Case study

The student must complete the Essential Skills table and the Analysis of Skills table.

Essential skills

Check the skills that a specialist needs to have at the work.

Job	Legiti- mate power	Capacity to reward work	Capacity to be an expert	Capacity of con- straint
Pharmacist manager of pharmaceutical warehouse				
Chief of department of industrial pharmaceuticals				
Chief of manufacturing department in the pharmaceutical factory				
Chief of a pharmacy subsidiary				
Pharmacist manager in a community pharmacy				
Pharmacist manager in a hospital pharmacy				
Pharmacist in a community pharmacy				
Pharmacist assistant				

Analysis of essential skills

For each job, explain why you have chosen this skill, or give an example.						
Pharmacist mana	ger of pharmaceutical warehouse					
Legitimate power						
Capacity to reward work						
Capacity of constraint						
Capacity to be an expert						
Chief of department of industrial pharmaceuticals						
Legitimate power						
Capacity to reward work						
Capacity of constraint						
Capacity to be an expert						
Chief of manufacturing d	Chief of manufacturing department in the pharmaceutical factory					
Legitimate power						
Capacity to reward work						
Capacity of constraint						

Capacity to be an expert								
Chief of	Chief of a pharmacy subsidiary							
Legitimate power								
Capacity to reward work								
Capacity of constraint								
Capacity to be an expert								
Pharmacist mar	nager in a community pharmacy							
Legitimate power								
Capacity to reward work								
Capacity of constraint								
Capacity to be an expert								
Pharmacist manager in a hospital pharmacy								
Legitimate power								
Capacity to reward work								
Capacity of constraint								
Capacity to be an expert								
Pharmacis	t in a community pharmacy							
Legitimate power								
Capacity to reward work								
Capacity of constraint								
Capacity to be an expert								
Pharmacist assistant								
Legitimate power								
Capacity to reward work								
Capacity of constraint								
Capacity to be an expert								

Field II. THE PHARMACEUTICAL SYSTEM - PART OF THE HEALTH SYSTEM.

Public health. The health system. The pharmaceutical system. Coordination of the pharmaceutical system. General notions of law and legislation. Pharmaceutical legislation - branch of health legislation. Pharmaceutical activity and authorization to exercise it.

Tasks of the individual study: *integration, search and evaluation, re-evaluation, improvement, innovative creation.*

Expected product: *individually identified case study, personal investigations.*

Exercises for self-solving

Exercise 1. Case study

There are 1168 community pharmacies in the Republic of Moldova, 24 of them offer preparations, 69 are hospital pharmacies, 36 sections of district health centers with 700 subsidiaries in rural localities.

At the same time, in 44 localities do not exist pharmacies.

Questions:

- 1. Analyzing the existing situation, indicate who performs the pharmaceutical assistance in the health center subsidiaries.
- 2. Identify problems in providing pharmaceutical assistance in rural areas.
- 3. Propose current regulatory solutions in pharmaceutical activity to ensure the population of all rural areas with professional and qualitative pharmaceutical assistance.

Exercise 2. Case study

Licensing a new pharmacy around an older represent a risk for the activity of the old one. Thus, the conflict between pharmaceutical companies in Moldovan urban areas is growing.

Small pharmacies (often owners of which are pharmacists) are covered by the big ones without any chance of survival.

Questions:

- 1. Which requirements for licensing pharmaceutical activity are applied in the countries of the European Union (Germany, France, Italy, Denmark, etc.)
- 2. Propose legislative mechanisms to protect small pharmacies in the Republic of Moldova.

Exercise 3. Case study

The manager of "M-Farm" LTD company submitted a month ago to the licensing authority all needed documents for licensing the activity. During this month, he received any answer about the decision of licensing authority. The manager being convinced that he submitted all documents, appealed to the tribunal, to resolve the issue with the license.

Questions:

- 1. Indicate where and what documents are submitted to receive a license for pharmaceutical activity.
- 2. Which legislative and regulatory acts regulate licensing of pharmaceutical activity?
- 3. Give your opinion on the actions taken by the manager of "M-Farm" LTD to solve the problem of licensing the activity of company.
- 4. What do you think about the professionalism of the manager?

Exercise 4. Essay

Topic: The specifics of obtaining the activity license in the pharmaceutical field through the prism of the legislation of the Republic of Moldova.

<u>Field III.</u> MEDICINES, PHARMACEUTICAL MARKET AND ACTIVITIES OF IT ASSURANCE. THE PHARMACOVIGILANCE SYSTEM.

The medicine and other pharmaceuticals as a subject of study of pharmaceutical assistance. Authorization of medicines. Pharmacovigilance activity. Ensuring the quality of medicines.

Tasks of the individual study: *integration, search and evaluation, re-evaluation, improvement, innovative creation.*

Expected product: *individually identified case study, personal investigations.*

Exercises for self-solving

Exercise 1. Report

Topic:

- 1. The particularities of the drug authorization procedure in Romania.
- 2. The particularities of the drug authorization procedure in Germany.
- 3. The particularities of the drug authorization procedure in France.
- 4. The particularities of the drug authorization procedure in Italy
- 5. The particularities of the drug authorization procedure in Great Britain.
- 6. The particularities of the drug authorization procedure in China.
- 7. The particularities of the drug authorization procedure in Japan.
- 8. The particularities of the drug authorization procedure in Ireland
- 9. The particularities of the drug authorization procedure in the USA.
- 10. The particularities of the drug authorization procedure in India.
- 11. The particularities of the drug authorization procedure in Australia.
- 12. The particularities of the drug authorization procedure in Mexico.

Exercise 2. Essay

Topic: Present the recommended international norms and standards for drug analysis and

control in WHO prequalified drug quality control laboratories.

Source: https://extranet.who.int/pqweb/medicines/medicines-quality-control-laborato-ries-list

Exercise 3. Case study

Use the ADRREPORTS Online Platform User Manual to study reports of suspected adverse reactions to 5 medications proposed by the professor (see https://www.adrre-ports.eu/ro/search.html).

Exercise 4. Case study

Study the VigiAccess online platform and select available statistical data on adverse reactions reported to the WHO Program for International Drug Monitoring (WHO PIDM) for 5 drugs/INNs proposed by the professor (see https://www.vigiaccess.org/).

Exercise 5. Case study

Carry out a comparative study between the pharmacovigilance system in the Republic of Moldova and that in Romania through the lens of the following criteria: national and international regulations; the responsible authority and its interaction with marketing authorization holders, specialists in the field and patients; collaboration with the Uppsala monitoring center.

Field IV. THE PRODUCTION AND SUPPLY OF MEDICINES.

Industrial production of medicines. Supply of medicines. Pharmaceutical warehouse, its tasks and functions.

Tasks of the individual study: *integration, search and evaluation, re-evaluation, improvement, innovative creation.*

Expected product: *individually identified case study, personal investigations.*

Exercises for self-solving

Exercise 1. Case study

On the basis of the licensing register, present a brief analysis of pharmaceutical companies producing drugs and argue for the supply of indigenous drugs to the pharmaceutical market in the Republic of Moldova. See also the State Nomenclature of Medicines.

Exercise 2. Essay.

Topic: Donations of medicines to the Republic of Moldova in the context of exceptional situations: notions, regulations, requirements.

Exercise 3. Report.

Topic: Harmonization of normative acts in the field of GMP implementation with the EC legislative framework.

Exercise 4. Case study

The manager of D-Farm Pharmaceutical Warehouse has concluded a sale and purchase agreement with the pharmaceutical company "Lekfarm" for the supply of following medicines:

- 1. Tab. Amlodipin 5mg N.30 1000 pcks
- 2. Tab. Arpetol 100mg N.10 500 pcks
- 3. Tab. Ambroxol 30mg N.20 1000 pcks
- 4. Tab. Viasil 50mg. N.2 500 pcks

In the agreement, the following criteria were considered: the price of the medicines, the terms of supply, the payment terms. 20 days after, Lekfarm provided the medicines required for the D-Farm pharmaceutical store. The medicines was received within 3 days, after which

a shortfall of 50 pcks of Tab. Amlodipin 5mg N.30 was detected. The provider was notified of the shortcomings 10 days later.

Questions:

- 1. What are the criteria of goods receiving?
- 2. When the supplier have to be announced about the shortfall notified while goods receiving?
- 3. What the responsible person should undertake when the shortcoming is identified?

THE CONTENT OF THE INDIVIDUAL WORKS FOR HE II SEMESTER.

Field V. THE OUTPATIENT PHARMACEUTICAL CARE SYSTEM.

Prescribing and dispensing medicines. The community pharmacy.

Tasks of the individual study: *integration, search and evaluation, re-evaluation, improvement, innovative creation.*

Expected product: *individually identified case study, qualified approach and resolved; personal investigations.*

Exercises for self-solving

Exercise 1. Case study

In the "L-Farm" pharmacy, a patient was referred to whom the doctor gave him a medical prescription, in fact, a sheet with the following content:

- 1.Sol. Ciprofloxacin 10.0; 2pic. three times in the eye.
- 2.Sol.Albucidi 30% 10.0; 2pic. three times in the eye.

The pharmacist refused to release prescription drugs. The patient requested the "Complaints Register", where he wrote a complaint to the pharmacist who did not release the required drugs.

Questions:

- 1. Indicate physician errors in this prescription.
- 2. Indicate steps to be taken by the pharmacist to solve the problem and regulatory normative acts.
- 3. What contraventions would the pharmacist tolerate if he releases the medicines according to this prescription.
- 4. Propose effective methods in prescribing medication.

Exercise 2. Case study

In the "K-Farm" pharmacy, t. Chişinău addressed a man with a prescription for his father, with the following content:

Sol. Promedol 1% 2ml N.30. Recipe prescribed on form N.3.

The pharmacist refused to release the prescribed medicine without any explanation. The restless patient left the pharmacy.

- 1. Indicate the reasons for the refusal.
- 2. What consequences can occur due to the failure to resolve this case in time.
- 3. How do you think this problem has to be solved.

Exercise 3. Report

Topic: WHO recommendations on the rational use of medicines.

Exercise 4. Report

Topic: The role of the pharmacist in implementing the concept of rational use of medicines.

Exercise 5. Report

Topic:

- 1. Specific features of drug dispensing in France
- 2. Specific features of drug dispensing in Germany
- 3. Specific features of drug dispensing in Denmark
- 4. Specific features of drug dispensing in Spain
- 5. Specific features of drug dispensing in Russia
- 6. Specific features of drug dispensing in the UK
- 7. Specific features of drug dispensing in Italy
- 8. Specific features of drug dispensing in the USA
- 9. Specific features of drug dispensing in Portugal
- 10. Specific features of drug dispensing in Romania
- 11. Specific features of drug dispensing in Bulgaria
- 12. Specific features of drug dispensing in Australia

<u>Field VI.</u> THE SYSTEM OF THE MEDICINES ASSISTANCE FOR THE STATIONARY PATIENTS.

Tasks of the individual study: *setting business objectives, designing integration, searching and evaluating, re-evaluating, improving, creating.*

Expected product: Case study; essay

Exercises for self-solving

Exercise 1. Case study.

Analyze the Pharmacotherapeutic Formulary of an MSI, perform a VEN and ABC analysis of the drugs included in the Formulary. Make these conclusions and suggestions.

Ouestions:

- 1. What laws regulate the use of medicines included in the Pharmacotherapeutic Formulary.
- 2. Indicate the criteria for including the medicines in the Pharmacotherapeutic Formulary.
- 3. Argument the results of the study.

Exercise 2. Essay

Topic: Comparative analysis of the National Pharmacotherapeutic Formulary and the Pharmacotherapeutic Formulary of a public medical-sanitary institution (as indicated by the teacher).

Exercise 3. Case study.

Superior Assistance of the Surgery Department of the hospital Drochia presented an order receipt - delivery to the hospital pharmacy, in this receipt were prescribed:

1. Sol, Morphini hydrochloride 1% 1 ml N, 10
2. Sol, Natrii chloride 0.9% 500ml
3. Sol. Cefazolin 1.0
4. Gossypium. 500,0
10 cans
20 vials
30 vials
10 pieces

The order-delivery coupon was signed by the senior assistant of the section.

The Pharmacist at receipt of delivery orders refused to deliver the medications on this order-delivery receipt.

Questions:

- 1. Indicate if the pharmacist has acted correctly in this situation and the reasons for the refusal.
- 2. Count the records of the circulation of medicines in the hospital pharmacy.
- 3. Indicate the rules for keeping the prescribed medication in the order-delivery order.

Exercise 4. Essay.

Topic: Highlighting drug delivery problems in stationary conditions.

<u>Field VII.</u> RECORDS AND PRIMARY MANAGEMENT IN PHARMACEUTICAL COM-PANIES.

Tasks of the individual study: essay writing, time budget distribution, database identification and search and evaluation materials, re-evaluation, improvement and production, innovative creation.

Expected product: case study; essay.

Exercises for self-solving

Exercise 1. Case study

Perform an economic analysis of the plan, taking into account the factors (the number of recipes and the average cost of a prescription) that influence the achievement of the Medication Plan, using the data below:

	The current year						
Economic Indicators	Plan	Factice	Absolute growth	Growth in %			
Output according to outpatient recipe (thousands of lei)	4155.00	5029.00					
Prescriptions (thousand units)	18608	17057					
The average price of a prescription							

Questions:

- 1. Determine the average cost of a faced and planned recipe
- 2. Determine the absolute and percent increase (or decrease) of the indices analyzed.
- 3. Determine the impact of each factor analyzed in the revenue obtained.
- 4. Make the respective conclusions.

Exercise 2. Case study

A young specialist pharmacist, with 2 years of work experience, receiving the salary was surprised by the calculated amount, the salary was lower than in the previous months. The pharmacist called the accountant for an explanation. The accountant reminded him that he was sick 10 days in the month for which the salary was calculated.

Ouestions:

- 1. Indicate which normative acts regulate the calculation method for temporary incapacity for work.
- 2. According to what criteria is the monthly amount of the allowance for temporary work incapacity calculated.
- 3. What documents serve as the basis for calculating the allowance for temporary incapacity for work.
- 4. Indicate the method of calculating the allowance for temporary incapacity for work for the given situation.

Exercise 3. Case study

In the "Arnica Farm" pharmacy, which opened recently, with working hours from 8:00 a.m. to 8:00 p.m., the average cash flow per day in the first month was 5,000 lei. All the expenses of the pharmacy constitute 59 thousand lei per month. The markup applied in the environment is 18.9% and is the only source of profit for the pharmacy.

Questions:

- 1. Determine what cash flow into the environment needs to be per day for the pharmacy to be profitable.
- 2. Indicate what factors influence cash flow

3. Indicate what steps could be taken to increase the cash flow.

Exercise 4. Case study

The "Levănţica Farm" pharmacy purchased a computer in the amount of 75000-00 lei, with a 5-year operating term. It was put into operation and registered on 01.06.2022.

Questions:

- 1. Indicate which normative acts regulate the classification and method of recording fixed assets.
- 2. Calculate, using the straight-line method, the value of the depreciation of the computer on 04/01/2023.

Exercise 5. *Case study*

The "Calendula Farm" community pharmacy has 2 sections. The production section and the industrial forms section and 4 branches.

According to the contracts, the pharmacy serves the municipal hospital No.4 with 90 beds, the republican narcological dispensary with 70 beds and the prophylactic of the "Franzeluţa" factory.

Questions:

- 1. Name the types of cash flows in the pharmacy according to the organizational structure and the companies served.
- 2. Indicate the factors influencing cash flow.
- 3. Plan the total flow for next year, if it is known that in the current year the pharmacy released products in the amount of 6200 thousand lei, of which 55% to the population and 45% to medical and sanitary institutions. Take into consideration that next year the financing for the purchase of medicines for the municipal hospital No.4 is expected in the amount of 1900 thousand lei, the narcological dispensary 750 thousand lei and the "Franzeluţa" factory has allocated an amount of 95 thousand lei. It is planned to increase the retail flow by 3%.

Exercise 6. Case study

An inventory of material values was made in the pharmacy "Valeriana Farm". As a result of the control in the production section, it was found that the balance of Ethyl alcohol 95% is 2.7 kg (the balance of ethyl alcohol according to the data of the previous inventory was 5.3 kg, the inputs in this period - 15 kg, the outputs according to the extemporaneous recipe were 17 kg.

Questions:

- 1. Indicate according to which document the inventory was spent in the pharmacy.
- 2. Indicate which accounting method was used to verify the actual balances of material values.
- 3. Indicate which drug groups are on the quantitative record in the community pharmacy.
- 4. Indicate when it applies and how to calculate the natural perishability within the limits of the norm.
- 5. Determine the inventory results of Ethyl Alcohol 95%.
- 6. Indicate to which expense item the losses within the limits of natural perishability will refer.

Exercise 7. *Report*

Topic: Drug pricing systems in some countries.

Exercise 8. Report

Topic: The world's experience in drug pricing.

Exercise 9. Report

Topic: Establishing a differentiated mechanism for applying the markup to the formation of prices for medicines in the Republic of Moldova - advantages and problems.

<u>Field VIII.</u> MONITORING MANAGEMENT OF PHARMACEUTICAL ACTIVITY AND THE INTEGRITY OF RESOURCES.

Tasks of the individual study: essay writing, time budget distribution, database identification and search and evaluation materials, re-evaluation, improvement and production, innovative creation.

Expected product: case scenario; essay.

Exercises for self-solving

Exercise 1. Case study

As a result of the planned control of the "Adonis-Farm" pharmacy by the pharmaceutical inspectorate, the following violations were found:

- 1. There was a medicine box in the box on the floor, with no accompanying documents.
- 2. Three packs of Prednizolon 0.1N 50 tablets were detected as expired.
- 3. Many prescriptions with errors have been detected during the examination of recipes remaining in the pharmacy for one month (medicines are prescribed under the trade names, the units of measurement of the drug are incorrectly indicated).
- 4. Only a pharmacist (pharmacist-supervisor) and a pharmacist are active in the pharmacy, noting that the pharmacy works from 8.00 to 20.00 without interruption and free days.

Questions:

- 1. Indicate the essence of drug control and indicate the violations found.
- 2. Indicate how to record and store medicines with an expired term.
- 3. Indicate which normative acts are violated in the pharmaceutical department.
- 4. What legislative and normative acts are violated in the activity of this pharmacy.
- 5. While the document will be drawn up at the end of the control of the pharmaceutical activity of the pharmacy "Adonis-Farm"
- 6. Indicate the contraventions that can be applied based on the control performed.

Exercise 2. Report

Topic: Regulation of the Control of the exercise of pharmaceutical activity in different countries.

Exercise 3. Report

Topic: Control of pharmaceutical activity in the Republic of Moldova, problems and solutions.

Exercise 4. Essay

Topic: Controlling the integrity of material, financial and human resources in pharmaceutical enterprises.

BASIC LITERATURE

- 1. V. Safta, M. Brumărel, N. Ciobanu, S. Adauji Management și legislație farmaceutică, F.E.P. "Tipografia Centrală", Chișinău, 2012. 800 p.
- 2. V. Procopișin, V. Safta, M. Brumărel Bazele activității farmaceutice, F.E.P. "Tipografia Centrală", Chișinău, 2002. 492 p., versiunea în limba rusă, ediția 2003. 488 p.
- 3. Reglementarea activității farmaceutice. (Culegere de acte legislative și normative). Colectiv de autori: redactor responsabil V. Procopișin, Editura "Vector", 2007, FEP "Tipografia Centrală". Chișinău, 2007. 1038 p.
- 4. Ețco C. Management în sistemul de sănătate. Ed. Epigraf, Chișinău, 2006, 862 p.
- 5. Carata A. Management, marketing și legislație farmaceutică. Vol.1. Management în domeniul farmaceutic. Editura Didactică și Pedagogică, R.A., București, 2008, 303 p.
- 6. Мескон М., Альберт М., Хедоури Ф. Основы менеджмента. Изд. ДЕЛО, Москва, 1998, 701 с.
- 7. Legislative and normative acts regulating the pharmaceutical activity available on the web page of the *Vasile Procopişin* Social Pharmacy Department. https://farmaciesociala.usmf.md/ro/acte-normative-0.
- 8. Lecture notes.



